U.S. patent application number 15/123974 was filed with the patent office on 2017-01-19 for method for generating t-cells compatible for allogenic transplantation.
The applicant listed for this patent is CELLECTIS. Invention is credited to Jean-Pierre CABANIOLS, Philippe DUCHATEAU, Laurent POIROT, David SOURDIVE.
Application Number | 20170016025 15/123974 |
Document ID | / |
Family ID | 50336023 |
Filed Date | 2017-01-19 |
United States Patent
Application |
20170016025 |
Kind Code |
A1 |
POIROT; Laurent ; et
al. |
January 19, 2017 |
METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC
TRANSPLANTATION
Abstract
The present invention pertains to engineered T-cells, method for
their preparation and their use as medicament, particularly for
immunotherapy. The engineered T-cells of the invention are
characterized in that the expression of beta 2-microglobulin (B2M)
and/or class II major histocompatibility complex transactivator
(CIITA) is inhibited, e.g., by using rare-cutting endonucleases
able to selectively inactivating by DNA cleavage the gene encoding
B2M and/or CIITA, or by using nucleic acid molecules which inhibit
the expression of B2M and/or CIITA. In order to further render the
T-cell non-alloreactive, at least one gene encoding a component of
the T-cell receptor is inactivated, e.g., by using a rare-cutting
endonucleases able to selectively inactivating by DNA cleavage the
gene encoding said TCR component. In addition, expression of
immunosuppressive polypeptide can be performed on those modified
T-cells in order to prolong the survival of these modified T cells
in host organism. Such modified T-cell is particularly suitable for
allogeneic transplantations, especially because it reduces both the
risk of rejection by the host's immune system and the risk of
developing graft versus host disease. The invention opens the way
to standard and affordable adoptive immunotherapy strategies using
T-Cells for treating cancer, infections and auto-immune
diseases.
Inventors: |
POIROT; Laurent; (Paris,
FR) ; SOURDIVE; David; (Levallois-Perret, FR)
; DUCHATEAU; Philippe; (Draveil, FR) ; CABANIOLS;
Jean-Pierre; (Saint Lau la For t, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CELLECTIS |
Paris |
|
FR |
|
|
Family ID: |
50336023 |
Appl. No.: |
15/123974 |
Filed: |
March 11, 2015 |
PCT Filed: |
March 11, 2015 |
PCT NO: |
PCT/EP2015/055097 |
371 Date: |
September 6, 2016 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 15/907 20130101;
C07K 14/70539 20130101; C07K 2317/24 20130101; C07K 2317/622
20130101; C12N 15/1138 20130101; C07K 14/70503 20130101; C12N 15/85
20130101; A61P 35/02 20180101; C12N 5/0636 20130101; A61P 31/12
20180101; A61P 35/00 20180101 |
International
Class: |
C12N 15/85 20060101
C12N015/85; C07K 14/74 20060101 C07K014/74; C07K 14/705 20060101
C07K014/705; C12N 15/90 20060101 C12N015/90; C12N 15/113 20060101
C12N015/113 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 11, 2014 |
DK |
PA201470119 |
Claims
1. A method for preparing an engineered T-cell comprising the steps
of: a) providing a T-cell; and b) inhibiting the expression of beta
2-microglobulin (B2M) and/or class II major histocompatibility
complex transactivator (CIITA) in said T-cell by using a
rare-cutting endonuclease able to selectively inactivate by DNA
cleavage gene encoding said B2M and/or CIITA.
2. The method according to claim 1, wherein step b) is performed by
using a rare-cutting endonuclease able to selectively inactivate by
DNA cleavage the gene encoding B2M.
3. The method according to claim 1, wherein step b) is performed by
using a rare-cutting endonuclease able to selectively inactivate by
DNA cleavage the gene encoding CIITA.
4. The method according to any one of claim 1 to claim 3, wherein
step b) is performed by using a TAL-nuclease, meganuclease,
zing-finger nuclease (ZFN), or RNA guided endonuclease.
5. The method according to claim 4, wherein step b) is performed
using a TAL-nuclease.
6. The method according to claim 4, wherein step b) is performed by
using a RNA-guided endonucleases.
7. The method according to claim 6, wherein the RNA-guided
endonuclease is Cas9.
8. The method according to any one of claims 1 to 7, further
comprising the step of: c) inactivating at least one gene encoding
a component of the T-cell receptor (TCR).
9. The method according to claim 8, wherein step c) is performed by
using a rare-cutting endonuclease able to selectively inactivate by
DNA cleavage, preferably double-strand break, at least one gene
encoding a component of the T-cell receptor (TCR).
10. The method according to claim 9, wherein the rare-cutting
endonuclease is a TAL-nuclease, meganuclease, zing-finger nuclease
(ZFN), or RNA guided endonuclease like Cas9/CRISPR.
11. The method according to any one of claims 8 to 10, wherein the
component of the TCR is TCR alpha.
12. The method according to any one of claims 1 to 11, further
comprising the step of: d) introducing into said T-cell an
exogenous nucleic acid molecule comprising a nucleotide sequence
coding for a Chimeric Antigen Receptor (CAR) directed against at
least one antigen expressed at the surface of a malignant or
infected cell.
13. The method according to claim 12, wherein said Chimeric Antigen
Receptor is directed against the B-lymphocyte antigen CD19.
14. The method according to claim 12, wherein said Chimeric Antigen
Receptor is directed against an antigen selected from a cluster of
differentiation molecule, such as CD16, CD64, CD78, CD96,CLL1,
CD116, CD117, CD71, CD45, CD71, CD123 and CD138, a tumor-associated
surface antigen, such as ErbB2 (HER2/neu), carcinoembryonic antigen
(CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth
factor receptor (EGFR), EGFR variant III (EGFRvIII), CD19, CD20,
CD30, CD40, disialoganglioside GD2, ductal-epithelial nnucine,
gp36, TAG-72, glycosphingolipids, glioma-associated antigen,
.beta.-human chorionic gonadotropin, alphafetoprotein (AFP),
lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human
telomerase reverse transcriptase, RU1, RU2 (AS), intestinal
carboxyl esterase, mut hsp70-2, M-CSF, prostase, prostase specific
antigen (PSA), PAP, NY-ESO-1, LAGA-1a, p53, prostein, PSMA,
surviving and telomerase, prostate-carcinoma tumor antigen-1
(PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22,
insulin growth factor (IGF1)-I, IGF-II, IGFI receptor, mesothelin,
a major histocompatibility complex (MHC) molecule presenting a
tumor-specific peptide epitope, 5T4, ROR1, Nkp30, NKG2D, tumor
stromal antigens, the extra domain A (EDA) and extra domain B (EDB)
of fibronectin and the A1 domain of tenascin-C (TnC A1) and
fibroblast associated protein (fap); a lineage-specific or tissue
specific antigen such as CD3, CD4, CD8, CD24, CD25, CD33, CD34,
CD133, CD138, CTLA-4, B7-1 (CD80), B7-2 (CD86), GM-CSF, cytokine
receptors, endoglin, a major histocompatibility complex (MHC)
molecule, BCMA (CD269, TNFRSF 17), multiple myeloma or
lymphoblastic leukaemia antigen, such as one selected from TNFRSF17
(UNIPROT Q02223), SLAMF7 (UNIPROT Q9NQ25), GPRC5D (UNIPROT Q9NZD1),
FKBP11 (UNIPROT Q9NYL4), KAMP3, ITGA8 (UNIPROT P53708), and FCRL5
(UNIPROT Q68SN8), a virus-specific surface antigen such as an
HIV-specific antigen (such as HIV gp120); an EBV-specific antigen,
a CMV-specific antigen, a HPV-specific antigen, a Lasse
Virus-specific antigen, an Influenza Virus-specific antigen as well
as any derivate or variant of these surface antigens.
15. The method according to any one of claims 1 to 14, further
comprising the step of : d') expressing at least one non-endogenous
immune-suppressive polypeptide.
16. The method according to claim 15, wherein said non-endogenous
immune-suppressive polypeptide is a viral MHC homolog.
17. The method according to claim 16, wherein said viral MHC
homolog is UL18.
18. The method according to any one of claims 15 to claim 17,
wherein the non-endogenous immune-suppressive polypeptide comprises
an amino acid sequence sharing at least 80%, preferably at least
90% and more preferably at least 95% of identity with SEQ ID NO:
89.
19. The method according to claim 15, wherein said non-endogenous
immune-suppressive polypeptide is a NKG2D ligand.
20. The method according to claim 15 or 19, wherein the
non-endogenous immune-suppressive polypeptide comprises an amino
acid sequence sharing at least 80%, preferably at least 90% and
more preferably at least 95% of identity with any one of SEQ ID NO:
90-97.
21. The method according to any one of claims 1 to 20, further
comprising the step of: e) expanding the resulting engineered
T-cell.
22. The method according to any one of claims 1 to 21, wherein said
T-cell in step a) is derived from an inflammatory T-lymphocyte, a
cytotoxic T-lymphocyte, a regulatory T-lymphocyte or a helper
T-lymphocyte.
23. The method according to claim 22, wherein said T-cell is
derived from a CD4+ T-lymphocyte or a CD8+ T-lymphocytes.
24. An engineered, preferably isolated, T-cell, wherein said T-cell
expresses a rare-cutting endonuclease able to selectively
inactivate by DNA cleavage the gene encoding B2M.
25. An engineered, preferably isolated, T-cell, wherein said T-cell
expresses a rare-cutting endonuclease able to selectively
inactivate by DNA cleavage the gene encoding CIITA.
26. The engineered T-cell according to claim 24 or 25, wherein said
T-cell comprises an exogenous nucleic acid molecule comprising a
nucleotide sequence encoding said rare-cutting endonuclease.
27. The engineered T-cell according to claim 26, wherein said
rare-cutting endonuclease is a TAL-nuclease, meganuclease,
zing-finger nuclease (ZFN), or RNA guided endonuclease.
28. The engineered T-cell according to claim 27, wherein said
rare-cutting endonuclease is a TAL-nuclease.
29. The engineered T-cell according to claim 27, wherein said
rare-cutting endonuclease is a RNA-guided endonucleases.
30. The engineered T-cell according to claim 29, wherein the
RNA-guided endonuclease is Cas9.
31. The engineered T-cell according to any one of claims 26 to 30,
wherein said nucleic acid is a vector allowing said rare-cutting
endonucleases to be expressed by said T-cell.
32. The engineered T-cell according to any one of claims 26 to 30,
wherein said nucleic acid is a transfected mRNA.
33. The engineered T-cell according to claim 24, wherein said
T-cell comprises an exogenous nucleic acid molecule that inhibits
the expression of B2M.
34. The engineered T-cell according to claim 34, wherein the
nucleic acid molecule comprises at least 10 consecutive nucleotides
of the complement of SEQ ID NO: 3.
35. The engineered T-cell according to claim 25, wherein said
T-cell comprises an exogenous nucleic acid molecule that inhibits
the expression of CIITA.
36. The engineered T-cell according to claim 35, wherein the
nucleic acid molecule comprises at least 10 consecutive nucleotides
of the complement of SEQ ID NO: 5.
37. The engineered T-cell according to any one of claims 33 to 36,
wherein the nucleic acid molecule is an antisense oligonucleotide,
ribozyme or interfering RNA (RNAi) molecule.
38. The engineered T-cell according to any one of claims 24 to 37,
further characterized in that at least one gene encoding a
component of the TCR receptor is inactivated.
39. The engineered T-cell according to claim 38 wherein said T-cell
expresses a rare-cutting endonuclease able to selectively
inactivate by DNA cleavage, preferably double-strand break, said at
least one gene encoding a component of the T-Cell receptor
(TCR).
40. The engineered T-cell according to claim 39, wherein said
T-cell comprises an exogenous nucleic acid molecule comprising a
nucleotide sequence encoding said rare-cutting endonuclease.
41. The engineered T-cell according to claim 40, wherein said said
rare-cutting endonuclease is a TAL-nuclease, nneganuclease,
zing-finger nuclease (ZFN), or RNA guided endonuclease.
42. The engineered T-cell according to any one of claims 24 to 41,
wherein said T-cell expresses a Chimeric Antigen Receptor (CAR)
directed against at least one antigen expressed at the surface of a
malignant or infected cell.
43. The engineered T-cell according to claim 42, wherein said
T-cell comprises an exogenous nucleic acid molecule comprising a
nucleotide sequence encoding said CAR.
44. The engineered T-cell according to claim 42 or 43, wherein said
CAR is directed against the B-lymphocyte antigen CD19.
45. The engineered T-cell according to claim 42 or 43, wherein said
CAR is directed against an antigen selected from a cluster of
differentiation molecule, such as CD16, CD64, CD78, CD96,CLL1,
CD116, CD117, CD71, CD45, CD71, CD123 and CD138, a tumor-associated
surface antigen, such as ErbB2 (HER2/neu), carcinoembryonic antigen
(CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth
factor receptor (EGFR), EGFR variant III (EGFRvIII), CD19, CD20,
CD30, CD40, disialoganglioside GD2, ductal-epithelial mucine, gp36,
TAG-72, glycosphingolipids, glioma-associated antigen, .beta.-human
chorionic gonadotropin, alphafetoprotein (AFP), lectin-reactive
AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse
transcriptase, RU1, RU2 (AS), intestinal carboxyl esterase, mut
hsp70-2, M-CSF, prostase, prostase specific antigen (PSA), PAP,
NY-ESO-1, LAGA-1a, p53, prostein, PSMA, surviving and telomerase,
prostate-carcinoma tumor antigen-1 (PCTA-1), MAGE, ELF2M,
neutrophil elastase, ephrin B2, CD22, insulin growth factor
(IGF1)-I, IGF-II, IGFI receptor, mesothelin, a major
histocompatibility complex (MHC) molecule presenting a
tumor-specific peptide epitope, 5T4, ROR1, Nkp30, NKG2D, tumor
stromal antigens, the extra domain A (EDA) and extra domain B (EDB)
of fibronectin and the A1 domain of tenascin-C (TnC A1) and
fibroblast associated protein (fap); a lineage-specific or tissue
specific antigen such as CD3, CD4, CD8, CD24, CD25, CD33, CD34,
CD133, CD138, CTLA-4, B7-1 (CD80), B7-2 (CD86), GM-CSF, cytokine
receptors, endoglin, a major histocompatibility complex (MHC)
molecule, BCMA (CD269, TNFRSF 17), multiple myeloma or
lymphoblastic leukaemia antigen, such as one selected from TNFRSF17
(UNIPROT Q02223), SLAMF7 (UNIPROT Q9NQ25), GPRC5D (UNIPROT Q9NZD1),
FKBP11 (UNIPROT Q9NYL4), KAMP3, ITGA8 (UNIPROT P53708), and FCRL5
(UNIPROT Q68SN8), a virus-specific surface antigen such as an
HIV-specific antigen (such as HIV gp120); an EBV-specific antigen,
a CMV-specific antigen, a HPV-specific antigen, a Lasse
Virus-specific antigen, an Influenza Virus-specific antigen as well
as any derivate or variant of these surface antigens.
46. The engineered T-cell according to any one of claims 24 to 45,
wherein said T-cell expresses at least one non-endogenous
immune-suppressive polypeptide.
47. The engineered T-cell according to claim 46, wherein said
non-endogenous immune-suppressive polypeptide is a viral MHC
homolog.
48. The engineered T-cell according to claim 47, wherein said a
viral MHC homolog is UL18.
49. The engineered T-cell according to any one of claims 46 to 48,
wherein said T-cell comprises an exogenous nucleic acid molecule
comprising a nucleotide sequence coding fora polypeptide sharing at
least 80%, preferably at least 90% and more preferably at least 95%
of identity with SEQ ID NO: 89.
50. The engineered T-cell according to claim 46, wherein said
non-endogenous immune-suppressive polypeptide is a NKG2D
ligand.
51. The engineered T-cell according to claim 46 or 50, wherein said
T-cell comprises an exogenous nucleic acid molecule comprising a
nucleotide sequence coding for a polypeptide sharing at least 80%,
preferably at least 90% and more preferably at least 95% of
identity with any one of SEQ ID NO: 90-97.
52. The engineered T-cell according to any one of claims 24 to 51,
wherein said T-cell is derived from an inflammatory T-lymphocyte, a
cytotoxic T-lymphocyte, a regulatory T-lymphocyte or a helper
T-lymphocyte.
53. The engineered T-cell according to claim 52, wherein said
T-cell is derived from a CD4+ T-lymphocyte or a CD8+
T-lymphocytes.
54. The engineered T-cell according to any one of claims 24 to 53
for use as a medicament.
55. The engineered T-cell according to any one of claims 24 to 53
for use in the treatment of a cancer or viral infection.
56. The engineered T-cell according to any one of claims 24 to 53
for use in the treatment of lymphoma.
57. The engineered T-cell according to any one of claims 48 to 56,
wherein said T-cell originates from a patient to be treated.
58. The engineered T-cell according to any one of claims 48 to 56,
wherein said T-cell originates from a donor.
59. A composition comprising at least one engineered T-cell
according to any one of claims 24 to 53.
Description
FIELD OF THE INVENTION
[0001] The present invention pertains to engineered T-cells, method
for their preparation and their use as medicament, particularly for
immunotherapy. The engineered T-cells of the invention are
characterized in that the expression of beta 2-microglobulin (B2M)
and/or class II major histocompatibility complex transactivator
(CIITA) is inhibited, e.g., by using rare-cutting endonucleases
able to selectively inactivating by DNA cleavage the gene encoding
B2M and/or CIITA, or by using nucleic acid molecules which inhibit
the expression of B2M and/or CIITA. In order to further render the
T-cell non-alloreactive, at least one gene encoding a component of
the T-cell receptor is inactivated, e.g., by using a rare-cutting
endonucleases able to selectively inactivating by DNA cleavage the
gene encoding said TCR component. In addition, a step of expression
of immunosuppressive polypeptide such as viral MHCI homolog or
NKG2D ligand can be performed on those modified T-cells in order to
prolong the survival of these modified T cells in host organism.
Such modified T-cell is particularly suitable for allogeneic
transplantations, especially because it reduces both the risk of
rejection by the host's immune system and the risk of developing
graft versus host disease. The invention opens the way to standard
and affordable adoptive immunotherapy strategies using T-Cells for
treating cancer, infections and auto-immune diseases.
BACKGROUND OF THE INVENTION
[0002] Adoptive immunotherapy, which involves the transfer of
autologous antigen-specific T-cells generated ex vivo, is a
promising strategy to treat viral infections and cancer. The
T-cells used for adoptive immunotherapy can be generated either by
expansion of antigen-specific T-cells or redirection of T-cells
through genetic engineering (Park, Rosenberg et al. 2011).
[0003] Novel specificities in T cells have been successfully
generated through the genetic transfer of transgenic T cell
receptors or chimeric antigen receptors (CARs) (Jena, Dotti et al.
2010). CARs are synthetic receptors consisting of a targeting
moiety that is associated with one or more signaling domains in a
single fusion molecule. In general, the binding moiety of a CAR
consists of an antigen-binding domain of a single-chain antibody
(scFv), comprising the light and variable fragments of a monoclonal
antibody joined by a flexible linker. Binding moieties based on
receptor or ligand domains have also been used successfully. The
signaling domains for first generation CARs are derived from the
cytoplasmic region of the CD3zeta or the Fc receptor gamma chains.
First generation CARs have been shown to successfully redirect
T-cell cytotoxicity, however, they failed to provide prolonged
expansion and anti-tumor activity in vivo. Signaling domains from
co-stimulatory molecules including CD28, OX-40 (CD134), and 4-1BB
(CD137) have been added alone (second generation) or in combination
(third generation) to enhance survival and increase proliferation
of CAR modified T cells. CARs have successfully allowed T cells to
be redirected against antigens expressed at the surface of tumor
cells from various malignancies including lymphomas and solid
tumors (Jena, Dotti et al. 2010).
[0004] The current protocol for treatment of patients using
adoptive immunotherapy is based on autologous cell transfer. In
this approach, T lymphocytes are recovered from patients,
genetically modified or selected ex vivo, cultivated in vitro in
order to amplify the number of cells if necessary and finally
infused into the patient. In addition to lymphocyte infusion, the
host may be manipulated in other ways that support the engraftment
of the T cells or their participation in an immune response, for
example pre-conditioning (with radiation or chemotherapy) and
administration of lymphocyte growth factors (such as IL-2). Each
patient receives an individually fabricated treatment, using the
patient's own lymphocytes (i.e. an autologous therapy). Autologous
therapies face substantial technical and logistic hurdles to
practical application, their generation requires expensive
dedicated facilities and expert personnel, they must be generated
in a short time following a patient's diagnosis, and in many cases,
pretreatment of the patient has resulted in degraded immune
function, such that the patient's lymphocytes may be poorly
functional and present in very low numbers. Because of these
hurdles, each patient's autologous cell preparation is effectively
a new product, resulting in substantial variations in efficacy and
safety.
[0005] Ideally, one would like to use a standardized therapy in
which allogeneic therapeutic cells could be pre-manufactured,
characterized in detail, and available for immediate administration
to patients. By allogeneic it is meant that the cells are obtained
from individuals belonging to the same species but are genetically
dissimilar. However, the use of allogeneic cells presently has many
drawbacks. In immune-competent hosts allogeneic cells are rapidly
rejected, a process termed host versus graft rejection (HvG), and
this substantially limits the efficacy of the transferred cells. In
immune-incompetent hosts, allogeneic cells are able to engraft, but
their endogenous T-cell receptors (TCR) specificities may recognize
the host tissue as foreign, resulting in graft versus host disease
(GvHD), which can lead to serious tissue damage and death.
[0006] In order to provide allogeneic T-cells, the inventors
previously disclosed a method to genetically engineer T-Cells, in
which different effector genes, in particular those encoding T-cell
receptors, were inactivated by using specific TAL-nucleases, better
known under the trade mark TALEN.TM. (Cellectis, 8, rue de la Croix
Jarry, 75013 PARIS). This method has proven to be highly efficient
in primary cells using RNA transfection as part of a platform
allowing the mass production of allogeneic T-cells (WO
2013/176915).
[0007] Beta-2 microglobulin, also known as B2M, is the light chain
of MHC class I molecules, and as such an integral part of the major
histocompatibility complex In human, B2M is encoded by the b2m gene
which is located on chromosome 15, opposed to the other MHC genes
which are located as gene cluster on chromosome 6. The human
protein is composed of 119 amino acids (SEQ I D NO: 1) and has a
molecular weight of 11.800 Daltons. Mice models deficient for
beta-2 microglobulin have shown that B2M is necessary for cell
surface expression of MHC class I and stability of the peptide
binding groove. It was further shown that haemopoietic transplants
from mice that are deficient for normal cell-surface MHC I
expression are rejected by NK1.1+cells in normal mice because of a
targeted mutation in the beta-2 micorglobulin gene, suggesting that
deficient expression of MHC I molecules renders marrow cells
susceptible to rejection by the host immune system (Bix et al.
1991).
[0008] CIITA protein (SEQ ID NO: 4 -NCBI Reference Sequence:
NP_000237.2) that acts as a positive regulator of class II major
histocompatibility complex gene transcription, including .beta.2m
gene transcription, and is often referred to as the "master control
factor" for the expression of these genes. CIITA mRNA (SEQ ID NO:
5) can only be detected in human leukocyte antigen (HLA) system
class II-positive cell lines and tissues. This highly restricted
tissue distribution suggests that expression of HLA class II genes
is to a large extent under the control of CIITA (Mach B., et al.
1994).
[0009] Adaptive immune response is a complex biological system
where numerous cellular components interact. Professional Antigen
Presenting Cells (APC) are able to process foreign bodies and
expose them to helper T cells in the context of MHC Class II
molecules. Activated helper T cells will in turn stimulate B cells
response and cytotoxic T (CTL) cells response. CTL recognize
foreign peptides presented by MHC Class I molecules but in the case
of alloreactivity, recognize and kill cells bearing foreign MHC
Class I. MHC Class I molecules are composed of 2 entities: the
highly polymorphic, transmembrane heavy chain and a small invariant
polypeptide, the beta2-microglobuline (beta2-m) encoded by B2M
gene. The expression of the MHC Class I heavy chain at the cell
surface requires its association with the beta2-m. Hence,
abrogation of beta2-m expression in CAR T cells will impair MHC
Class I expression and make them invisible to host CTL. However,
MHC Class I deficient CAR T cells are susceptibe to lysis by host
NK cells, which target cells lacking MHC Class I molecules
[Ljunggren HG et al. (1990), Immunl Today. 11:237-244].
[0010] NK cells exert cytotoxic functions towards the cells they
interact with based on the balance between activating and
inhibitory signals they received through different monomorphic or
polymorphic receptors. One central activating receptor on human NK
cells is NKG2D and its ligands include proteins such as MICA, MICB,
ULBP1, ULBP2, ULBP3 [Raulet DH, (2003), Nature Reviews Immunology 3
(10): 781-79]. On the other hand, the inhibitory signal is mediated
through the interaction between NK receptors like LIR-1/ILT2 and
MHC Class I molecules [Ljunggren HG et al. (1990), Immunl Today.
11:237-244]. Some viruses such as cytomegaloviruses have aquired
mechanisms to avoid NK cell mediate immune surveillance. HCMV
genome encodes proteins that are able to prevent MHC Class! surface
expression (i.e. U52, US3, US6 and US11) while expressing a MHC
classl homolog protein (UL18) that acts as a decoy to block
NK-mediated cell lysis [Kim, Y et al. (2008), PLOS Pathogens. 4:
e1000123, and Wilkinson G. et al. (2010). J [lin Virol.
41(3):206-212]. Moreover, HCMV interferes with the NKG2D pathway by
secreting a protein able to bind NKG2D ligands and prevent their
surface expression [Welte SA et al. (2003), Eur J Innmunol 33 (1):
194-203]. In tumor cells, some mechanisms have evolved to evade
NKG2D response by secreting NKG2D ligands such as ULBP2, MICB or
MICA (Waldhauer I, Steinle A (2003). Proteolytic release of soluble
UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66(5):
2520-2526; Salih HR et al. (2006), Hum Immunol. 2006
March;67(3):188-95; Salih HR et al. (2003) Blood. 2003 Aug. 15;
102(4):1389-96; Salih HR et al. (2002) J
Imnnunol.;169(8):4098-102].
[0011] The present inventor here provides strategies for
immunotherapy by which T-cells, especially allogeneic T-cells, are
made particular suitable for allogeneic transplantations, reducing
the risk for host versus graft rejections and for developing graft
versus host disease and to render the T cells "stealthy", in
particular with respect to APC cells or NK cells.
SUMMARY OF THE INVENTION
[0012] The present invention concerns methods for preparing
engineered T-cells, in particular allogeneic T-cells obtained from
a donor, to make them suitable for immunotherapy purposes. The
methods of the present invention more particularly allow the
precise modulation of expression of certain effector molecules
important for immune recognition and histocompatibility.
[0013] According to one aspect, the present invention provides a
method for preparing an engineered T-cell, preferably an allogeneic
T-cell obtained from a donor, comprising the steps of: [0014] a)
providing a T-cell, preferably an allogeneic T-cell obtained from a
donor; and [0015] b) inhibiting the expression of beta
2-microglobulin (B2M) and/or class II major histocompatibility
complex transactivator (CIITA) in said T-cell.
[0016] According to certain embodiments, inhibition of expression
of B2M is achieved by a genome modification, more particularly
through the expression in the T-cell of a rare-cutting endonuclease
able to selectively inactivate by DNA cleavage the gene encoding
B2M, such as the human .beta.2m gene set forth in SEQ ID NO: 2
(NCBI Reference Sequence: NG_012920.1), or a gene having at least
70%, such as at least 80%, at least 90% at least 95%, or at least
99%, sequence identify with the human .beta.2m gene set forth in
SEQ ID NO: 2 over the entire length of SEQ ID NO: 2. Such
rare-cutting endonuclease may be a TAL-nuclease, meganuclease,
zing-finger nuclease (ZFN), or RNA guided endonuclease (such as
Cas9).
[0017] According to certain other embodiments, inhibition of
expression of B2M is achieved by using (e.g., introducing into the
T-cell) a nucleic acid molecule that specifically hybridizes (e.g.
binds) under cellular conditions with the cellular mRNA and/or
genomic DNA encoding B2M, thereby inhibiting transcription and/or
translation of the gene. In accordance with particular embodiments,
the inhibition of expression of B2M is achieved by using ((e.g.,
introducing into the T-cell) an antisense oligonucleotide, ribozyme
or interfering RNA (RNAi) molecule. Preferably, such nucleic acid
molecule comprises at least 10 consecutive nucleotides of the
complement of SEQ ID NO: 3 (i.e., the mRNA encoding human B2M; NCBI
Reference Sequence: NM_004048).
[0018] According to certain embodiments, inhibition of expression
of CIITA is achieved by a genome modification, more particularly
through the expression in the T-cell of a rare-cutting endonuclease
able to selectively inactivate by DNA cleavage the gene encoding
CIITA, such as the human CIITA gene (NCBI Reference Sequence:
NG_009628.1), or a gene having at least 70%, such as at least 80%,
at least 90% at least 95%, or at least 99%, sequence identify with
the human CIITA gene according to NG_009628.1 over the entire
length of the human CIITA gene according to NG_009628.1. Such
rare-cutting endonuclease may be a TAL-nuclease, meganuclease,
zing-finger nuclease (ZFN), or RNA guided endonuclease (such as
Cas9).
[0019] According to certain other embodiments, inhibition of
expression of CIITA is achieved by using (e.g., introducing into
the T-cell) a nucleic acid molecule that specifically hybridizes
(e.g. binds) under cellular conditions with the cellular mRNA
and/or genomic DNA encoding CIITA, thereby inhibiting transcription
and/or translation of the gene. In accordance with particular
embodiments, the inhibition of expression of CIITA is achieved by
using ((e.g., introducing into the T-cell) an antisense
oligonucleotide, ribozyme or interfering RNA (RNAi) molecule.
Preferably, such nucleic acid molecule comprises at least 10
consecutive nucleotides of the complement of SEQ ID NO: 5 (i.e.,
the mRNA encoding human CIITA isoform 2).
[0020] According to particular embodiments, the T-cell may be
further engineered to make it non-alloreactive, especially by
inactivating one or more genes involved in self-recognition, such
as those, for instance, encoding components of T-cell receptors
(TCR). This can be achieved by a genome modification, more
particularly through the expression in the T-cell of a rare-cutting
endonuclease able to selectively inactivate by DNA cleavage,
preferably double-strand break, at least one gene encoding a
component of the T-Cell receptor (TCR), such as the gene encoding
TCR alpha or TCR beta. Such rare-cutting endonuclease may be a
TAL-nuclease, meganuclease, zing-finger nuclease (ZFN), or RNA
guided endonuclease (such as, Cas9). Preferably, the rare-cutting
endonuclease is able to selectively inactivate by DNA cleavage the
gene coding for TCR alpha.
[0021] According to optional embodiments, the T-cell may be further
engineered to express a Chimeric Antigen Receptor (CAR) directed
against at least one antigen expressed at the surface of a
malignant or infected cell, such as the B-lymphocyte antigen
CD19.
[0022] The present invention thus provides in a further aspect
engineered T-cells, in particular engineered isolated T-cells,
characterized in that the expression of beta 2-microglobulin (B2M)
is inhibited.
[0023] According to certain embodiments, a T-cell is provided which
expresses a rare-cutting endonuclease able to selectively
inactivate by DNA cleavage the gene encoding B2M. More
particularly, such T-cell comprises an exogenous nucleic acid
molecule comprising a nucleotide sequence encoding said
rare-cutting endonuclease, which may be a TAL-nuclease,
meganuclease, zing-finger nuclease (ZFN), or RNA guided
endonuclease.
[0024] According to certain other embodiments, a T-cell is provided
which comprises an exogenous nucleic acid molecule that inhibits
the expression of B2M. According to particular embodiments, such
nucleic acid molecule is an antisense oligonucleotide, ribozyme or
interfering RNA (RNAi) molecule. According to preferred
embodiments, such nucleic acid molecule comprises at least 10
consecutive nucleotides of the complement of SEQ ID NO: 3.
[0025] The present invention further provides engineered T-cells,
in particular engineered isolated T-cells, characterized in that
the expression of class II major histocompatibility complex
transactivator (CIITA) is inhibited.
[0026] According to certain embodiments, a T-cell is provided which
expresses a rare-cutting endonuclease able to selectively
inactivate by DNA cleavage the gene encoding CIITA. More
particularly, such T-cell comprises an exogenous nucleic acid
molecule comprising a nucleotide sequence encoding said
rare-cutting endonuclease, which may be a TAL-nuclease,
meganuclease, zing-finger nuclease (ZFN), or RNA guided
endonuclease.
[0027] According to certain other embodiments, a T-cell is provided
which comprises an exogenous nucleic acid molecule that inhibits
the expression of CIITA. According to particular embodiments, such
nucleic acid molecule is an antisense oligonucleotide, ribozyme or
interfering RNA (RNAi) molecule. According to preferred
embodiments, such nucleic acid molecule comprises at least 10
consecutive nucleotides of the complement of SEQ ID NO: 5.
[0028] According to particular embodiments, the T-cell may further
have at least one inactivated gene encoding a component of the TCR
receptor. More particularly, such T-cell may express a rare-cutting
endonuclease able to selectively inactivate by DNA cleavage,
preferably double-strand break, said at least one gene encoding a
component of the T-Cell receptor (TCR). Accordingly, said T-cell
may comprise an exogenous nucleic acid molecule comprising a
nucleotide sequence coding for a rare-cutting endonuclease able to
selectively inactivate by DNA cleavage at least one gene coding for
one component of the T-Cell receptor (TCR). The disruption of TCR
provides a non-alloreactive T-cell that can be used in allogeneic
treatment strategies.
[0029] According to optional embodiments, the T-cell may be
engineered to express a Chimeric Antigen Receptor (CAR) directed
against at least one antigen expressed at the surface of a
malignant or infected cell, such as the B-lymphocyte antigen CD19.
Particularly, the T-cell comprises an exogenous nucleic acid
molecule comprising a nucleotide sequence encoding said CAR. The
binding of the target antigen by the CAR has the effect of
triggering an immune response by the T-cell directed against the
pathological cell, which results in degranulation of various
cytokine and degradation enzymes in the interspace between the
cells.
[0030] According to some embodiments, an additional modification of
T-cells is performed to render them stealthy by expression of at
least one non-endogenous immunosuppressive polypeptide such as a
viral MHC honnolog, for instance, UL18, or such as a NKG2D
ligand.
[0031] According to some embodiments, the T-cell of the present
invention expresses at least one non-endogenous immune-suppressive
polypeptide. According to more particular embodiments, said
non-endogenous immune-suppressive polypeptide is a viral MHC
homolog, such as UL18. The T-cell may comprise an exogenous nucleic
acid molecule comprising a nucleotide sequence cording for a
polypeptide sharing at least 80%, preferably at least 90% and more
preferably at least 95% of identity with SEQ ID NO: 89. According
to other more particular embodiments, said non-endogenous
immune-suppressive polypeptide is a NKG2D ligand. The T-cell may
comprise an exogenous nucleic acid molecule comprising a nucleotide
sequence cording for a polypeptide sharing at least 80%, preferably
at least 90% and more preferably at least 95% of identity with any
one of SEQ ID NO: 90-97.
[0032] As a result of the present invention, engineered T-cells can
be used as therapeutic products, ideally as an "off the shelf"
product, for use in the treatment or prevention cancer, bacterial
or viral infections, or auto-immune diseases.
[0033] Thus, the present invention further provides an engineered
T-cell or a composition, such as a pharmaceutical composition,
comprising same for use as a medicament. According to certain
embodiments, the engineered T-cell or composition is for use in the
treatment of a cancer, and more particularly for use in the
treatment of lymphoma. According to certain other embodiments, the
engineered T-cell or composition is for use in the treatment of
viral infection. According to certain other embodiments, the
engineered T-cell or composition is for use in the treatment of
bacterial infection.
[0034] It is understood that the details given herein with respect
to one aspect of the invention also apply to any of the other
aspects of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0035] FIG. 1: Schematic representation of the normal relationship
between donor's T-cells, host T-cells and antigen presenting
cells.
[0036] FIG. 2: Schematic representation of the genetically modified
therapeutic T-cells according to the invention and the patient's
T-cells and tumor cells.
[0037] FIG. 3: Comparison of the forward side scatter (FSC)
distribution, an indicator of cell size, between TCR-positive and
TCR-negative cells.
[0038] FIG. 4: Flow cytometry analysis of TCR alpha/beta and CD3
expression on human primary T cells following TRAC TALE-nuclease
mRNA electroporation (top).
[0039] FIG. 5: Flow cytometry analysis of HLA_ABC expression on the
surface of human primary T cells in: A. Control T-cells. B.
following .beta.2m TALE-nuclease mRNA electroporation.
[0040] FIG. 6: A. Flow cytometry analysis of CAR expression (anti
F(ab')2) after electroporation of T cells with or without mRNA
encoding a single chain CAR. B. Flow cytometry analysis of CD107a
expression (marker of degranulation) on electroporated T cells
cocultured with daudi cells.
[0041] FIG. 7: Schematic representation of the potential
interactions between an allogeneic CAR T cell with diverse host
immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and
NK cell), the CAR T cell having its B2M gene inactivated by KO.
Sign (+) represents activation and sign (-) inhibition. The
potential interaction between CAR T cell with the tumor cell
remains unchanged. The inactivation of B2M gene which is one
component of the MCHI, renders the latter non-functional in regards
to the interactions with host cytotoxic T cell (CD8+) and with NK
cell. Then, NK cell can exert its activation on allogeneic CAR T
cell via activator pathway such NKG2D/NKG2D ligand.
[0042] FIG. 8: Schematic representation of the potential
interactions between an allogeneic CAR T cell with diverse host
immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and
NK cell), the CAR T cell having its B2M gene inactivated by KO and
expressing viral MHCI homolog. Sign (+) represents activation and
sign (-) inhibition. The potential interaction between CAR T cell
with the tumor cell remains unchanged. As for the preceding figure
(only B2M KO), the interaction between CAR T cell and host CD8+ T
cell is alleviated. In this case, the expression of viral MHCI
homolog renders the interaction with NK cell inoperative via
MHCl/inhibitor receptor. The double genetic modification of
allogeneic CAR T cells by KO of B2M combined with the expression of
viral MHCI homolog strengthens their immunosuppressive
protection.
[0043] FIG. 9: Schematic representation of the potential
interactions between an allogeneic CAR T cell with diverse host
immune cells (CD8+ and CD4+ T cell, APC such as dendritic cell and
NK cell), the CAR T cell having its B2M gene inactivated by KO and
expressing a soluble NKG2D ligand. Sign (+) represents activation
and sign (-) inhibition. The potential interaction between CAR T
cell with the tumor cell remains unchanged. As for the preceding
figure (only B2M KO), the interaction between CAR T cell and host
CD8+ T cell is alleviated. The expression of soluble NKG2D ligand
is another way to inactivation the interaction with NK cell. In
this case, the soluble NKG2D ligand can bind to NKG2D receptor on
NK cell but exerts no action, in contrast to the NKG2D ligand of
CAR T cell with which it exerts an inhibitory competition. The
double genetic modification of allogeneic CAR T cells by KO of B2M
combined with the expression of soluble NKG2D ligand strengthens
their immunosuppressive protection.
[0044] FIG. 10: FACS analysis of .beta.2-m expression in T cells.
Untransfected (top) and transfected T cells (middle and bottom) are
analysed by FACS for viability (left) and .beta.2-m expression
(right).
DETAILED DESCRIPTION OF THE INVENTION
[0045] Unless specifically defined herein, all technical and
scientific terms used have the same meaning as commonly understood
by a skilled artisan in the fields of gene therapy, biochemistry,
genetics, and molecular biology.
[0046] All methods and materials similar or equivalent to those
described herein can be used in the practice or testing of the
present invention, with suitable methods and materials being
described herein. All publications, patent applications, patents,
and other references mentioned herein are incorporated by reference
in their entirety. In case of conflict, the present specification,
including definitions, will prevail. Further, the materials,
methods, and examples are illustrative only and are not intended to
be limiting, unless otherwise specified.
[0047] The practice of the present invention will employ, unless
otherwise indicated, conventional techniques of cell biology, cell
culture, molecular biology, transgenic biology, microbiology,
recombinant DNA, and immunology, which are within the skill of the
art. Such techniques are explained fully in the literature. See,
for example, Current Protocols in Molecular Biology (Frederick M.
AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA);
Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et
al, 2001, Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory
Press); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et
al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D.
Harries & S. J. Higgins eds. 1984); Transcription And
Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of
Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987);
Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A
Practical Guide To Molecular Cloning (1984); the series, Methods In
ENZYMOLOGY (J. Abelson and M. Simon, eds.-in-chief, Academic Press,
Inc., New York), specifically, Vols. 154 and 155 (Wu et al. eds.)
and Vol. 185, "Gene Expression Technology" (D. Goeddel, ed.); Gene
Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Cabs
eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods
In Cell And Molecular Biology (Mayer and Walker, eds., Academic
Press, London, 1987); Handbook Of Experimental Immunology, Volumes
I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); and Manipulating
the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, N.Y., 1986).
[0048] Methods for Preparing Engineered T-Cells
[0049] In a general aspect, the present invention pertains to
methods for preparing engineered T-cells, in particular allogeneic
T-cells obtained from a donor.
[0050] Accordingly, the present invention provides a method for
preparing an engineered T-cell, preferably an allogeneic T-cell
obtained from a donor, said method comprises the steps of:
[0051] a) providing a T-cell, preferably an allogeneic T-cell
obtained from a donor; and
[0052] b) inhibiting the expression of beta 2-microglobulin (B2M)
and/or class II major histocompatibility complex transactivator
(CIITA) in said T-cell.
[0053] According to certain embodiments, the method comprises
inhibiting the expression of beta 2-microglobulin (B2M).
Alternatively, or in addition, the method may comprise inhibiting
the expression of class II major histocompatibility complex
transactivator (CIITA).
[0054] According to certain embodiments, inhibition of expression
of B2M is achieved by a genome modification, more particularly
through the expression in the T-cell of a rare-cutting endonuclease
able to selectively inactivate by DNA cleavage the gene encoding
B2M (e.g. the human .beta.2m gene set forth in SEQ ID NO: 2).
[0055] According to certain other embodiments, inhibition of
expression of CIITA is achieved by a genome modification, more
particularly through the expression in the T-cell of a rare-cutting
endonuclease able to selectively inactivate by DNA cleavage the
gene encoding CIITA (e.g. the human CIITA gene).
[0056] By "inactivating" or "inactivation of" a gene it is intended
that the gene of interest (e.g. the gene encoding B2M or CIITA) is
not expressed in a functional protein form. In particular
embodiments, the genetic modification of the method relies on the
expression, in provided cells to engineer, of a rare-cutting
endonuclease such that same catalyzes cleavage in one targeted gene
thereby inactivating said targeted gene. The nucleic acid strand
breaks caused by the endonuclease are commonly repaired through the
distinct mechanisms of homologous recombination or non-homologous
end joining (NHEJ). However, NHEJ is an imperfect repair process
that often results in changes to the DNA sequence at the site of
the cleavage. Mechanisms involve rejoining of what remains of the
two DNA ends through direct re-ligation (Critchlow and Jackson
1998) or via the so-called nnicrohomology-mediated end joining
(Betts, Brenchley et al. 2003; Ma, Kim et al. 2003). Repair via
non-homologous end joining (NHEJ) often results in small insertions
or deletions and can be used for the creation of specific gene
knockouts. Said modification may be a substitution, deletion, or
addition of at least one nucleotide. Cells in which a
cleavage-induced mutagenesis event, i.e. a mutagenesis event
consecutive to an NHEJ event, has occurred can be identified and/or
selected by well-known method in the art.
[0057] A rare-cutting endonuclease to be used in accordance of the
present invention to inactivate the .beta.2m gene may, for
instance, be a TAL-nuclease, meganuclease, zing-finger nuclease
(ZFN), or RNA guided endonuclease (such as Cas9).
[0058] According to a particular embodiment, the rare-cutting
endonuclease is a TAL-nuclease.
[0059] According to another particular embodiment, the rate-cutting
endonuclease is a homing endonuclease, also known under the name of
meganuclease.
[0060] According to another particular embodiment, the rare-cutting
endonuclease is a zing-finger nuclease (ZNF).
[0061] According to another particular embodiment, the rare-cutting
endonuclease is a RNA guided endonuclease. According to a preferred
embodiment, the RNA guided endonuclease is the Cas9/CRISPR
complex.
[0062] According to a specific embodiment, the rare-cutting
endonuclease is a TAL-nuclease encoded by a nucleic acid molecule
comprising the nucleotide sequence set for in SEQ ID NO: 67.
According to another specific embodiment, the rare-cutting
endonuclease is a TAL-nuclease encoded by a nucleic acid molecule
comprising the nucleotide sequence set for in SEQ ID NO: 68. In yet
another specific embodiment, the rare-cutting endonuclease is a
combination of a TAL-nuclease encoded by a nucleic acid molecule
comprising the nucleotide sequence set for in SEQ ID NO: 67 and a
TAL-nuclease encoded by a nucleic acid molecule comprising the
nucleotide sequence set for in SEQ ID NO: 68.
[0063] In order to be expressed in the T-cell, said rare-cutting
endonuclease may be introduced into the cell by way of an exogenous
nucleic acid molecule comprising a nucleotide sequence encoding
said rare-cutting endonuclease. According to particular
embodiments, the method of the invention further comprises
introducing into said T-cell an exogenous nucleic acid molecule
comprising a nucleotide sequence coding for a rare-cutting
endonuclease, preferably a rare-cutting endonuclease able to
selectively inactivate by DNA cleavage the gene encoding B2M (e.g.
the human .beta.2m gene set forth in SEQ ID NO: 2). For example,
the exogenous nucleic acid molecule may comprising the nucleotide
sequence set for in SEQ ID NO: 67 or SEQ ID NO: 68.
[0064] As a result, an engineered T-cell is obtained which
expresses a rare-cutting endonuclease, preferably a rare-cutting
endonuclease able to selectively inactivate by DNA cleavage the
gene encoding B2M. In consequence, inactivation of the B2M gene by
said rare-cutting endonuclease leads to the inhibition of the
expression of B2M in the engineered T-cell. Hence, an engineered
T-cell is obtained which is characterized in that the expression of
B2M is inhibited.
[0065] A rare-cutting endonuclease to be used in accordance of the
present invention to inactivate the CIITA gene may, for instance,
be a TAL-nuclease, meganuclease, zing-finger nuclease (ZFN), or RNA
guided endonuclease (such as Cas9).
[0066] According to a particular embodiment, the rare-cutting
endonuclease is a TAL-nuclease.
[0067] According to another particular embodiment, the rate-cutting
endonuclease is a homing endonuclease, also known under the name of
meganuclease.
[0068] According to another particular embodiment, the rare-cutting
endonuclease is a zing-finger nuclease (ZNF).
[0069] According to another particular embodiment, the rare-cutting
endonuclease is a RNA guided endonuclease. According to a preferred
embodiment, the RNA guided endonuclease is the Cas9/CRISPR
complex.
[0070] In order to be expressed in the T-cell, said rare-cutting
endonuclease may be introduced into the cell by way of an exogenous
nucleic acid molecule comprising a nucleotide sequence encoding
said rare-cutting endonuclease. According to particular
embodiments, the method of the invention further comprises
introducing into said T-cell an exogenous nucleic acid molecule
comprising a nucleotide sequence coding for a rare-cutting
endonuclease, preferably a rare-cutting endonuclease able to
selectively inactivate by DNA cleavage the gene encoding CIITA
(e.g. the human CIITA gene).
[0071] As a result, an engineered T-cell is obtained which
expresses a rare-cutting endonuclease, preferably a rare-cutting
endonuclease able to selectively inactivate by DNA cleavage the
gene encoding CIITA. In consequence, inactivation of the CIITA gene
by said rare-cutting endonuclease leads to the inhibition of the
expression of CIITA in the engineered T-cell. Hence, an engineered
T-cell is obtained which is characterized in that the expression of
CIITA is inhibited. According to certain other embodiments,
inhibition of expression of B2M is achieved by using (e.g.,
introducing into the T-cell) a nucleic acid molecule that
specifically hybridizes (e.g. binds) under cellular conditions with
the cellular mRNA and/or genomic DNA encoding B2M, thereby
inhibiting transcription and/or translation of the gene. In
accordance with particular embodiments, the inhibition of
expression of B2M is achieved by using (e.g., introducing into the
T-cell) an antisense oligonucleotide, ribozyme or interfering RNA
(RNAi) molecule.
[0072] According to a particular embodiment, the nucleic acid
molecule is an antisense oligonucleotide.
[0073] According to other particular embodiments, the nucleic acid
molecule is a ribozyme, preferably a hammerhead ribozyme.
[0074] According to other particular embodiments, the nucleic acid
is an interfering RNA (RNAi) molecule, such as a micro RNA (miRNA),
small interfering RNA (siRNA) or short hairpin RNA (shRNA). Hence,
in accordance with a preferred embodiment, the nucleic acid
molecule is a micro RNA. In accordance with another preferred
embodiment, the nucleic acid molecule is a small interfering RNA.
In accordance with another preferred embodiment, the nucleic acid
molecule is a short hairpin RNA.
[0075] As a result, an engineered T-cell is obtained which is
characterized in that the expression of B2M is inhibited.
[0076] Because B2M is an important structural component of the
major histocompatibility complex (MHC), inhibition of B2M
expression leads to a reduction or elimination of MHC molecules on
the surface of the engineered T-cell. In consequence, the
engineered T-cell no longer presents antigens on the surface which
are recognized by CD8+cells. Especially in case of an allogeneic
T-cell obtained from a donor, reduction or elimination of
nonself-antigen presenting MHC molecules on the surface of the
T-cell prevents the engineered T-cell, when infused into an
allogeneic host, from being recognized by the host CD8+cells. This
makes the engineered T-cell particular suitable for allogeneic
transplantations, especially because it reduces the risk of
rejection by the host's immune system.
[0077] According to certain other embodiments, inhibition of
expression of CIITA is achieved by using (e.g., introducing into
the T-cell) a nucleic acid molecule that specifically hybridizes
(e.g. binds) under cellular conditions with the cellular mRNA
and/or genomic DNA encoding CIITA, thereby inhibiting transcription
and/or translation of the gene. In accordance with particular
embodiments, the inhibition of expression of CIITA is achieved by
using (e.g., introducing into the T-cell) an antisense
oligonucleotide, ribozyme or interfering RNA (RNAi) molecule.
[0078] According to a particular embodiment, the nucleic acid
molecule is an antisense oligonucleotide.
[0079] According to other particular embodiment, the nucleic acid
molecule is a ribozyme, preferably a hammerhead ribozyme.
[0080] According to other particular embodiment, the nucleic acid
is an interfering RNA (RNAi) molecule, such as a micro RNA (miRNA),
small interfering RNA (siRNA) or short hairpin RNA (shRNA). Hence,
in accordance with a preferred embodiment, the nucleic acid
molecule is a micro RNA. In accordance with another preferred
embodiment, the nucleic acid molecule is a small interfering RNA.
In accordance with another preferred embodiment, the nucleic acid
molecule is a short hairpin RNA.
[0081] As a result, an engineered T-cell is obtained which is
characterized in that the expression of CIITA is inhibited. It is
also contemplated by the present invention that the engineered
T-cell of the present invention does not express a functional
T-cell receptor (TCR) on its cell surface. T-cell receptors are
cell surface receptors that participate in the activation of T
cells in response to the presentation of antigen. The TCR is
generally made from two chains, alpha and beta, which assemble to
form a heterodinner and associates with the CD3-transducing
subunits to form the T-cell receptor complex present on the cell
surface. Each alpha and beta chain of the TCR consists of an
immunoglobulin-like N-terminal variable (V) and constant (C)
region, a hydrophobic transmembrane domain, and a short cytoplasmic
region. As for immunoglobulin molecules, the variable region of the
alpha and beta chains are generated by V(D)J recombination,
creating a large diversity of antigen specificities within the
population of T cells. However, in contrast to immunoglobulins that
recognize intact antigen, T-cells are activated by processed
peptide fragments in association with an MHC molecule, introducing
an extra dimension to antigen recognition by T cells, known as MHC
restriction. Recognition of MHC disparities between the donor and
recipient through the T-cell receptor leads to T-cell proliferation
and the potential development of graft versus host disease (GVHD).
It has been shown that normal surface expression of the TCR depends
on the coordinated synthesis and assembly of all seven components
of the complex (Ashwell and Klusner 1990). The inactivation of TCR
alpha or TCR beta can result in the elimination of the TCR from the
surface of T-cells preventing recognition of alloantigen and thus
GVHD. The inactivation of at least one gene coding for a TCR
component thus renders the engineered T-cell less alloreactive. By
"inactivating" or "inactivation of" a gene it is meant that the
gene of interest (e.g., at least one gene coding for a TCR
component) is not expressed in a functional protein form.
[0082] Therefore, the method of the present invention in accordance
with particular embodiments further comprises inactivating at least
one gene encoding a component of the T-cell receptor. More
particularly, the inactivation is achieved by using (e.g.,
introducing into the T-cell) a rare-cutting endonuclease able to
selectively inactivate by DNA cleavage, preferably double-strand
break, at least one gene encoding a component of the T-Cell
receptor (TCR). According to particular embodiments, the
rare-cutting endonuclease is able to selectively inactivate by DNA
cleavage the gene coding for TCR alpha or TCR beta. According to a
preferred embodiment, the rare-cutting endonuclease is able to
selectively inactivate by DNA cleavage the gene coding for TCR
alpha. Especially in case of an allogeneic T-cell obtained from a
donor, inactivating of at least one gene encoding a component of
TCR, notably TCR alpha, leads to engineered T-cells, when infused
into an allogeneic host, which are non-alloreactive. This makes the
engineered T-cell particular suitable for allogeneic
transplantations, especially because it reduces the risk of graft
versus host disease.
[0083] A rare-cutting endonuclease to be used in accordance of the
present invention to inactivate at least one gene encoding a
component of the T-cell receptor may, for instance, be a
TAL-nuclease, meganuclease, zing-finger nuclease (ZFN), or RNA
guided endonuclease (such as Cas9).
[0084] According to a particular embodiment, the rare-cutting
endonuclease is a TAL-nuclease.
[0085] According to another particular embodiment, the rate-cutting
endonuclease is a homing endonuclease, also known under the name of
nneganuclease.
[0086] According to another particular embodiment, the rare-cutting
endonuclease is a zing-finger nuclease (ZNF).
[0087] According to another particular embodiment, the rare-cutting
endonuclease is a RNA guided endonuclease. According to a preferred
embodiment, the RNA guided endonuclease is the Cas9/CRISPR
complex.
[0088] In order to be expressed in the T-cell, said rare-cutting
endonuclease may be introduced into the cell by way of an exogenous
nucleic acid molecule comprising a nucleotide sequence encoding
said rare-cutting endonuclease. According to particular
embodiments, the method of the invention further comprises
introducing into said T-cell an exogenous nucleic acid molecule
comprising a nucleotide sequence coding for a rare-cutting
endonuclease able to selectively inactivate by DNA cleavage,
preferably double-strand break, at least one gene encoding a
component of the T-cell receptor (TCR).
[0089] As a result, an engineered T-cell is obtained which further
expresses a rare-cutting endonuclease able to selectively
inactivate by DNA cleavage at least one gene encoding a component
of the T-cell receptor (TCR). In consequence, an engineered T-cell
is obtained which is characterized in that at least at least one
gene encoding a component of the T-cell receptor (TCR) is
inactivated.
[0090] It is also contemplated by the present invention that the
engineered T-cell further expresses a Chimeric Antigen Receptor
(CAR) directed against at least one antigen expressed at the
surface of a malignant or infected cell. Hence, in accordance with
certain embodiments, the method of the invention furthers comprise
introducing into said T-cell an exogenous nucleic acid molecule
comprising a nucleotide sequence coding for a Chimeric Antigen
Receptor (CAR) directed against at least one antigen expressed at
the surface of a malignant or infected cell.
[0091] The T-cell to be modified according to the present invention
may be any suitable T-cell. For example, the T-cell can be an
inflammatory T-lymphocyte, cytotoxic T-lymphocyte, regulatory
T-cell or helper T-lymphocyte. Particularly, the T-cell is a
cytotoxic T-lymphocyte. In certain embodiments, said T-cell is
selected from CD4+ T-lymphocytes and CD8+ T-lymphocytes. They can
be extracted from blood or derived from stem cells. The stem cells
can be adult stem cells, embryonic stem cells, more particularly
non-human stem cells, cord blood stem cells, progenitor cells, bone
marrow stem cells, induced pluripotent stem cells, totipotent stem
cells or hematopoietic stem cells. Representative human cells are
CD34+cells. In particular embodiments, the T-cell to be modified
according to the present invention is a human T-cell. Prior to
expansion and genetic modification of the cells of the invention, a
source of cells can be obtained from a subject, such as a patient,
through a variety of non-limiting methods. T-cell can be obtained
from a number of non-limiting sources, including peripheral blood
mononuclear cells, bone marrow, lymph node tissue, cord blood,
thymus tissue, tissue from a site of infection, ascites, pleural
effusion, spleen tissue, and tumors. In certain embodiments of the
present invention, any number of T cell lines available and known
to those skilled in the art, may be used. In another embodiment,
said cell can be derived from a healthy donor, from a patient
diagnosed with cancer or from a patient diagnosed with an
infection. In another embodiment, said cell is part of a mixed
population of cells which present different phenotypic
characteristics.
[0092] Rare-Cutting Endonuclease
[0093] In accordance with certain embodiments of the present
invention, rare-cutting endonucleases are employed which are able
to selectively inactivate by DNA cleavage the gene of interest,
such as the gene encoding B2M.
[0094] The term "rare-cutting endonuclease" refers to a wild type
or variant enzyme capable of catalyzing the hydrolysis (cleavage)
of bonds between nucleic acids within a DNA or RNA molecule,
preferably a DNA molecule. Particularly, said nuclease can be an
endonuclease, more preferably a rare-cutting endonuclease which is
highly specific, recognizing nucleic acid target sites ranging from
10 to 45 base pairs (bp) in length, usually ranging from 10 to 35
base pairs in length, more usually from 12 to 20 base pairs. The
endonuclease according to the present invention recognizes at
specific polynucleotide sequences, further referred to as "target
sequence" and cleaves nucleic acid inside these target sequences or
into sequences adjacent thereto, depending on the molecular
structure of said endonuclease. The rare-cutting endonuclease can
recognize and generate a single- or double-strand break at specific
polynucleotides sequences.
[0095] In particular embodiments, said rare-cutting endonuclease
according to the present invention is a RNA-guided endonuclease
such as the Cas9/CRISPR complex. RNA guided endonucleases
constitute a new generation of genome engineering tool where an
endonuclease associates with a RNA molecule. In this system, the
RNA molecule nucleotide sequence determines the target specificity
and activates the endonuclease (Gasiunas, Barrangou et al. 2012;
Jinek, Chylinski et al. 2012; Cong, Ran et al. 2013; Mali, Yang et
al. 2013). Cas9, also named Csn1 is a large protein that
participates in both crRNA biogenesis and in the destruction of
invading DNA. Cas9 has been described in different bacterial
species such as S. thermophiles, Listeria innocua (Gasiunas,
Barrangou et al. 2012; Jinek, Chylinski et al. 2012) and S.
Pyogenes (Deltcheva, Chylinski et al. 2011). The large Cas9 protein
(>1200 amino acids) contains two predicted nuclease domains,
namely HNH (McrA-like) nuclease domain that is located in the
middle of the protein and a splitted RuvC-like nuclease domain
(RNase H fold). Cas9 variant can be a Cas9 endonuclease that does
not naturally exist in nature and that is obtained by protein
engineering or by random mutagenesis. Cas9 variants according to
the invention can for example be obtained by mutations i.e.
deletions from, or insertions or substitutions of at least one
residue in the amino acid sequence of a Si pyogenes Cas9
endonuclease (COG3513).
[0096] In other particular embodiments, said rare-cutting
endonuclease can also be a homing endonuclease, also known under
the name of meganuclease. Such homing endonucleases are well-known
to the art (Stoddard 2005). Homing endonucleases are highly
specific, recognizing DNA target sites ranging from 12 to 45 base
pairs (bp) in length, usually ranging from 14 to 40 bp in length.
The homing endonuclease according to the invention may for example
correspond to a LAGLIDADG endonuclease, to a HNH endonuclease, or
to a GIY-YIG endonuclease. Preferred homing endonuclease according
to the present invention can be an I-Crel variant. A "variant"
endonuclease, i.e. an endonuclease that does not naturally exist in
nature and that is obtained by genetic engineering or by random
mutagenesis can bind DNA sequences different from that recognized
by wild-type endonucleases (see international application
WO2006/097854).
[0097] In other particular embodiments, said rare-cutting
endonuclease can be a "Zinc Finger Nucleases" (ZFNs), which are
generally a fusion between the cleavage domain of the type IIS
restriction enzyme, Fokl, and a DNA recognition domain containing 3
or more C2H2 zinc finger motifs. The heterodimerization at a
particular position in the DNA of two individual ZFNs in precise
orientation and spacing leads to a double-strand break (DSB) in the
DNA. The use of such chimeric endonucleases have been extensively
reported in the art as reviewed by Urnov et a/. (Genome editing
with engineered zinc finger nucleases (2010) Nature reviews
Genetics 11:636-646). Standard ZFNs fuse the cleavage domain to the
C-terminus of each zinc finger domain. In order to allow the two
cleavage domains to dimerize and cleave DNA, the two individual
ZFNs bind opposite strands of DNA with their C-termini a certain
distance apart. The most commonly used linker sequences between the
zinc finger domain and the cleavage domain requires the 5' edge of
each binding site to be separated by 5 to 7 bp. The most
straightforward method to generate new zinc-finger arrays is to
combine smaller zinc-finger "modules" of known specificity. The
most common modular assembly process involves combining three
separate zinc fingers that can each recognize a 3 base pair DNA
sequence to generate a 3-finger array that can recognize a 9 base
pair target site. Numerous selection methods have been used to
generate zinc-finger arrays capable of targeting desired sequences.
Initial selection efforts utilized phage display to select proteins
that bound a given DNA target from a large pool of partially
randomized zinc-finger arrays. More recent efforts have utilized
yeast one-hybrid systems, bacterial one-hybrid and two-hybrid
systems, and mammalian cells.
[0098] In other particular embodiments, said rare-cutting
endonuclease is a "TALE-nuclease" or a "MBBBD-nuclease" resulting
from the fusion of a DNA binding domain typically derived from
Transcription Activator Like Effector proteins (TALE) or from a
Modular Base-per-Base Binding domain (MBBBD), with a catalytic
domain having endonuclease activity. Such catalytic domain usually
comes from enzymes, such as for instance I-Tevl, CoIE7, NucA and
Fok-I. TALE-nuclease can be formed under monomeric or dimeric forms
depending of the selected catalytic domain (WO2012138927). Such
engineered TALE-nucleases are commercially available under the
trade name TALEN.TM. (Cellectis, 8 rue de la Croix Jarry, 75013
Paris, France). In general, the DNA binding domain is derived from
a Transcription Activator like Effector (TALE), wherein sequence
specificity is driven by a series of 33-35 amino acids repeats
originating from Xanthomonas or Ralstonia bacterial proteins
AvrBs3, PthXo1, AvrHah1, PthA, Tal1c as non-limiting examples.
These repeats differ essentially by two amino acids positions that
specify an interaction with a base pair (Bach, Scholze et al. 2009;
Moscou and Bogdanove 2009). Each base pair in the DNA target is
contacted by a single repeat, with the specificity resulting from
the two variant amino acids of the repeat (the so-called repeat
variable dipeptide, RVD). TALE binding domains may further comprise
an N-terminal translocation domain responsible for the requirement
of a first thymine base (TO) of the targeted sequence and a
C-terminal domain that containing a nuclear localization signals
(NLS). A TALE nucleic acid binding domain generally corresponds to
an engineered core TALE scaffold comprising a plurality of TALE
repeat sequences, each repeat comprising a RVD specific to each
nucleotides base of a TALE recognition site. In the present
invention, each TALE repeat sequence of said core scaffold is made
of 30 to 42 amino acids, more preferably 33 or 34 wherein two
critical amino acids (the so-called repeat variable dipeptide, RVD)
located at positions 12 and 13 mediates the recognition of one
nucleotide of said TALE binding site sequence; equivalent two
critical amino acids can be located at positions other than 12 and
13 specially in TALE repeat sequence taller than 33 or 34 amino
acids long. Preferably, RVDs associated with recognition of the
different nucleotides are HD for recognizing C, NG for recognizing
T, NI for recognizing A, NN for recognizing G or A. In another
embodiment, critical amino acids 12 and 13 can be mutated towards
other amino acid residues in order to modulate their specificity
towards nucleotides A, T, C and G and in particular to enhance this
specificity. A TALE nucleic acid binding domain usually comprises
between 8 and 30 TALE repeat sequences. More preferably, said core
scaffold of the present invention comprises between 8 and 20 TALE
repeat sequences; again more preferably 15 TALE repeat sequences.
It can also comprise an additional single truncated TALE repeat
sequence made of 20 amino acids located at the C-terminus of said
set of TALE repeat sequences, i.e. an additional C-terminal half-
TALE repeat sequence. Other modular base-per-base specific nucleic
acid binding domains (MBBBD) are described in WO 2014/018601. Said
MBBBD can be engineered, for instance, from newly identified
proteins, namely EAV36_BURRH, E5AW43_BURRH, E5AW45_BURRH and
E5AW46_BURRH proteins from the recently sequenced genome of the
endosymbiont fungi Burkholderia Rhizoxinica. These nucleic acid
binding polypeptides comprise modules of about 31 to 33 amino acids
that are base specific. These modules display less than 40%
sequence identity with Xanthomonas TALE common repeats and present
more polypeptides sequence variability. The different domains from
the above proteins (modules, N and C-terminals) from Burkholderia
and Xanthomonas are useful to engineer new proteins or scaffolds
having binding properties to specific nucleic acid sequences and
may be combined to form chimeric TALE-MBBBD proteins.
[0099] Inhibitory Nucleic Acid Molecules
[0100] In accordance with certain other embodiments of the present
invention, nucleic acid molecules are employed which inhibit the
expression of B2M. More particularly, the nucleic acid may be an
antisense oligonucleotide, ribozyme or interfering RNA (RNAi)
molecule. Preferably, such nucleic acid molecule comprises at least
10 consecutive nucleotides of the complement of SEQ ID NO: 3.
[0101] According to particular embodiments, the inhibitory nucleic
acid is an antisense oligonucleotide which inhibits the expression
of B2M. Such antisense oligonucleotide is an nucleic acid (either
DNA or RNA) which specifically hybridizes (e.g. binds) under
cellular conditions with the cellular mRNA and/or genomic DNA
encoding B2M, thereby inhibiting transcription and/or translation
of the gene. The binding may be by conventional base pair
complementarity. Alternatively, the binding may be, for example, in
case of binding to DNA duplexes, through specific interactions in
the major groove of the double helix. Absolute complementarity,
although preferred, is not required.
[0102] Also contemplated by the present invention is that nucleic
acid molecules are employed which inhibit the expression ofCIITA.
More particularly, the nucleic acid may be an antisense
oligonucleotide, ribozyme or interfering RNA (RNAi) molecule.
Preferably, such nucleic acid molecule comprises at least 10
consecutive nucleotides of the complement of SEQ ID NO: 5.
[0103] Antisense oligonucleotides employed according to the
invention may be DNA or RNA or chimeric mixtures or derivatives or
modified versions thereof, and may be single-stranded or double
stranded. Thus, according to a preferred embodiment, the antisense
oligonucleotide is a single-stranded or double-stranded DNA
molecule, more preferably a double-stranded DNA molecule. According
to another preferred embodiment, the antisense oligonucleotide is a
single-stranded or double-stranded RNA molecule, more preferably a
single-stranded RNA molecule.
[0104] According to preferred embodiments, the antisense
oligonucleotide is a modified oligonucleotide which is resistant to
endogenous nucleases, e.g., exonucleases and/or endonucleases, and
is therefore stable in vivo and in vitro.
[0105] The antisense oligonucleotide may be modified at the base
moiety, sugar moiety, or phosphate backbone, for example, to
improve stability of the molecule. The antisense oligonucleotide
may include other appended groups such as peptides (e.g., for
targeting host cell receptors), or agents facilitating transport
across the cell membrane. Hence, the antisense oligonucleotide may
be conjugated to another molecule such as a peptide or transport
agent.
[0106] According to particular embodiments, the antisense
oligonucleotide comprises at least one modified base moiety which
is selected from the group including, but not limited to,
5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil,
hypoxanthine, xanthine, 4-acetylcytosine,
5-(carboxyhydroxytriethyl) uracil,
5-carboxymethylaminomethyl-2-thiouridine,
5-carboxymethylanninonnethyluracil, dihydrouracil,
beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,
1-nnethylguanine, 1-methylinosine, 2,2-dimethylguanine,
2-methyladenine, 2-methylguanine, 3-methylcytosine,
5-methylcytosine, N6-adenine, 7-nnethylguanine,
5-methylaminonnethyluracil, 5-methoxyaminomethyl-2-thiouracil,
beta-D-mannosylqueosine, 5-methoxycarboxymethyluracil,
5-methoxyuracil, 2-methylthio-N6-isopentenyladenine,
uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,
2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,
5-methyl uracil, uracil-5-oxyacetic acid methylester,
uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil,
3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w and
2,6-diaminopurine.
[0107] According to other particular embodiments, the antisense
oligonucleotide comprise at least one modified sugar moiety
selected from the group including, but not limited to, arabinose,
2-fluoroara binose, xylulose and hexose.
[0108] According to other particular embodiments, the antisense
oligonucleotide comprises at least one modified phosphate backbone
selected from the group including, but not limited to, a
phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a
phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl
phosphotriester, and a formacetal or analog thereof.
[0109] An antisense oligonucleotide may be delivered into the cell,
for example, in form of an expression vector, such as a plasmid or
viral vector, which, when transcribed in the cells, produces RNA
which is complementary to at least a unique portion of the cellular
mRNA for B2M. Alternatively, the antisense oligonucleotide may be
generated ex vivo and introduced into the cell by any known means
in the art. The antisense oligonucleotide may be synthesise ex vivo
by standard method known in the art, e.g., by use of an automated
DNA synthesizer (such as automated DNA synthesizer are commercially
available from, e.g., Applied Biosystems). A number of methods have
been developed for delivering antisense DNA or RNA to cells, e.g.
by direct injection or through modification designed to target the
desired cell (e.g., using antisense oligonucleotides linked to
peptides or antibodies that specifically bind receptors or antigens
expressed on the target cell surface.
[0110] According to preferred embodiments, a recombinant DNA vector
is used in which a nucleotide sequence coding for an antisense
oligonucleotide inhibiting the expression of B2M or CIITA is placed
under the control of a promoter, such as a strong pol III or pol II
promoter. The use of such a construct to transfect a target cell,
such as a T-cell, will result in the transcription of a sufficient
amount of single-stranded RNA that will form complementary base
pairs with the endogenous transcript and thereby prevent
translation of the B2M or CIITA mRNA. In accordance with these
embodiments, a DNA vector comprising the nucleotide sequence
encoding the antisense oligonucleotide is introduced into the cell
where the transcription of an antisense RNA occurs. Such vector can
remain episomal or be chromosomally integrated, as long as it can
be transcribed to produce the antisense RNA. The expression of the
sequence encoding the antisense RNA can be by any promoter known in
the art to act in mammalian, preferably human cells. Such promoter
can be inducible or constitutive. Exemplary promoters include, but
are not limited to, the SV40 early promoter region, the promoter
containing the 3' long terminal repeat of Rous sarcoma virus, the
herpes thymidine promoter, and the regulatory sequences of the
methallothionein gene.
[0111] Alternatively, antisense cDNA constructs that synthesize
antisense RNA constitutively or inducibly, depending on the
promoter used, can be introduced into the cell.
[0112] According to preferred embodiments, the antisense
oligonucleotide comprises at least 10 consecutive nucleotides of
the complement of SEQ ID NO: 3. In case of a double stranded
molecule, such double-stranded antisense oligonucleotide comprises
a first strand comprising at least 10 consecutive nucleotide of SEQ
ID NO: 3, and a second strand complementary to said first strand.
In case of a single-stranded molecule, such single-stranded
oligonucleotide comprises at least 10 consecutive nucleotides of
the complement of SEQ ID NO: 3.
[0113] According to other preferred embodiments, the antisense
oligonucleotide comprises at least 10 consecutive nucleotides of
the complement of SEQ ID NO: 5. In case of a double stranded
molecule, such double-stranded antisense oligonucleotide comprises
a first strand comprising at least 10 consecutive nucleotide of SEQ
ID NO: 5, and a second strand complementary to said first strand.
In case of a single-stranded molecule, such single-stranded
oligonucleotide comprises at least 10 consecutive nucleotides of
the complement of SEQ ID NO: 5.
[0114] The antisense oligonucleotide may comprise a nucleotide
sequence complementary to a non-coding or a coding region of the
B2M or CIITA mRNA. According to preferred embodiments, the
antisense oligonucleotide comprises a nucleotide sequence
complementary to the 5' end of the B2M or CIITA mRNA, e.g., the 5'
untranslated sequence up to and including the AUG initiation codon.
According to other preferred embodiments, the antisense
oligonucleotide comprises a nucleotide sequence complementary to
the 3' untranslated sequence of the B2M or CIITA mRNA. According to
other preferred embodiments, the antisense oligonucleotide
comprises a nucleotide sequence complementary to the coding region
of the B2M or CIITA mRNA. Whether designed to hybridize to the 5',
3' or coding region of the B2M or CIITA mRNA, an antisense
oligonucleotide should be at least six nucleotides in length,
preferably at least 10 nucleotide in length, and is preferably less
than about 100, and more preferably less than about 50, 25, 20, 15
or 10 nucleotides in length. According to preferred embodiments,
the antisense oligonucleotide is 6 to 25, such as 10 to 25
nucleotides in length.
[0115] In accordance with other particular embodiments, a ribozyme
molecule designed to catalytically cleave the B2M or CIITA mRNA
transcript is used to prevent translation and expression of B2M or
CIITA in the T-cell, respectively (see, e.g., WO 90/11364 and U.S.
Pat. No. 5,093,246 for general guidance). According to preferred
embodiments, the ribozyme is a hammerhead ribozyme. Hammerhead
ribozymes cleave mRNAs at locations dictated by flanking regions
that form complementary base pairs with the target mRNA, e.g. the
B2M mRNA, such as the human B2M mRNA set forth in SEQ ID NO: 3. The
sole requirement is that the target mRNA has the following sequence
of two bases: 5'-UG-3'. The constructions and production of
hammerhead ribozymes is well known in the art and is described in
more detail in Haseloff and Gerlach (1988). In accordance with
preferred embodiments, the ribozyme is engineered such that the
cleavage recognition site is located near the 5' end of the B2M
mRNA. In accordance with preferred other embodiments, the ribozyme
is engineered such that the cleavage recognition site is located
near the 5' end of the CIITA mRNA. This increases the efficiency
and minimizes the intracellular accumulation of non-functional mRNA
transcripts.
[0116] Like with antisense oligonucleotides, a riboyzme used in
accordance with the invention may be composed of modified
oligonucleotides to, e.g., improve stability. The ribozyme may be
delivered to the cell by any means known in the art. The ribozyme
may be delivered to the T-cell in form of an expression vector,
such as a plasmid or viral vector, which, when transcribed in the
cells, produces the ribozyme. According to preferred embodiments, a
recombinant DNA vector is used in which a nucleotide sequence
coding for the ribozyme is placed under the control of a promoter,
such as a strong pol III or pol II promoter, so that a transfected
cell will produce sufficient amounts of the ribozyme to destroy
endogenous mRNA and inhibit translation. Because riboyzmes, unlike
antisense oligonucleotides, are cataylitc, a lower intracellular
concentration is required for efficiency.
[0117] In accordance with other particular embodiments, the
inhibitory nucleic acid is an interfering RNA (RNAi) molecule. RNA
interference is a biological process in which RNA molecules inhibit
gene expression, typically causing the destruction of specific
mRNA. Exemplary types of RNAi molecules include microRNA (miRNA),
small interfering RNA (siRNA) and short hairpin RNA (shRNA).
According to a preferred embodiment, the RNAi molecule is a miRNA.
According to another preferred embodiment, the RNAi molecule is a
siRNA. According to yet another preferred embodiment, the RNAi
molecule is a shRNA. The production of RNAi molecules in vivo and
in vitro and their methods of use are described in, e.g., U.S. Pat.
No. 6,506,559, WO 01/36646, WO 00/44895, US2002/01621126,
US2002/0086356, US2003/0108923, WO 02/44321, WO 02/055693, WO
02/055692 and WO 03/006477.
[0118] In accordance with a preferred embodiment, the RNAi molecule
is an interfering RNA complementary to SEQ ID NO: 3. In accordance
to another preferred embodiment, the RNAi molecule is a ribonucleic
acid molecule comprising at least 10 consecutive nucleotides of the
complement of SEQ ID NO: 3. In accordance with another preferred
embodiment, the RNAi molecule is a double-stranded ribonucleic acid
molecule comprising a first strand identical to 20 to 25, such as
21 to 23, consecutive nucleotides of SEQ ID NO: 3, and a second
strand complementary to said first strand.
[0119] In accordance with a preferred embodiment, the RNAi molecule
is an interfering RNA complementary to SEQ ID NO: 5. In accordance
to another preferred embodiment, the RNAi molecule is a ribonucleic
acid molecule comprising at least 10 consecutive nucleotides of the
complement of SEQ ID NO: 5. In accordance with another preferred
embodiment, the RNAi molecule is a double-stranded ribonucleic acid
molecule comprising a first strand identical to 20 to 25, such as
21 to 23, consecutive nucleotides of SEQ ID NO: 5, and a second
strand complementary to said first strand.
[0120] Engineering of the PD1/PDL1 Pathway of T-Cell Regulation
[0121] The present invention aims at facilitating the engraftment
of T-cells, especially allogeneic T-cells, preferably by inhibiting
the expression of B2M and/or CIITA in combination with inactivation
of TCR.
[0122] As an alternative to or in combination with this approach,
the inventors have found that T-cells can be disrupted for PD1
(Programmed cell death protein 1, also known as PD1; PD-1; CD279;
SLEB2; hPD-1; hPD-I or hSLE1), which is a 288 amino acid cell
surface protein molecule encoded by the PDCD1 gene
(NCBI-NC_000002.12). This protein is expressed on T cells and pro-B
cells and has been found to negatively regulate T-cell responses
(Carter L., et al., 2002). The formation of PD-1 receptor/PD-L1
ligand complex transmits an inhibitory signal, which reduces the
proliferation of T-cells.
[0123] Programmed death ligand 1 (PD-L1) is a 40 kDa type 1
transmembrane protein that is deemed to .sub.playa major role in
suppressing the immune system during particular events such as
pregnancy, tissue allografts, autoimmune disease and other disease
states such as hepatitis. PDL-1 (also called CD274 or B7H1) is
encoded by CD274 gene (NCBI-NM_014143).
[0124] According to a particular aspect, the expression of both
PD-1 and TCR are inhibited in the engineered T-cells of the
invention, which has the dual effect of activating the T-cells as
part of an allogeneic transplantation. However, the inactivation or
inhibition of PD-1 can be also implemented as part of an autologous
transplantation of T-cells, where the inhibition or disruption of
TCR would not be required.
[0125] According to a further aspect of the invention, the
inhibition or disruption of PD1 is combined with the
over-expression of its ligand PDL-1 in the transplanted T-cells.
This over-expression can be obtained, for instance, upon lentiviral
or retroviral transformation in T-cells, in which PD-1 is inhibited
or disrupted, or by any other means reported in the art.
Accordingly, PDL1 that is over-expressed by the T-cells will not
affect the [PD1.sup.-] transplanted cells, but only the [PD1.sup.+]
T-cells from the patient. As a result, the T-cells from the patient
are inhibited and do not activate against the transplanted cells,
which facilitates their engraftment and persistence into the
host.
[0126] According to a preferred embodiment, the invention provides
engineered T-cells which are [PD1.sup.-][TCR.sup.-], while
overexpressing PDL1 to facilitate their transplantation into a
patient, in particular as part of an immunotherapy.
[0127] Expression of at Least One Non-Endogenous Immunosuppressive
Polypeptide
[0128] According to some preferred embodiments, the inhibition of
the expression of the beta-2m and/or the CIITA is carried out with
an additional step of expression in said T-cell of at least one
non-endogenous immunosuppressive polypeptide.
[0129] By "non-endogenous" polypeptide is meant a polypeptide not
normally expressed by a donor's immune cell, preferably a
polypeptide expressed by an exogenous polynucleotide that has been
imported into the immune's cell genome. For instance, IL12 is not
considered hereby as being a non-endogenous polypeptide because it
is expressed from a preexisting gene from the donor's immune
cell.
[0130] By "immunosuppressive" is meant that the expression of said
non-endogenous polypeptide has the effect of alleviating the immune
response of the patient host against the donor's immune cells.
[0131] The method of the present invention may thus comprise
introducing into said T-cell an exogenous nucleic acid molecule
comprising a nucleotide sequence coding for at least one
non-endogenous immunosuppressive polypeptide, such as a viral MHC
homolog or an NKG2D ligand.
[0132] Expression of Viral MHC Homoloq
[0133] According to particularly preferred embodiments, said
non-endogenous immunosuppressive polypeptide expressed in said
T-cell is a viral MHC homolog, such as for instance UL18 (referred
to as NP_044619 in the NCBI protein database).
[0134] According to these embodiments, the method of the present
invention may thus comprise introducing into said T-cell an
exogenous nucleic acid molecule comprising a nucleotide sequence
coding for a viral MHC homolog, such as UL18. The exogenous nucleic
acid molecule may comprise a nucleotide sequence coding for a
polypeptide sharing at least 80%, preferably at least 90% and more
preferably at least 95% of identity with SEQ ID NO: 89.
[0135] The interaction between the allogeneic T cell and host
immune cells is schematically represented in FIG. 8 (expression of
viral MHC homolog) in regard to the situation to FIG. 7 (no
expression). In both figures, the MHC class I is preferably
inactivated by disrupting (KO) the beta2M gene.
[0136] Expression of NKG2D Ligand
[0137] Some viruses such as cytomegaloviruses have acquired
mechanisms to avoid NK cell mediate immune surveillance and
interfere with the NKG2D pathway by secreting a protein able to
bind NKG2D ligands and prevent their surface expression (Welte, S.
A.; Sinzger, C.; Lutz, S. Z.; Singh-Jasuja, H.; Sampaio, K. L.;
Eknigk, U.; Rammensee, H. G.; Steinle, A. 2003 "Selective
intracellular retention of virally induced NKG2D ligands by the
human cytomegalovirus UL16 glycoprotein". Eur. J. Immunol., 33,
194-203). In tumors cells, some mechanisms have evolved to evade
NKG2D response by secreting NKG2D ligands such as ULBP2, MICB or
MICA (Salih H R, Antropius H, Gieseke F, Lutz S Z, Kanz L, et al.
(2003) Functional expression and release of ligands for the
activating immunoreceptor NKG2D in leukemia. Blood 102:
1389-1396)
[0138] According to other particularly preferred embodiments, the
non-endogenous immunosuppressive polypeptide to be expressed in
said T-cell is an NKG2D ligand.
[0139] According to these embodiments, the method of the present
invention may thus comprise introducing into said T-cell an
exogenous nucleic acid molecule comprising a nucleotide sequence
coding for an NKG2D ligand. The nucleic acid molecule may comprise
a nucleotide sequence coding for a polypeptide sharing at least
80%, preferably at least 90% and more preferably at least 95% of
identity with any one of SEQ ID NO: 90-97.
[0140] The interaction between the allogeneic T cell and host
immune cells is schematically represented in FIG. 9 (expression of
soluble NKG2D ligand) in regard to the situation to FIG. 7 (no
expression). In both figures, the MHC class I is inactivated by
disrupting (KO) the beta2M gene.
[0141] The Table 10 presented further in the text represents a
viral MHC honnolog (UL18) and a panel of NKG2D ligands and their
polypeptide sequence to be expressed according to the present
invention.
[0142] Chimeric Antigen Receptors (CARs)
[0143] Adoptive immunotherapy, which involves the transfer of
autologous antigen-specific T-cells generated ex vivo, is a
promising strategy to treat cancer or viral infections. The T-cells
used for adoptive immunotherapy can be generated either by
expansion of antigen-specific T cells or redirection of T cells
through genetic engineering (Park, Rosenberg et al. 2011). Transfer
of viral antigen specific T-cells is a well-established procedure
used for the treatment of transplant associated viral infections
and rare viral-related malignancies. Similarly, isolation and
transfer of tumor specific T cells has been shown to be successful
in treating melanoma.
[0144] Novel specificities in T-cells have been successfully
generated through the genetic transfer of transgenic T-cell
receptors or chimeric antigen receptors (CARs) (Jena, Dotti et al.
2010). CARs are synthetic receptors consisting of a targeting
moiety that is associated with one or more signaling domains in a
single fusion molecule. In general, the binding moiety of a CAR
consists of an antigen-binding domain of a single-chain antibody
(scFv), comprising the light and variable fragments of a monoclonal
antibody joined by a flexible linker. Binding moieties based on
receptor or ligand domains have also been used successfully. The
signaling domains for first generation CARs are derived from the
cytoplasmic region of the CD3zeta or the Fc receptor gamma chains.
First generation CARs have been shown to successfully redirect T
cell cytotoxicity, however, they failed to provide prolonged
expansion and anti-tumor activity in vivo. Signaling domains from
co-stimulatory molecules including CD28, OX-40 (CD134), and 4-1BB
(CD137) have been added alone (second generation) or in combination
(third generation) to enhance survival and increase proliferation
of CAR modified T-cells. CARs have successfully allowed T-cells to
be redirected against antigens expressed at the surface of tumor
cells from various malignancies including lymphomas and solid
tumors (Jena, Dotti et al. 2010).
[0145] CD19 is an attractive target for immunotherapy because the
vast majority of B-acute lymphoblastic leukemia (B-ALL) uniformly
express CD19, whereas expression is absent on non hematopoietic
cells, as well as myeloid, erythroid, and T cells, and bone marrow
stem cells. Clinical trials targeting CD19 on B-cell malignancies
are underway with encouraging anti-tumor responses. Most infuse T
cells genetically modified to express a chimeric antigen receptor
(CAR) with specificity derived from the scFv region of a
CD19-specific mouse monoclonal antibody FMC63 (WO2013/126712).
[0146] Therefore, in accordance with certain embodiments, the
Chimeric Antigen Receptor expressed by the engineered T-cell is
directed against the B-lymphocyte antigen CD19.
[0147] In accordance with certain embodiments, the Chimeric Antigen
Receptor is a single chain Chimeric Antigen Receptor. As an example
of single-chain Chimeric Antigen Receptor to be expressed in the
engineered T-cells according to the present invention is a single
polypeptide that comprises at least one extracellular ligand
binding domain, a transmembrane domain and at least one signal
transducing domain, wherein said extracellular ligand binding
domain comprises a scFV derived from the specific anti-CD19
monoclonal antibody 4G7. Once transduced into the T-cell, for
instance by using retroviral or lentiviral transduction, this CAR
contributes to the recognition of CD19 antigen present at the
surface of malignant B-cells involved in lymphoma or leukemia.
[0148] In accordance with particular embodiments, the Chimeric
Antigen Receptor is a polypeptide comprising the amino acid
sequence forth in SEQ ID NO: 6 or a variant thereof comprising an
amino acid sequence that has at least 70%, such as at least 80%, at
least 90%, at least 95%, or at least 99%, sequence identity with
the amino acid sequence set forth in SEQ ID NO: 6 over the entire
length of SEQ ID NO: 6. Preferably, the variant is capable of
binding CD19.
[0149] A particularly preferred Chimeric Antigen Receptor is a
polypeptide comprising the amino acid sequence set forth in SEQ ID
NO: 7 or a variant thereof comprising an amino acid sequence that
has at least 80%, such as at least 90%, at least 95%, or at least
99%, sequence identity with the amino acid sequence set forth in
SEQ ID NO: 7 over the entire length of SEQ ID NO: 7. Such variant
may differ from the polypeptide set forth in SEQ ID NO: 7 in the
substitution of at least one, at least two or at least three amino
acid residue(s). Preferably, said variant is capable of binding
CD19.
[0150] In accordance with other certain embodiments, the Chimeric
Antigen Receptor may be directed against another antigen expressed
at the surface of a malignant or infected cell, such as a cluster
of differentiation molecule, such as CD16, CD64, CD78, CD96,CLL1,
CD116, CD117, CD71, CD45, CD71, CD123 and CD138, a tumor-associated
surface antigen, such as ErbB2 (HER2/neu), carcinoembryonic antigen
(CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth
factor receptor (EGFR), EGFR variant III (EGFRvIII), CD19, CD20,
CD30, CD40, disialoganglioside GD2, ductal-epithelial mucine, gp36,
TAG-72, glycosphingolipids, glioma-associated antigen, .beta.-human
chorionic gonadotropin, alphafetoprotein (AFP), lectin-reactive
AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse
transcriptase, RU1, RU2 (AS), intestinal carboxyl esterase, mut
hsp70-2, M-CSF, prostase, prostase specific antigen (PSA), PAP,
NY-ESO-1, LAGA-1a, p53, prostein, PSMA, surviving and telomerase,
prostate-carcinoma tumor antigen-1 (PCTA-1), MAGE, ELF2M,
neutrophil elastase, ephrin B2, CD22, insulin growth factor
(IGF1)-I, IGF-II, IGFI receptor, mesothelin, a major
histocompatibility complex (MHC) molecule presenting a
tumor-specific peptide epitope, 5T4, ROR1, Nkp30, NKG2D, tumor
stromal antigens, the extra domain A (EDA) and extra domain B (EDB)
of fibronectin and the A1 domain of tenascin-C (TnC A1) and
fibroblast associated protein (fap); a lineage-specific or tissue
specific antigen such as CD3, CD4, CD8, CD24, CD25, CD33, CD34,
CD133, CD138, CTLA-4, B7-1 (CD80), B7-2 (CD86), GM-CSF, cytokine
receptors, endoglin, a major histocompatibility complex (MHC)
molecule, BCMA (CD269, TNFRSF 17), multiple myeloma or
lymphoblastic leukaemia antigen, such as one selected from TNFRSF17
(UNIPROT Q02223), SLAMF7 (UNIPROT Q9NQ25), GPRC5D (UNIPROT Q9NZD1),
FKBP11 (UNIPROT Q9NYL4), KAMP3, ITGA8 (UNIPROT P53708), and FCRL5
(UNIPROT Q68SN8). a virus-specific surface antigen such as an
HIV-specific antigen (such as HIV gp120); an EBV-specific antigen,
a CMV-specific antigen, a HPV-specific antigen, a Lasse
Virus-specific antigen, an Influenza Virus-specific antigen as well
as any derivate or variant of these surface antigens.
[0151] In other certain embodiments, the Chimeric Antigen Receptor
is a multi-chain Chimeric Antigen Receptor. Chimeric Antigen
Receptors from the prior art introduced in T-cells have been formed
of single chain polypeptides that necessitate serial appending of
signaling domains. However, by moving signaling domains from their
natural juxtamembrane position may interfere with their function.
To overcome this drawback, the applicant recently designed a
multi-chain CAR derived from Fc.epsilon.RI to allow normal
juxtamembrane position of all relevant signaling domains. In this
new architecture, the high affinity IgE binding domain of
Fc.epsilon.RI alpha chain is replaced by an extracellular
ligand-binding domain such as scFy to redirect T-cell specificity
against cell targets and the N and/or C-termini tails of
Fc.epsilon.RI beta chain are used to place costimulatory signals in
normal juxtamembrane positions as described in WO 2013/176916.
[0152] Accordingly, a CAR expressed by the engineered T-cell
according to the invention can be a multi-chain chimeric antigen
receptor particularly adapted to the production and expansion of
engineered T-cells of the present invention. Such multi-chain CARs
comprise at least two of the following components: [0153] a) one
polypeptide comprising the transmembrembrane domain of
Fc.epsilon.RI alpha chain and an extracellular ligand-binding
domain, [0154] b) one polypeptide comprising a part of N- and C-
terminal cytoplasmic tail and the transmembrane domain of
Fc.epsilon.RI beta chain and/or [0155] c) at least two polypeptides
comprising each a part of intracytoplasmic tail and the
transmembrane domain of Fc.epsilon.RI gamma chain, whereby
different polypeptides multimerize together spontaneously to form
dimeric, trimeric or tetrameric CAR.
[0156] According to such architectures, ligands binding domains and
signaling domains are born on separate polypeptides. The different
polypeptides are anchored into the membrane in a close proximity
allowing interactions with each other. In such architectures, the
signaling and co-stimulatory domains can be in juxtamembrane
positions (i.e. adjacent to the cell membrane on the internal side
of it), which is deemed to allow improved function of
co-stimulatory domains. The multi-subunit architecture also offers
more flexibility and possibilities of designing CARs with more
control on T-cell activation. For instance, it is possible to
include several extracellular antigen recognition domains having
different specificity to obtain a multi-specific CAR architecture.
It is also possible to control the relative ratio between the
different subunits into the multi-chain CAR. This type of
architecture has been recently detailed by the applicant in
PCT/US2013/058005.
[0157] The assembly of the different chains as part of a single
multi-chain CAR is made possible, for instance, by using the
different alpha, beta and gamma chains of the high affinity
receptor for IgE (Fc.epsilon.RI) (Metzger, Alcaraz et al. 1986) to
which are fused the signaling and co-stimulatory domains. The gamma
chain comprises a transmembrane region and cytoplasmic tail
containing one immunoreceptor tyrosine-based activation motif
(ITAM) (Cambier 1995).
[0158] The multi-chain CAR can comprise several extracellular
ligand-binding domains, to simultaneously bind different elements
in target thereby augmenting immune cell activation and function.
In one embodiment, the extracellular ligand-binding domains can be
placed in tandem on the same transmembrane polypeptide, and
optionally can be separated by a linker. In another embodiment,
said different extracellular ligand-binding domains can be placed
on different transmembrane polypeptides composing the multi-chain
CAR.
[0159] The signal transducing domain or intracellular signaling
domain of the multi-chain CAR(s) of the invention is responsible
for intracellular signaling following the binding of extracellular
ligand binding domain to the target resulting in the activation of
the immune cell and immune response. In other words, the signal
transducing domain is responsible for the activation of at least
one of the normal effector functions of the immune cell in which
the multi-chain CAR is expressed. For example, the effector
function of a T cell can be a cytolytic activity or helper activity
including the secretion of cytokines.
[0160] In the present application, the term "signal transducing
domain" refers to the portion of a protein which transduces the
effector signal function signal and directs the cell to perform a
specialized function.
[0161] Preferred examples of signal transducing domain for use in
single or multi-chain CAR can be the cytoplasmic sequences of the
Fc receptor or T cell receptor and co-receptors that act in concert
to initiate signal transduction following antigen receptor
engagement, as well as any derivate or variant of these sequences
and any synthetic sequence that as the same functional capability.
Signal transduction domain comprises two distinct classes of
cytoplasmic signaling sequence, those that initiate
antigen-dependent primary activation, and those that act in an
antigen-independent manner to provide a secondary or co-stimulatory
signal. Primary cytoplasmic signaling sequence can comprise
signaling motifs which are known as imnnunoreceptor tyrosine-based
activation motifs of ITAMs. ITAMs are well defined signaling motifs
found in the intracytoplasmic tail of a variety of receptors that
serve as binding sites for syk/zap70 class tyrosine kinases.
Examples of ITAM used in the invention can include as non-limiting
examples those derived from TCRzeta, FcRgamma, FcRbeta, FcRepsilon,
CD3gamnna, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b and CD66d.
According to particular embodiments, the signaling transducing
domain of the multi-chain CAR can comprise the CD3zeta signaling
domain, or the intracytoplasmic domain of the Fc.epsilon.RI beta or
gamma chains.
[0162] According to particular embodiments, the signal transduction
domain of multi-chain CARs of the present invention comprises a
co-stimulatory signal molecule. A co-stimulatory molecule is a cell
surface molecule other than an antigen receptor or their ligands
that is required for an efficient immune response.
[0163] Ligand binding-domains can be any antigen receptor
previously used, and referred to, with respect to single-chain CAR
referred to in the literature, in particular scFv from monoclonal
antibodies.
[0164] Engineered T-Cells
[0165] As a result of the present invention, engineered T-cells can
be obtained having improved characteristics. In particular, the
present invention provides an engineered, preferably isolated,
T-cell which is characterized in that the expression of B2M and/or
CIITA is inhibited.
[0166] According to certain embodiments, the present invention
provides an engineered, preferably isolated, T-cell which expresses
a rare-cutting endonuclease able to selectively inactivate by DNA
cleavage, preferably double-strand break, the gene encoding B2M.
According to particular embodiments, said T-cell comprises an
exogenous nucleic acid molecule comprising a nucleotide sequence
encoding said rare-cutting endonuclease. According to more
particular embodiments, said rare-cutting endonuclease is a
TAL-nuclease, meganuclease, zinc-finger nuclease (ZFN), or RNA
guided endonuclease. Hence, in accordance with a specific
embodiment, the rare-cutting endonuclease is a TAL-nuclease. In
accordance with another specific embodiment, the rare-cutting
endonuclease is a meganuclease. In accordance with another specific
embodiment, the rare-cutting endonuclease is a zinc-finger
nuclease. In accordance with yet another specific embodiment, the
rare-cutting endonuclease is a RNA guided endonuclease, such as
Cas9.
[0167] According to certain other embodiments, the present
invention provides an engineered, preferably isolated, T-cell which
comprises an exogenous nucleic acid molecule that inhibits the
expression of B2M. According to particular embodiments, said T-cell
comprises an exogenous nucleic acid molecule comprising a
nucleotide sequence encoding a nucleic acid molecule that inhibits
the expression of B2M. According to more particular embodiments,
the nucleic acid molecule that inhibits the expression of B2M is an
antisense oligonucleotide, ribozyme or interfering RNA (RNAi)
molecule. Hence, in accordance with a specific embodiment, nucleic
acid molecule that inhibits the expression of B2M is an antisense
oligonucleotide. In accordance with another specific embodiment,
nucleic acid molecule that inhibits the expression of B2M is a
ribozyme, and preferably a hammerhead riboyzme. In accordance with
another specific embodiment, nucleic acid molecule that inhibits
the expression of B2M is an interfering RNA molecule.
[0168] According to certain embodiments, the present invention
provides an engineered, preferably isolated, T-cell which expresses
a rare-cutting endonuclease able to selectively inactivate by DNA
cleavage, preferably double-strand break, the gene encoding CIITA.
According to particular embodiments, said T-cell comprises an
exogenous nucleic acid molecule comprising a nucleotide sequence
encoding said rare-cutting endonuclease. According to more
particular embodiments, said rare-cutting endonuclease is a
TAL-nuclease, meganuclease, zinc-finger nuclease (ZFN), or RNA
guided endonuclease. Hence, in accordance with a specific
embodiment, the rare-cutting endonuclease is a TAL-nuclease. In
accordance with another specific embodiment, the rare-cutting
endonuclease is a meganuclease. In accordance with another specific
embodiment, the rare-cutting endonuclease is a zinc-finger
nuclease. In accordance with yet another specific embodiment, the
rare-cutting endonuclease is a RNA or DNA guided endonuclease, such
as Cas9 or Argonaute.
[0169] According to certain other embodiments, the present
invention provides an engineered, preferably isolated, T-cell which
comprises an exogenous nucleic acid molecule that inhibits the
expression of CIITA. According to particular embodiments, said
T-cell comprises an exogenous nucleic acid molecule comprising a
nucleotide sequence encoding a nucleic acid molecule that inhibits
the expression of CIITA. According to more particular embodiments,
the nucleic acid molecule that inhibits the expression of CIITA is
an antisense oligonucleotide, ribozyme or interfereing RNA (RNAi)
molecule. Hence, in accordance with a specific embodiment, nucleic
acid molecule that inhibits the expression of CIITA is an antisense
oligonucleotide. In accordance with another specific embodiment,
nucleic acid molecule that inhibits the expression of CIITA is a
ribozyme, and preferably a hammerhead riboyzme. In accordance with
another specific embodiment, nucleic acid molecule that inhibits
the expression of CIITA is an interfering RNA molecule.
[0170] According to certain embodiments, the engineered T-cell
further expresses a rare-cutting endonuclease able to selectively
inactivate by DNA cleavage, preferably double-strand break, at
least one gene coding for a component of the T-cell receptor (TCR),
such as TCR alpha. According to particular embodiments, said T-cell
comprises an exogenous nucleic acid molecule comprising a
nucleotide sequence encoding said rare-cutting endonuclease.
[0171] According to certain embodiments, the engineered T-cell
further comprises expresses a Chimeric Antigen Receptor (CAR)
directed against at least one antigen expressed at the surface of a
malignant or infected cell. According to particular embodiments,
said T-cell comprises an exogenous nucleic acid molecule comprising
a nucleotide sequence encoding said CAR.
[0172] According to some embodiments, the present invention
provides an engineered, preferably isolated, T-cell which expresses
at least one non-endogenous immune-suppressive polypeptide.
According to particular embodiments, said non-endogenous
immune-suppressive polypeptide is a viral MHC homolog, such as
UL18. The T-cell may thus comprise an exogenous nucleic acid
molecule comprising a nucleotide sequence coding for a polypeptide
sharing at least 80%, preferably at least 90% and more preferably
at least 95% of identity with SEQ ID NO: 89. According to other
particular embodiments, said non-endogenous immune-suppressive
polypeptide is a NKG2D ligand. The T-cell may thus comprise an
exogenous nucleic acid molecule comprising a nucleotide sequence
coding for a polypeptide sharing at least 80%, preferably at least
90% and more preferably at least 95% of identity with any one of
SEQ ID NO: 90-97.
[0173] It is understood that the details given herein in
particularly with respect to the rare-cutting endonuclease able to
selectively inactivate by DNA cleavage the gene encoding B2M, the
nucleic acid molecule that inhibits the expression of B2M, the
rare-cutting endonuclease able to selectively inactivate by DNA
cleavage at least one gene coding for a component of the T-cell
receptor (TCR), and the Chimeric Antigen Receptor also apply to
this aspect of the invention.
[0174] Further, in the scope of the present invention is also
encompassed a cell or cell line obtained from an engineered T-cell
according to the invention, preferably displaying one of these
phenotypes:
[0175] [b2m].sup.-[TCR].sup.-
[0176] [TCR].sup.-[PD1].sup.-[PDL-1].sup.+
[0177] [b2m].sup.-[TCR].sup.-[PD1].sup.+
[0178] [b2m].sup.-[TCR].sup.-[PD1].sup.-[PDL-1].sup.+
[0179] [b2m].sup.-[viral MHC homolog].sup.+
[0180] [b2m].sup.-[TCR].sup.-[viral MHC homolog].sup.+
[0181] [b2m].sup.-[NKG2D ligand].sup.+
[0182] [b2m].sup.-[TCR].sup.-[NKG2D ligand].sup.+
[0183] The T cells according to the present invention are
preferably [CAR].sup.+--i.e. armed with a chimeric antigen receptor
to direct the specific recognition of tumor cells.
[0184] Delivery Methods
[0185] The inventors have considered any means known in the art to
allow delivery inside cells or subcellular compartments of said
cells the nucleic acid molecules employed in accordance with the
invention. These means include viral transduction, electroporation
and also liposomal delivery means, polymeric carriers, chemical
carriers, lipoplexes, polyplexes, dendrimers, nanoparticles,
emulsion, natural endocytosis or phagocytose pathway as
non-limiting examples.
[0186] In accordance with the present invention, the nucleic acid
molecules detailed herein may be introduced in the T-cell by any
suitable methods known in the art. Suitable, non-limiting methods
for introducing a nucleic acid molecule into a T-cell according
include stable transformation methods, wherein the nucleic acid
molecule is integrated into the genome of the cell, transient
transformation methods wherein the nucleic acid molecule is not
integrated into the genome of the cell and virus mediated methods.
Said nucleic acid molecule may be introduced into a cell by, for
example, a recombinant viral vector (e.g., retroviruses,
adenoviruses), liposome and the like. Transient transformation
methods include, for example, microinjection, electroporation or
particle bombardment. In certain embodiments, the nucleic acid
molecule is a vector, such as a viral vector or plasmid. Suitably,
said vector is an expression vector enabling the expression of the
respective polypeptide(s) or protein(s) detailed herein by the
T-cell.
[0187] A nucleic acid molecule introduced into the T-cell may be
DNA or RNA. In certain embodiments, a nucleic acid molecule
introduced into the T-cell is DNA. In certain embodiments, a
nucleic acid molecule introduced into the T-cell is RNA, and in
particular an mRNA encoding a polypeptide or protein detailed
herein, which mRNA is introduced directly into the T-cell, for
example by electroporation. A suitable electroporation technique is
described, for example, in International Publication WO2013/176915
(in particular the section titled "Electroporation" bridging pages
29 to 30). A particular nucleic acid molecule which may be an mRNA
is the nucleic acid molecule comprising a nucleotide sequence
coding for a rare-cutting endonuclease able to selectively
inactivate by DNA cleavage the gene encoding B2M. Another
particular nucleic acid molecule which may be an mRNA is the
nucleic acid molecule comprising a nucleotide sequence coding for a
rare-cutting endonuclease able to selectively inactivate by DNA
cleavage the gene encoding CIITA. A yet other particular nucleic
acid molecule which may be an mRNA is the nucleic acid molecule
comprising a nucleotide sequence coding for a rare-cutting
endonuclease able to selectively inactivate by DNA cleavage at
least one gene coding for one component of the T-Cell Receptor
(TCR).
[0188] As a preferred embodiment of the invention, nucleic acid
molecules encoding the endonucleases of the present invention are
transfected under mRNA form in order to obtain transient expression
and avoid chromosomal integration of foreign DNA, for example by
electroporation. The inventors have determined different optimal
conditions for mRNA electroporation in T-cell displayed in Table 1.
The inventor used the cytoPulse technology which allows, by the use
of pulsed electric fields, to transiently permeabilize living cells
for delivery of material into the cells (U.S. Pat. No. 6,010,613
and WO 2004/083379). Pulse duration, intensity as well as the
interval between pulses can be modified in order to reach the best
conditions for high transfection efficiency with minimal mortality.
Basically, the first high electric field pulses allow pore
formation, while subsequent lower electric field pulses allow to
moving the polynucleotide into the cell. In one aspect of the
present invention, the inventor describe the steps that led to
achievement of >95% transfection efficiency of mRNA in T cells,
and the use of the electroporation protocol to transiently express
different kind of proteins in T cells. In particular the invention
relates to a method of transforming T cell comprising contacting
said T cell with RNA and applying to T cell an agile pulse sequence
consisting of: [0189] (a) one electrical pulse with a voltage range
from 2250 to 3000 V per centimeter, a pulse width of 0.1 ms and a
pulse interval of 0.2 to 10 ms between the electrical pulses of
step (a) and (b); [0190] (b) one electrical pulse with a voltage
range from 2250 to 3000 V with a pulse width of 100 ms and a pulse
interval of 100 ms between the electrical pulse of step (b) and the
first electrical pulse of step (c); and [0191] (c) 4 electrical
pulses with a voltage of 325 V with a pulse width of 0.2 ms and a
pulse interval of 2 ms between each of 4 electrical pulses.
[0192] In particular embodiment, the method of transforming T cell
comprising contacting said T cell with RNA and applying to T cell
an agile pulse sequence consisting of: [0193] (a) one electrical
pulse with a voltage of 2250, 2300, 2350, 2400, 2450, 2500, 2550,
2400, 2450, 2500, 2600, 2700, 2800, 2900 or 3000V per centimeter, a
pulse width of 0.1 ms and a pulse interval of 0.2, 0.5, 1, 2, 3, 4,
5, 6, 7, 8, 9 or 10 ms between the electrical pulses of step (a)
and (b); [0194] (b) one electrical pulse with a voltage range from
2250, of 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2400, 2450,
2500, 2600, 2700, 2800, 2900 or 3000V with a pulse width of 100 ms
and a pulse interval of 100 ms between the electrical pulse of step
(b) and the first electrical pulse of step (c); and [0195] (c) 4
electrical pulses with a voltage of 325 V with a pulse width of 0.2
ms and a pulse interval of 2 ms between each of 4 electrical
pulses.
[0196] Any values included in the value range described above are
disclosed in the present application. Electroporation medium can be
any suitable medium known in the art. Preferably, the
electroporation medium has conductivity in a range spanning 0.01 to
1.0 milliSiemens.
TABLE-US-00001 TABLE 1 Different cytopulse programs used to
determine the minimal voltage required for electroporation in PBMC
derived T-cells. Cyto- Group 1 Group 2 Group 3 pulse duration
Interval duration Interval duration Interval program Pulses V (ms)
(ms) Pulses V (ms) (ms) Pulses V (ms) (ms) 1 1 600 0.1 0.2 1 600
0.1 100 4 130 0.2 2 2 1 900 0.1 0.2 1 900 0.1 100 4 130 0.2 2 3 1
1200 0.1 0.2 1 1200 0.1 100 4 130 0.2 2 4 1 1200 0.1 10 1 900 0.1
100 4 130 0.2 2 5 1 900 0.1 20 1 600 0.1 100 4 130 0.2 2
[0197] Non Alloreactive T-Cells:
[0198] Although the method of the invention could be carried out
in-vivo as part of a gene therapy, for instance, by using viral
vectors targeting T-cells in blood circulation, which would include
genetic sequences expressing a specific rare-cutting endonuclease
along with other genetic sequences expressing, e.g., a CAR, the
method of the invention is more generally intended to be practiced
ex-vivo on cultured T-cells obtainable from patients or donors. The
engineered T-cells engineered ex-vivo can be either re-implanted
into a patient from where they originate, as part of an autologous
treatment, or to be used as part of an allogeneic treatment. In
this later case, it is preferable to further engineer the cells to
make them non-alloreactive to ensure their proper engraftment.
Accordingly, the method of the invention may include additional
steps of procuring the T-cells from a donor and to inactivate genes
thereof involved in MHC recognition and or being targets of
immunosuppressive drugs such as described for instance in WO
2013/176915.
[0199] T-cell receptors (TCR) are cell surface receptors that
participate in the activation of T-cells in response to the
presentation of antigen. The TCR is generally made from two chains,
alpha and beta, which assemble to form a heterodimer and associates
with the CD3-transducing subunits to form the T-cell receptor
complex present on the cell surface. Each alpha and beta chain of
the TCR consists of an immunoglobulin-like N-terminal variable (V)
and constant (C) region, a hydrophobic transmembrane domain, and a
short cytoplasmic region. As for immunoglobulin molecules, the
variable region of the alpha and beta chains are generated by V(D)J
recombination, creating a large diversity of antigen specificities
within the population of T cells. However, in contrast to
immunoglobulins that recognize intact antigen, T cells are
activated by processed peptide fragments in association with an MHC
molecule, introducing an extra dimension to antigen recognition by
T cells, known as MHC restriction. Recognition of MHC disparities
between the donor and recipient through the T cell receptor leads
to T cell proliferation and the potential development of GVHD. It
has been shown that normal surface expression of the TCR depends on
the coordinated synthesis and assembly of all seven components of
the complex (Ashwell and Klusner 1990). The inactivation of TCR
alpha or TCR beta can result in the elimination of the TCR from the
surface of T cells preventing recognition of alloantigen and thus
GVHD.
[0200] Thus, still according to the invention, engraftment of the
T-cells may be improved by inactivating at least one gene encoding
a TCR component. TCR is rendered not functional in the cells by
inactivating TCR alpha gene and/or TCR beta gene(s).
[0201] With respect to the use of Cas9/CRISPR system, the inventors
have determined appropriate target sequences within the 3 exons
encoding TCR, allowing a significant reduction of toxicity in
living cells, while retaining cleavage efficiency. The preferred
target sequences are noted in Table 2 (+ for lower ratio of TCR
negative cells, ++ for intermediate ratio, +++ for higher
ratio).
TABLE-US-00002 TABLE 2 appropriate target sequences for the guide
RNA using Cas9 in T-cells Exon Target SEQ TCR Position Strand
genomic sequence ID efficiency Ex1 78 -1 GAGAATCAAAATCGGTGAATAGG 8
+++ Ex3 26 1 TTCAAAACCTGTCAGTGATTGGG 9 +++ Ex1 153 1
TGTGCTAGACATGAGGTCTATGG 10 +++ Ex3 74 -1 CGTCATGAGCAGATTAAACCCGG 11
+++ Ex1 4 -1 TCAGGGTTCTGGATATCTGTGGG 12 +++ Ex1 5 -1
GTCAGGGTTCTGGATATCTGTGG 13 +++ Ex3 33 -1 TTCGGAACCCAATCACTGACAGG 14
+++ Ex3 60 -1 TAAACCCGGCCACTTTCAGGAGG 15 +++ Ex1 200 -1
AAAGTCAGATTTGTTGCTCCAGG 16 ++ Ex1 102 1 AACAAATGTGTCACAAAGTAAGG 17
++ Ex1 39 -1 TGGATTTAGAGTCTCTCAGCTGG 18 ++ Ex1 59 -1
TAGGCAGACAGACTTGTCACTGG 19 ++ Ex1 22 -1 AGCTGGTACACGGCAGGGTCAGG 20
++ Ex1 21 -1 GCTGGTACACGGCAGGGTCAGGG 21 ++ Ex1 28 -1
TCTCTCAGCTGGTACACGGCAGG 22 ++ Ex3 25 1 TTTCAAAACCTGTCAGTGATTGG 23
++ Ex3 63 -1 GATTAAACCCGGCCACTTTCAGG 24 ++ Ex2 17 -1
CTCGACCAGCTTGACATCACAGG 25 ++ Ex1 32 -1 AGAGTCTCTCAGCTGGTACACGG 26
++ Ex1 27 -1 CTCTCAGCTGGTACACGGCAGGG 27 ++ Ex2 12 1
AAGTTCCTGTGATGTCAAGCTGG 28 ++ Ex3 55 1 ATCCTCCTCCTGAAAGTGGCCGG 29
++ Ex3 86 1 TGCTCATGACGCTGCGGCTGTGG 30 ++ Ex1 146 1
ACAAAACTGTGCTAGACATGAGG 31 + Ex1 86 -1 ATTTGITTGAGAATCAAAATCGG 32 +
Ex2 3 -1 CATCACAGGAACTTTCTAAAAGG 33 + Ex2 34 1
GTCGAGAAAAGCTTTGAAACAGG 34 + Ex3 51 -1 CCACTTTCAGGAGGAGGATTCGG 35 +
Ex3 18 -1 CTGACAGGTTTTGAAAGTTTAGG 36 + Ex2 43 1
AGCTTTGAAACAGGTAAGACAGG 37 + Ex1 236 -1 TGGAATAATGCTGTTGTTGAAGG 38
+ Ex1 182 1 AGAGCAACAGTGCTGTGGCCTGG 39 + Ex3 103 1
CTGTGGTCCAGCTGAGGTGAGGG 40 + Ex3 97 1 CTGCGGCTGTGGTCCAGCTGAGG 41 +
Ex3 104 1 TGTGGTCCAGCTGAGGTGAGGGG 42 + Ex1 267 1
CTTCTTCCCCAGCCCAGGTAAGG 43 + Ex1 15 -1 ACACGGCAGGGTCAGGGTTCTGG 44 +
Ex1 177 1 CTTCAAGAGCAACAGTGCTGTGG 45 + Ex1 256 -1
CTGGGGAAGAAGGTGTCTTCTGG 46 + Ex3 56 1 TCCTCCTCCTGAAAGTGGCCGGG 47 +
Ex3 80 1 TTAATCTGCTCATGACGCTGCGG 48 + Ex3 57 -1
ACCCGGCCACTTTCAGGAGGAGG 49 + Ex1 268 1 TTCTTCCCCAGCCCAGGTAAGGG 50 +
Ex1 266 -1 CTTACCTGGGCTGGGGAAGAAGG 51 + Ex1 262 1
GACACCTTCTTCCCCAGCCCAGG 52 + Ex3 102 1 GCTGTGGTCCAGCTGAGGTGAGG 53 +
Ex3 51 1 CCGAATCCTCCTCCTGAAAGTGG 54 +
[0202] MHC antigens are also proteins that played a major role in
transplantation reactions. Rejection is mediated by T cells
reacting to the histocompatibility antigens on the surface of
implanted tissues, and the largest group of these antigens is the
major histocompatibility antigens (MHC). These proteins are
expressed on the surface of all higher vertebrates and are called
HLA antigens (for human leukocyte antigens) in human cells. Like
TCR, the MHC proteins serve a vital role in T cell stimulation.
Antigen presenting cells (often dendritic cells) display peptides
that are the degradation products of foreign proteins on the cell
surface on the MHC. In the presence of a co-stimulatory signal, the
T cell becomes activated, and will act on a target cell that also
displays that same peptide/MHC complex. For example, a stimulated T
helper cell will target a macrophage displaying an antigen in
conjunction with its MHC, or a cytotoxic T cell (CTL) will act on a
virally infected cell displaying foreign viral peptides.
[0203] Thus, in order to provide less alloreactive T-cells, the
method of the invention can further comprise the step of
inactivating or mutating one HLA gene.
[0204] The class I HLA gene cluster in humans comprises three major
loci, B, C and A, as well as several minor loci. The class II HLA
cluster also comprises three major loci, DP, DQ and DR, and both
the class I and class II gene clusters are polymorphic, in that
there are several different alleles of both the class I and II
genes within the population. There are also several accessory
proteins that play a role in HLA functioning as well. The Tapl and
Tap2 subunits are parts of the TAP transporter complex that is
essential in loading peptide antigens on to the class I HLA
complexes, and the LMP2 and LMP7 proteosome subunits play roles in
the proteolytic degradation of antigens into peptides for display
on the HLA. Reduction in LMP7 has been shown to reduce the amount
of MHC class I at the cell surface, perhaps through a lack of
stabilization (Fehling et al. (1999) Science 265:1234-1237). In
addition to TAP and LMP, there is the tapasin gene, whose product
forms a bridge between the TAP complex and the HLA class I chains
and enhances peptide loading. Reduction in tapasin results in cells
with impaired MHC class I assembly, reduced cell surface expression
of the MHC class I and impaired immune responses (Grandea et al.
(2000) Immunity 13:213-222 and Garbi et al. (2000) Nat. Immunol.
1:234-238). Any of the above genes may be inactivated as part of
the present invention as disclosed, for instance in WO
2012/012667.
[0205] Hence, in accordance with certain embodiments, the method of
the invention further comprises inactivating at least one gene
selected from the group consisting of RFXANK, RFX5, RFXAP, TAP1,
TAP2, ZXDA, ZXDB and ZXDC. Inactivation may, for instance, be
achieved by using a genome modification, more particularly through
the expression in the T-cell of a rare-cutting endonuclease able to
selectively inactivate by DNA cleavage a gene selected from the
group consisting of RFXANK, RFX5, RFXAP, TAP1, TAP2, ZXDA, ZXDB and
ZXDC.
[0206] Activation and Expansion of T Cells
[0207] The method according to the invention may include a further
step of activating and/or expanding the T-cell(s). This can be done
prior to or after genetic modification of the T-cell(s), using the
methods as described, for example, in U.S. Pat. Nos. 6,352,694;
6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681;
7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223;
6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application
Publication No. 20060121005. According to these methods, the T
cells of the invention can be expanded by contact with a surface
having attached thereto an agent that stimulates a CD3 TCR complex
associated signal and a ligand that stimulates a co-stimulatory
molecule on the surface of the T cells.
[0208] In particular, T cell populations may be stimulated in vitro
such as by contact with an anti-CD3 antibody, or antigen-binding
fragment thereof, or an anti-CD2 antibody immobilized on a surface,
or by contact with a protein kinase C activator (e.g., bryostatin)
in conjunction with a calcium ionophore. For co-stimulation of an
accessory molecule on the surface of the T cells, a ligand that
binds the accessory molecule is used. For example, a population of
T cells can be contacted with an anti-CD3 antibody and an anti-CD28
antibody, under conditions appropriate for stimulating
proliferation of the T cells. To stimulate proliferation of either
CD4+ T cells or CD8+ T cells, an anti-CD3 antibody and an anti-CD28
antibody. For example, the agents providing each signal may be in
solution or coupled to a surface. As those of ordinary skill in the
art can readily appreciate, the ratio of particles to cells may
depend on particle size relative to the target cell. In further
embodiments of the present invention, the cells, such as T cells,
are combined with agent-coated beads, the beads and the cells are
subsequently separated, and then the cells are cultured. In an
alternative embodiment, prior to culture, the agent-coated beads
and cells are not separated but are cultured together. Cell surface
proteins may be ligated by allowing paramagnetic beads to which
anti-CD3 and anti-CD28 are attached (3.times.28 beads) to contact
the T cells. In one embodiment the cells (for example, 4 to 10 T
cells) and beads (for example, DYNABEADS.RTM. M-450 CD3/CD28 T
paramagnetic beads at a ratio of 1:1) are combined in a buffer,
preferably PBS (without divalent cations such as, calcium and
magnesium). Again, those of ordinary skill in the art can readily
appreciate any cell concentration may be used. The mixture may be
cultured for several hours (about 3 hours) to about 14 days or any
hourly integer value in between. In another embodiment, the mixture
may be cultured for 21 days. Conditions appropriate for T cell
culture include an appropriate media (e.g., Minimal Essential Media
or RPMI Media 1640 or, X-vivo 5, (Lonza)) that may contain factors
necessary for proliferation and viability, including serum (e.g.,
fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-g
1L-4, 1L-7, GM-CSF, -10, -2, 1L-15, TGFp, and TNF- or any other
additives for the growth of cells known to the skilled artisan.
Other additives for the growth of cells include, but are not
limited to, surfactant, plasmanate, and reducing agents such as
N-acetyl-cysteine and 2-mercaptoethanoi. Media can include RPMI
1640, A1M-V, DMEM, MEM, a-MEM, F-12, X-Vivo 1 , and X-Vivo 20,
Optimizer, with added amino acids, sodium pyruvate, and vitamins,
either serum-free or supplemented with an appropriate amount of
serum (or plasma) or a defined set of hormones, and/or an amount of
cytokine(s) sufficient for the growth and expansion of T cells.
Antibiotics, e.g., penicillin and streptomycin, are included only
in experimental cultures, not in cultures of cells that are to be
infused into a subject. The target cells are maintained under
conditions necessary to support growth, for example, an appropriate
temperature (e.g., 37.degree. C.) and atmosphere (e.g., air plus 5%
CO2). T cells that have been exposed to varied stimulation times
may exhibit different characteristics
[0209] In another particular embodiment, said cells can be expanded
by co-culturing with tissue or cells. Said cells can also be
expanded in vivo, for example in the subject's blood after
administrating said cell into the subject.
[0210] Therapeutic Applications
[0211] The T-cells obtainable in accordance with the present
invention are intended to be used as a medicament, and in
particular for treating, among others, cancer, infections (such
viral infections) or immune diseases in a patient in need thereof.
Accordingly, the present invention provides engineered T-cells for
use as a medicament. Particularly, the present invention provides
engineered T-cells for use in the treatment of a cancer, such as
lymphoma, or viral infection. Also provided are compositions,
particularly pharmaceutical compositions, which comprise at least
one engineered T-cell of the present invention. In certain
embodiments, a composition may comprise a population of engineered
T-cell of the present invention.
[0212] The treatment can be ameliorating, curative or prophylactic.
It may be either part of an autologous immunotherapy or part of an
allogenic immunotherapy treatment. By autologous, it is meant that
cells, cell line or population of cells used for treating patients
are originating from said patient or from a Human Leucocyte Antigen
(HLA) compatible donor. By allogeneic is meant that the cells or
population of cells used for treating patients are not originating
from said patient but from a donor.
[0213] The invention is particularly suited for allogenic
immunotherapy, insofar as it enables the transformation of T-cells,
typically obtained from donors, into non-alloreactive cells. This
may be done under standard protocols and reproduced as many times
as needed. The resulted modified T-cells may be pooled and
administrated to one or several patients, being made available as
an "off the shelf" therapeutic product.
[0214] The treatments are primarily to treat patients diagnosed
with cancer. Cancers are preferably leukemias and lymphomas, which
have liquid tumors, but may also concern solid tumors. Types of
cancers to be treated with the genetically engineered T-cells of
the invention include, but are not limited to, carcinoma, blastoma,
and sarcoma, and certain leukemia or lymphoid malignancies, benign
and malignant tumors, and malignancies e.g., sarcomas, carcinomas,
and melanomas. Adult tumors/cancers and pediatric turnors/cancers
are also included.
[0215] The treatment can take place in combination with one or more
therapies selected from the group of antibodies therapy,
chemotherapy, cytokines therapy, dendritic cell therapy, gene
therapy, hormone therapy, laser light therapy and radiation
therapy.
[0216] According to certain embodiments, T-cells of the invention
can undergo robust in vivo T-cell expansion upon administration to
a patient, and can persist in the body fluids for an extended
amount of time, preferably for a week, more preferably for 2 weeks,
even more preferably for at least one month. Although the T-cells
according to the invention are expected to persist during these
periods, their life span into the patient's body are intended not
to exceed a year, preferably 6 months, more preferably 2 months,
and even more preferably one month.
[0217] The administration of the cells or population of cells
according to the present invention may be carried out in any
convenient manner, including by aerosol inhalation, injection,
ingestion, transfusion, implantation or transplantation. The
compositions described herein may be administered to a patient
subcutaneously, intradermaliy, intratumorally, intranodally,
intramedullary, intramuscularly, by intravenous or intralymphatic
injection, or intraperitoneally. In one embodiment, the cell
compositions of the present invention are preferably administered
by intravenous injection.
[0218] The administration of the cells or population of cells can
consist of the administration of 104-109 cells per kg body weight,
preferably 105 to 106 cells/kg body weight including all integer
values of cell numbers within those ranges. The cells or population
of cells can be administrated in one or more doses. In another
embodiment, said effective amount of cells are administrated as a
single dose. In another embodiment, said effective amount of cells
are administrated as more than one dose over a period time. Timing
of administration is within the judgment of managing physician and
depends on the clinical condition of the patient. The cells or
population of cells may be obtained from any source, such as a
blood bank or a donor. While individual needs vary, determination
of optimal ranges of effective amounts of a given cell type for a
particular disease or conditions within the skill of the art. An
effective amount means an amount which provides a therapeutic or
prophylactic benefit. The dosage administrated will be dependent
upon the age, health and weight of the recipient, kind of
concurrent treatment, if any, frequency of treatment and the nature
of the effect desired.
[0219] In other embodiments, said effective amount of cells or
composition comprising those cells are administrated parenterally.
Said administration can be an intravenous administration. Said
administration can be directly done by injection within a
tumor.
[0220] In certain embodiments, cells are administered to a patient
in conjunction with (e.g., before, simultaneously or following) any
number of relevant treatment modalities, including but not limited
to treatment with agents such as antiviral therapy, cidofovir and
interleukin-2, Cytarabine (also known as ARA-C) or nataliziimab
treatment for MS patients or efaliztimab treatment for psoriasis
patients or other treatments for PML patients. In further
embodiments, the T cells of the invention may be used in
combination with chemotherapy, radiation, immunosuppressive agents,
such as cyclosporin, azathioprine, methotrexate, mycophenolate, and
FK506, antibodies, or other immunoablative agents such as CAMPATH,
anti-CD3 antibodies or other antibody therapies, cytoxin,
fludaribine, cyclosporin, FK506, rapamycin, mycoplienolic acid,
steroids, FR901228, cytokines, and irradiation. These drugs inhibit
either the calcium dependent phosphatase calcineurin (cyclosporine
and FK506) or inhibit the p70S6 kinase that is important for growth
factor induced signaling (rapamycin) (Liu et al., Cell 66:807-815,
1 1; Henderson et al., Immun. 73:316-321, 1991; Bierer et al.,
Citrr. Opin. mm n. 5:763-773, 93). In a further embodiment, the
cell compositions of the present invention are administered to a
patient in conjunction with (e.g., before, simultaneously or
following) bone marrow transplantation, T cell ablative therapy
using either chemotherapy agents such as, fludarabine,
external-beam radiation therapy (XRT), cyclophosphamide, or
antibodies such as OKT3 or CAMPATH, In another embodiment, the cell
compositions of the present invention are administered following
B-cell ablative therapy such as agents that react with CD20, e.g.,
Rituxan. For example, in one embodiment, subjects may undergo
standard treatment with high dose chemotherapy followed by
peripheral blood stem cell transplantation. In certain embodiments,
following the transplant, subjects receive an infusion of the
expanded genetically engineered T-cells of the present invention.
In an additional embodiment, expanded cells are administered before
or following surgery.
[0221] Also encompassed within this aspect of the invention are
methods for treating a patient in need thereof, comprising a)
providing at least one engineered T-cell of the present invention,
preferably a population of said T-cell; and b) administering said
T-cell or population to said patient.
[0222] Also encompassed within this aspect of the invention are
methods for preparing a medicament using at least one engineered
T-cell of the present invention, and preferably a population of
said T-cell. Accordingly, the present invention provides the use of
at least one engineered T-cell of the present invention, and
preferably a population of said T-cell, in the manufacture of a
medicament. Preferably, such medicament is for use in the treatment
of a cancer, such as lymphoma, or viral infection.
[0223] Other Definitions
[0224] Amino acid residues in a polypeptide sequence are designated
herein according to the one-letter code, in which, for example, Q
means Gln or Glutamine residue, R means Arg or Arginine residue and
D means Asp or Aspartic acid residue.
[0225] Amino acid substitution means the replacement of one amino
acid residue with another, for instance the replacement of an
Arginine residue with a Glutamine residue in a peptide sequence is
an amino acid substitution.
[0226] Nucleotides are designated as follows: one-letter code is
used for designating the base of a nucleoside: a is adenine, t is
thymine, c is cytosine, and g is guanine. For the degenerated
nucleotides, r represents g or a (purine nucleotides), k represents
g or t, s represents g or c, w represents a or t, m represents a or
c, y represents t or c (pyrimidine nucleotides), d represents g, a
or t, v represents g, a or c, b represents g, t or c, h represents
a, t or c, and n represents g, a, t or c.
[0227] "As used herein, "nucleic acid" or "polynucleotides" refers
to nucleotides and/or polynucleotides, such as deoxyribonucleic
acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments
generated by the polymerase chain reaction (PCR), and fragments
generated by any of ligation, scission, endonuclease action, and
exonuclease action. Nucleic acid molecules can be composed of
monomers that are naturally-occurring nucleotides (such as DNA and
RNA), or analogs of naturally-occurring nucleotides (e.g.,
enantiomeric forms of naturally-occurring nucleotides), or a
combination of both. Modified nucleotides can have alterations in
sugar moieties and/or in pyrimidine or purine base moieties. Sugar
modifications include, for example, replacement of one or more
hydroxyl groups with halogens, alkyl groups, amines, and azido
groups, or sugars can be functionalized as ethers or esters.
Moreover, the entire sugar moiety can be replaced with sterically
and electronically similar structures, such as aza-sugars and
carbocyclic sugar analogs. Examples of modifications in a base
moiety include alkylated purines and pyrimidines, acylated purines
or pyrimidines, or other well-known heterocyclic substitutes.
Nucleic acid monomers can be linked by phosphodiester bonds or
analogs of such linkages. Nucleic acids can be either single
stranded or double stranded.
[0228] by "polynucleotide successively comprising a first region of
homology to sequences upstream of said double-stranded break, a
sequence to be inserted in the genome of said cell and a second
region of homology to sequences downstream of said double-stranded
break" it is intended to mean a DNA construct or a matrix
comprising a first and second portion that are homologous to
regions 5' and 3' of a DNA target in situ. The DNA construct also
comprises a third portion positioned between the first and second
portion which comprise some homology with the corresponding DNA
sequence in situ or alternatively comprise no homology with the
regions 5' and 3' of the DNA target in situ. Following cleavage of
the DNA target, a homologous recombination event is stimulated
between the genome containing the targeted gene comprised in the
locus of interest and this matrix, wherein the genomic sequence
containing the DNA target is replaced by the third portion of the
matrix and a variable part of the first and second portions of said
matrix.
[0229] by "DNA target", "DNA target sequence", "target DNA
sequence", "nucleic acid target sequence", "target sequence", or
"processing site" is intended a polynucleotide sequence that can be
targeted and processed by a rare-cutting endonuclease according to
the present invention. These terms refer to a specific DNA
location, preferably a genomic location in a cell, but also a
portion of genetic material that can exist independently to the
main body of genetic material such as plasmids, episomes, virus,
transposons or in organelles such as mitochondria as non-limiting
example. As non-limiting examples of RNA guided target sequences,
are those genome sequences that can hybridize the guide RNA which
directs the RNA guided endonuclease to a desired locus.
[0230] By " delivery vector" or " delivery vectors" is intended any
delivery vector which can be used in the present invention to put
into cell contact (i.e "contacting") or deliver inside cells or
subcellular compartments (i.e "introducing") agents/chemicals and
molecules (proteins or nucleic acids) needed in the present
invention. It includes, but is not limited to liposomal delivery
vectors, viral delivery vectors, drug delivery vectors, chemical
carriers, polymeric carriers, lipoplexes, polyplexes, dendrimers,
microbubbles (ultrasound contrast agents), nanoparticles, emulsions
or other appropriate transfer vectors. These delivery vectors allow
delivery of molecules, chemicals, macromolecules (genes, proteins),
or other vectors such as plasmids, or penetrating peptides. In
these later cases, delivery vectors are molecule carriers.
[0231] The terms "vector" or "vectors" refer to a nucleic acid
molecule capable of transporting another nucleic acid to which it
has been linked. A "vector" in the present invention includes, but
is not limited to, a viral vector, a plasmid, a RNA vector or a
linear or circular DNA or RNA molecule which may consists of a
chromosomal, non-chromosomal, semi-synthetic or synthetic nucleic
acids. Preferred vectors are those capable of autonomous
replication (episomal vector) and/or expression of nucleic acids to
which they are linked (expression vectors). Large numbers of
suitable vectors are known to those of skill in the art and
commercially available.
[0232] Viral vectors include retrovirus, adenovirus, parvovirus
(e.g. adenoassociated viruses), coronavirus, negative strand RNA
viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus
(e. g., rabies and vesicular stomatitis virus), paramyxovirus (e.g.
measles and Sendai), positive strand RNA viruses such as
picornavirus and alphavirus, and double-stranded DNA viruses
including adenovirus, herpesvirus (e.g., Herpes Simplex virus types
1 and 2, Epstein-Barr virus, cytomega-lovirus), and poxvirus (e.g.,
vaccinia, fowlpox and canarypox). Other viruses include Norwalk
virus, togavirus, flavivirus, reoviruses, papovavirus,
hepadnavirus, and hepatitis virus, for example. Examples of
retroviruses include: avian leukosis-sarcoma, mammalian C-type,
B-type viruses, D type viruses, HTLV-BLV group, lentivirus,
spumavirus (Coffin, J. M., Retroviridae: The viruses and their
replication, In Fundamental Virology, Third Edition, B. N. Fields,
et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
[0233] By "lentiviral vector" is meant HIV-Based lentiviral vectors
that are very promising for gene delivery because of their
relatively large packaging capacity, reduced immunogenicity and
their ability to stably transduce with high efficiency a large
range of different cell types. Lentiviral vectors are usually
generated following transient transfection of three (packaging,
envelope and transfer) or more plasmids into producer cells. Like
HIV, lentiviral vectors enter the target cell through the
interaction of viral surface glycoproteins with receptors on the
cell surface. On entry, the viral RNA undergoes reverse
transcription, which is mediated by the viral reverse transcriptase
complex. The product of reverse transcription is a double-stranded
linear viral DNA, which is the substrate for viral integration in
the DNA of infected cells. By "integrative lentiviral vectors (or
LV)", is meant such vectors as non limiting example, that are able
to integrate the genome of a target cell. At the opposite by "non
integrative lentiviral vectors (or NILV)" is meant efficient gene
delivery vectors that do not integrate the genome of a target cell
through the action of the virus integrase.
[0234] Delivery vectors and vectors can be associated or combined
with any cellular permeabilization techniques such as sonoporation
or electroporation or derivatives of these techniques.
[0235] By "cell" or "cells" is intended any eukaryotic living
cells, primary cells and cell lines derived from these organisms
for in vitro cultures.
[0236] By "primary cell" or "primary cells" are intended cells
taken directly from living tissue (i.e. biopsy material) and
established for growth in vitro, that have undergone very few
population doublings and are therefore more representative of the
main functional components and characteristics of tissues from
which they are derived from, in comparison to continuous
tumorigenic or artificially immortalized cell lines.
[0237] As non-limiting examples cell lines can be selected from the
group consisting of CHO-K1 cells; HEK293 cells; Caco2 cells; U2-OS
cells; NIH 3T3 cells; NSO cells; SP2 cells; CHO-S cells; DG44
cells; K-562 cells, U-937 cells; MRC5 cells; IMR90 cells; Jurkat
cells; HepG2 cells; HeLa cells; HT-1080 cells; HCT-116 cells; Hu-h7
cells; Huvec cells; Molt 4 cells.
[0238] All these cell lines can be modified by the method of the
present invention to provide cell line models to produce, express,
quantify, detect, study a gene or a protein of interest; these
models can also be used to screen biologically active molecules of
interest in research and production and various fields such as
chemical, biofuels, therapeutics and agronomy as non-limiting
examples.
[0239] by "mutation" is intended the substitution, deletion,
insertion of up to one, two three, four, five, six, seven, eight,
nine, ten, eleven, twelve, thirteen, fourteen, fifteen, twenty,
twenty five, thirty, fourty, fifty, or more nucleotides/amino acids
in a polynucleotide (cDNA, gene) or a polypeptide sequence. The
mutation can affect the coding sequence of a gene or its regulatory
sequence. It may also affect the structure of the genomic sequence
or the structure/stability of the encoded mRNA.
[0240] by "variant(s)", it is intended a repeat variant, a variant,
a DNA binding variant, a TALE-nuclease variant, a polypeptide
variant obtained by mutation or replacement of at least one residue
in the amino acid sequence of the parent molecule.
[0241] by "functional variant" is intended a catalytically active
mutant of a protein or a protein domain; such mutant may have the
same activity compared to its parent protein or protein domain or
additional properties, or higher or lower activity.
[0242] By "gene" is meant the basic unit of heredity, consisting of
a segment of DNA arranged in a linear manner along a chromosome,
which codes for a specific protein or segment of protein. A gene
typically includes a promoter, a 5' untranslated region, one or
more coding sequences (exons), optionally introns, a 3'
untranslated region. The gene may further comprise a terminator,
enhancers and/or silencers.
[0243] As used herein, the term "locus" is the specific physical
location of a DNA sequence (e.g. of a gene) on a chromosome. The
term "locus" can refer to the specific physical location of a
rare-cutting endonuclease target sequence on a chromosome. Such a
locus can comprise a target sequence that is recognized and/or
cleaved by a rare-cutting endonuclease according to the invention.
It is understood that the locus of interest of the present
invention can not only qualify a nucleic acid sequence that exists
in the main body of genetic material (i.e. in a chromosome) of a
cell but also a portion of genetic material that can exist
independently to said main body of genetic material such as
plasmids, episomes, virus, transposons or in organelles such as
mitochondria as non-limiting examples.
[0244] The term "cleavage" refers to the breakage of the covalent
backbone of a polynucleotide. Cleavage can be initiated by a
variety of methods including, but not limited to, enzymatic or
chemical hydrolysis of a phosphodiester bond. Both single-stranded
cleavage and double-stranded cleavage are possible, and
double-stranded cleavage can occur as a result of two distinct
single-stranded cleavage events. Double stranded DNA, RNA, or
DNA/RNA hybrid cleavage can result in the production of either
blunt ends or staggered ends.
[0245] By "fusion protein" is intended the result of a well-known
process in the art consisting in the joining of two or more genes
which originally encode for separate proteins or part of them, the
translation of said "fusion gene" resulting in a single polypeptide
with functional properties derived from each of the original
proteins.
[0246] "identity" refers to sequence identity between two nucleic
acid molecules or polypeptides. Identity can be determined by
comparing a position in each sequence which may be aligned for
purposes of comparison. When a position in the compared sequence is
occupied by the same base or amino acid, then the molecules are
identical at that position. A degree of similarity or identity
between nucleic acid or amino acid sequences is a function of the
number of identical or matching nucleotides or amino acids at
positions shared by the nucleic acid or amino acid sequences,
respectively. Various alignment algorithms and/or programs may be
used to calculate the identity between two sequences, including
FASTA, or BLAST which are available as a part of the GCG sequence
analysis package (University of Wisconsin, Madison, Wis.), and can
be used with, e.g., default setting. For example, polypeptides
having at least 70%, 85%, 90%, 95%, 98% or 99% identity to specific
polypeptides described herein and preferably exhibiting
substantially the same functions, as well as polynucleotide
encoding such polypeptides, are contemplated.
[0247] "inhibiting" or "inhibit" expression of B2M means that the
expression of B2M in the cell is reduced by at least 1%, at least
5%, at least 10%, at least 20%, at least 30%, at least 40%, at
least 50% at least 60%, at least 70%, at least 80%, at least 90%,
at least 95%, at least 99% or 100%. More particularly, "inhibiting"
or "inhibit" expression of B2M means that the amount of B2M in the
cell is reduced by at least 1%, at least 5%, at least 10%, at least
20%, at least 30%, at least 40%, at least 50% at least 60%, at
least 70%, at least 80%, at least 90%, at least 95%, at least 99%
or 100%. The expression or amount of protein in a cell can be
determined by any suitable means know in the art, such as ELISA,
Immunohistochemistry, Western Blotting or Flow Cytometry using B2M
specific antibodies. Such antibodies are commercially available
from various sources, such from Merck Millipore, Billerica, Mass.,
USA; or Abcam plc, Cambridge, UK.
[0248] "inhibiting" or "inhibit" expression of CIITA means that the
expression of CIITA in the cell is reduced by at least 1%, at least
5%, at least 10%, at least 20%, at least 30%, at least 40%, at
least 50% at least 60%, at least 70%, at least 80%, at least 90%,
at least 95%, at least 99% or 100%. More particularly, "inhibiting"
or "inhibit" expression of CIITA means that the amount of CIITA in
the cell is reduced by at least 1%, at least 5%, at least 10%, at
least 20%, at least 30%, at least 40%, at least 50% at least 60%,
at least 70%, at least 80%, at least 90%, at least 95%, at least
99% or 100%. The expression or amount of protein in a cell can be
determined by any suitable means know in the art, such as ELISA,
Immunohistochemistry, Western Blotting or Flow Cytometry using
CIITA specific antibodies. Such antibodies are commercially
available from various sources, such from Abcam plc, Cambridge, UK;
or Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., USA.
[0249] "signal-transducing domain" or "co-stimulatory ligand"
refers to a molecule on an antigen presenting cell that
specifically binds a cognate co-stimulatory molecule on a T-cell,
thereby providing a signal which, in addition to the primary signal
provided by, for instance, binding of a TCR/CD3 complex with an MHC
molecule loaded with peptide, mediates a T cell response,
including, but not limited to, proliferation activation,
differentiation and the like. A co-stimulatory ligand can include
but is not limited to CD7, B7(CD80), B7-2 (CD86), PD-L1, PD-L2,
4-1BBL, OX40L, inducible costimulatory igand (ICOS-L),
intercellular adhesion molecule (ICAM, CD30L, CD40, CD70, CD83,
HLA-G, MICA, M1CB, HVEM, lymphotoxin beta receptor, 3/TR6, ILT3,
ILT4, an agonist or antibody that binds Toll ligand receptor and a
ligand that specifically binds with B7-H3. A co-stimulatory ligand
also encompasses, inter alia, an antibody that specifically binds
with a co-stimulatory molecule present on a T cell, such as but not
limited to, CD27, CD28, 4-IBB, OX40, CD30, CD40, PD-1, ICOS,
lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LTGHT,
NKG2C, B7-H3, a ligand that specifically binds with CD83.
[0250] A "co-stimulatory molecule" refers to the cognate binding
partner on a Tcell that specifically binds with a co-stimulatory
ligand, thereby mediating a co-stimulatory response by the cell,
such as, but not limited to proliferation. Co-stimulatory molecules
include, but are not limited to an MHC class I molecule, BTLA and
Toll ligand receptor.
[0251] A "co-stimulatory signal" as used herein refers to a signal,
which in combination with primary signal, such as TCR/CD3 ligation,
leads to T cell proliferation and/or upregulation or downregulation
of key molecules.
[0252] "bispecific antibody" refers to an antibody that has binding
sites for two different antigens within a single antibody molecule.
It will be appreciated by those skilled in the art that other
molecules in addition to the canonical antibody structure may be
constructed with two binding specificities. It will further be
appreciated that antigen binding by bispecific antibodies may be
simultaneous or sequential. Bispecific antibodies can be produced
by chemical techniques (see e.g., Kranz et al. (1981) Proc. Natl.
Acad. Sci. USA 78, 5807), by "polydoma" techniques (See U.S. Pat.
No. 4,474,893) or by recombinant DNA techniques, which all are
known per se. As a non-limiting example, each binding domain
comprises at least one variable region from an antibody heavy chain
("VH or H region"), wherein the VH region of the first binding
domain specifically binds to the lymphocyte marker such as CD3, and
the VH region of the second binding domain specifically binds to
tumor antigen.
[0253] The term "extracellular ligand-binding domain" as used
herein is defined as an oligo- or polypeptide that is capable of
binding a ligand. Preferably, the domain will be capable of
interacting with a cell surface molecule. For example, the
extracellular ligand-binding domain may be chosen to recognize a
ligand that acts as a cell surface marker on target cells
associated with a particular disease state. Thus examples of cell
surface markers that may act as ligands include those associated
with viral, bacterial and parasitic infections, autoimmune disease
and cancer cells.
[0254] The term "subject" or "patient" as used herein includes all
members of the animal kingdom including non-human primates and
humans.
[0255] The above written description of the invention provides a
manner and process of making and using it such that any person
skilled in this art is enabled to make and use the same, this
enablement being provided in particular for the subject matter of
the appended claims, which make up a part of the original
description.
[0256] Where a numerical limit or range is stated herein, the
endpoints are included. Also, all values and subranges within a
numerical limit or range are specifically included as if explicitly
written out.
[0257] Having generally described this invention, a further
understanding can be obtained by reference to certain specific
examples, which are provided herein for purposes of illustration
only, and are not intended to be limiting unless otherwise
specified.
EXAMPLES
[0258] TALE-Nucleases Cleaving Human CIITA
[0259] mRNA encoding the TALE-nucleases targeting exons of the
human CIITA gene were ordered from Cellectis Bioresearch (8, rue de
la Croix Jarry, 75013 PARIS). Table 3 below indicates the target
sequences cleaved by each of the two independent entities (called
half TALE-nucleases) each containing a repeat sequence engineered
to bind and cleave between target sequences consisting of two 17-bp
long sequences (called half targets) separated by a 15-bp spacer.
Because Exon 2 and 3 are shared by all transcript variants of
CIITA, two TALEN pairs were designed for Exon 2 and 3. No obvious
offsite targeting in the human genome have been predicted using
TALE-Nucleases targeting these sequences.
TABLE-US-00003 TABLE 3 Description of the CIITA TALE-nucleases and
related target sequences Target name Target sequence TALEN 1_Exon
2_CMH-II-TA TTCCCTCCCAGGCAGCTC acagtgtgccacca TGGAGTTGGGGCCCCTA
(SEQ ID NO: 55) TALEN 2_Exon 2_CMH-II-TA TGCCTCTACCACTTCTA
Tgaccagatggacct GGCTGGAGAAGAAGAGA (SEQ ID NO: 56) TALEN 1_Exon
3_CMH-II-TA 5'TCTTCATCCAAGGGACT Tttcctcccagaacc CGACACAGACACCATCA
(SEQ ID NO: 57) TALEN 2_Exon 3_CMH-II-TA TGTTGTGTGACATGGAA
Ggtgatgaagagacc AGGGAGGCTTATGCCAA (SEQ ID NO: 58)
[0260] TALE-Nucleases Cleaving Human .beta.2m
[0261] mRNA encoding the TALE-nucleases targeting exons of the
human .beta.2m gene were ordered from Cellectis Bioresearch (8, rue
de la Croix Jarry, 75013 PARIS). Table 4 below indicates the target
sequences cleaved by each of the two independent entities (called
half TALE-nucleases) each containing a repeat sequence engineered
to bind and cleave between target sequences consisting of two 17-bp
long sequences (called half targets) separated by a 15-bp
spacer.
TABLE-US-00004 TABLE 4 Description of the .beta.2m TALE-nucleases
and related target sequences Half TALE-nuclease Target name Target
sequence sequence B2M_T03 5'-CCAAAGATTCAG Repeat B2M_T03-L
GTTTactcacgtcat (pCLS24605) ccagc(spacer)AG SEQ ID NO: 67
AGAATGGAAAGTC-3' B2M_T03-R (SEQ ID NO: 59) (pCLS24606) SEQ ID NO:
68
[0262] TALE-Nucleases Cleaving Human TCR Genes (TRAC and TRBC)
[0263] The human genome contains two functional T-cell receptor
beta chains (TRBC1 and TRBC2). During the development of alpha/beta
T lymphocytes, one of these two constant chains is selected in each
cell to be spliced to the variable region of TCR-beta and form a
functional full length beta chain. Table 5 below presents a TRAC
and 2 TRBC target sequences and their corresponding TALEN
sequences. The 2 TRBC targets were chosen in sequences conserved
between TRBC1 and TRBC2 so that the corresponding TALE-nuclease
would cleave both TRBC1 and TRBC2 at the same time.
TABLE-US-00005 TABLE 5 Description of the TRAC and TRBC
TALE-nucleases and sequences of the TALE-nucleases target sites in
the human corresponding genes. Target Target sequence Half
TALE-nuclease TRAC_T01 TTGTCCCACAGATATCC TRAC_T01-L TALEN
Agaaccctgaccctg (SEQ ID NO: 69) CCGTGTACCAGCTGAGA TRAC_T01-R TALEN
(SEQ ID NO: 60) (SEQ ID NO: 70) TRBC_T01 TGTGTTTGAGCCATCAG
TRBC_T01-L TALEN aagcagagatctccc (SEQ ID NO: 71) ACACCCAAAAGGCCACA
TRBC_T01-R TALEN (SEQ ID NO: 61) (SEQ ID NO: 72) TRBC_T02
TTCCCACCCGAGGTCGC TRBC_T02-L TALEN tgtgtttgagccatca (SEQ ID NO: 73)
GAAGCAGAGATCTCCCA TRBC_T02-R TALEN (SEQ ID NO: 62) (SEQ ID NO:
74)
[0264] Other target sequences in TRAC and CD52 genes have been
designed, which are displayed in Table 6.
TABLE-US-00006 TABLE 6 Additional target sequences for TRAC
TALE-nucleases. Target Target sequence TRAC_T02 TTTAGAAAGTTCCTGTG
atgtcaagctggtcg AGAAAAGCTTTGAAACA (SEQ ID NO: 63) TRAC_T03
TCCAGTGACAAGTCTGT ctgcctattcaccga TTTTGATTCTCAAACAA (SEQ ID NO: 64)
TRAC_T04 TATATCACAGACAAAAC tgtgctagacatgag GTCTATGGACTTCAAGA (SEQ
ID NO: 65) TRAC_T05 TGAGGTCTATGGACTTC aagagcaacagtgct
GTGGCCTGGAGCAACAA (SEQ ID NO: 66)
[0265] Electroporation of MRNA of Purified Tcells Activated using
Cytopulse Technology
[0266] After determining the best cytopulse program that allows an
efficient DNA electroporation of T cells, we tested whether this
method was applicable to the mRNA electroporation.
[0267] 5.times.106 purified T cells preactivated 6 days with
PHA/IL2 were resupended in cytoporation buffer T (BTX-Harvard
apparatus) and electroporated in 0.4 cm cuvettes with 10 .mu.g of
mRNA encoding GFP or 20 .mu.g of plasmids encoding GFP or pUC using
the preferred cytopulse program of table 7.
TABLE-US-00007 TABLE 7 Cytopulse program used to electroporate
purified T-cells. Cyto- Group 1 Group 2 Group 3 pulse duration
Interval duration Interval duration Interval program Pulse V (ms)
(ms) Pulse V (ms) (ms) Pulse V (ms) (ms) 3 1 1200 0.1 0.2 1 1200
0.1 100 4 130 0.2 2
[0268] 48 h after transfection cells were stained with viability
dye (eFluor-450) and the cellular viability and % of viable GFP+
cells was determined by flow cytometry.
[0269] The electroporation of RNA with the optimal condition
determined here was not toxic and allowed transfection of more than
95% of the viable cells.
[0270] In synthesis, the whole dataset shows that T-cells can be
efficiently transfected either with DNA or RNA. In particular, RNA
transfection has no impact on cellular viability and allows uniform
expression levels of the transfected gene of interest in the
cellular population.
[0271] Efficient transfection can be achieved early after cellular
activation, independently of the activation method used (PHA/IL-2
or CD3/CD28-coated-beads). The inventors have succeeded in
transfecting cells from 72 h after activation with efficiencies of
>95%. In addition, efficient transfection of T cells after
thawing and activation can also be obtained using the same
electroporation protocol.
[0272] mRNA Electroporation in Primary Human T cells for
TALE-Nuclease Functional Expression
[0273] After demonstrating that mRNA electroporation allow
efficient expression of GFP in primary human T cells, we tested
whether this method was applicable to the expression of other
proteins of interest. Transcription activator-like effector
nucleases (TALE-nuclease) are site-specific nucleases generated by
the fusion of a TAL DNA binding domain to a DNA cleavage domain.
They are powerful genome editing tools as they induce double-strand
breaks at practically any desired DNA sequence. These double-strand
breaks activate Non-homologous end-joining (NHEJ), an error-prone
DNA repair mechanism, potentially leading to inactivation of any
desired gene of interest. Alternatively, if an adequate repair
template is introduced into the cells at the same time,
TALE-nuclease-induced DNA breaks can be repaired by homologous
recombination, therefore offering the possibility of modifying at
will the gene sequence.
[0274] We have used mRNA electroporation to express a TALE-nuclease
designed to specifically cleave a sequence in the human gene coding
for the alpha chain of the T cell antigen receptor (TRAC).
Mutations induced in this sequence are expected to result in gene
inactivation and loss of TCR.alpha..beta. complex from the cell
surface. TRAC TALE-nuclease RNA or non-coding RNA as control are
transfected into activated primary human T lymphocytes using
Cytopulse technology. The electroporation sequence consisted in 2
pulses of 1200 V followed by four pulses of 130 V as described in
Table 7.
[0275] By flow cytometry analysis of TCR surface expression 7 days
post electroporation (FIG. 4, top panel), we observed that 44% of T
cells lost the expression of TCRaB. We analyzed the genomic DNA of
the transfected cells by PCR amplification of the TRAC locus
followed by 454 high throughput sequencing. 33% of alleles
sequenced (727 out of 2153) contained insertion or deletion at the
site of TALE-nuclease cleavage.
[0276] These data indicate that electroporation of mRNA using
cytopulse technology results in functional expression of TRAC
TALE-nuclease.
[0277] Activity of TRAC-TALE-Nuclease and TRBC-TALE-Nuclease in
HEK293 Cells
[0278] Each TALE-nuclease construct was subcloned using restriction
enzyme digestion in a mammalian expression vector under the control
of pEF1alpha long promoter. One million HEK293 cells were seeded
one day prior to transfection. Cells were transfected with 2.5
.mu.g of each of the two plasmids encoding the TALE-nucleases
recognizing the two half targets in the genomic sequence of
interest in the T-cell receptor alpha constant chain region (TRAC)
or T-cell receptor beta constant chain region (TRBC) under the
control of the EF1-alpha promoter or 5 .mu.g of a control pUC
vector (pCLS0003) using 25 .mu.l of lipofectamine (Invitrogen)
according to the manufacturer's instructions. The double stranded
cleavage generated by TALE-nucleases in TRAC coding sequences is
repaired in live cells by non homologous end joining (NHEJ), which
is an error-prone mechanism. Activity of TALE-nucleases in live
cells is measured by the frequency of insertions or deletions at
the genomic locus targeted. 48 hours after transfection, genomic
DNA was isolated from transfected cells and locus specific PCRs
were performed using the following primers: for TRAC:
5'-ATCACTGGCATCTGGACTCCA-3' (SEQ ID NO: 75), for TRBC1:
5'-AGAGCCCCTACCAGAACCAGAC-3' (SEQ ID NO: 76, or for TRBC2:
5'-GGACCTAGTAACATAATTGTGC-3' (SEQ ID NO: 77), and the reverse
primer for TRAC: 5'-CCTCATGTCTAGCACAGITT-3'(SEQ ID NO: 78), for
TRBC1 and TRBC2: 5'-ACCAGCTCAGCTCCACGTGGT-3' (SEQ ID NO: 79). PCR
products were sequenced by a 454 sequencing system (454 Life
Sciences). Approximately 10,000 sequences were obtained per PCR
product and then analyzed for the presence of site-specific
insertion or deletion events; results are in Table 8.
TABLE-US-00008 TABLE 8 Percentages of indels for TALE-nuclease
targeting TRAC_T01, TRBC_T01 and TRBC_T02 targets. % Indels with
TALE-nuclease % Indels with pUC Target transfection control
transfection TRAC_T01 41.9 0.3 TRBC_T01 in constant chain 1 3.81 0
TRBC_T01 in constant chain 2 2.59 0 TRBC_T02 in constant chain 1
14.7 0 TRBC_T02 in constant chain 1 5.99 0
[0279] Activity of .beta.2m and TRAC-TALE-Nuclease in Primary T
Lymphocytes
[0280] Each TALE-nuclease construct was subcloned using restriction
enzyme digestion in a mammalian expression vector under the control
of the T7 promoter.
[0281] mRNA encoding TALE-nuclease cleaving 132m, TRAC and TRBC
genomic sequence were synthesized from plasmid carrying the coding
sequences downstream from the T7 promoter. T lymphocytes isolated
from peripheral blood were activated for 5 days using anti-CD3/CD28
activator beads (Life technologies) and 5 million cells were then
transfected by electroporation with 10 .mu.g of each of 2 mRNAs
encoding both half TALE-nuclease (or non coding RNA as controls)
using a CytoLVT-P instrument. As a consequence of the insertions
and deletions induced by NHEJ, the coding sequence for .beta.2m
and/or TRAC will be out of frame in a fraction of the cells
resulting in non-functional genes. 5 days after electroporation,
cells were labeled with fluorochrome-conjugated anti-.beta.2m or
anti-TCR antibody by flow cytometry for the presence of .beta.2m or
TCR at their cell surface. Since all T lymphocytes expanded from
peripheral blood normally express .beta.2m and TCR, the proportion
of 132m-negative or TCR-negative cells is a direct measure of
TALE-nuclease activity.
[0282] Functional Analysis of T Cells with Targeted TRAC Gene
[0283] The goal of TRAC gene inactivation is to render T
lymphocytes unresponsive to T-cell receptor stimulation. As
described in the previous paragraph, T lymphocytes were transfected
with mRNA encoding TALE-nuclease cleaving TRAC. 16 days after
transfection, cells were treated with up to 5 .mu.g/ml of
phytohemagglutinin (PHA, Sigma-Aldrich), a T-cell mitogen acting
through the T cell receptor. Cells with a functional T-cell
receptor should increase in size following PHA treatment. After
three days of incubation, cells were labeled with a
fluorochrome-conjugated anti-TCR antibody and analyzed by flow
cytometry to compare the cell size distribution between
TCR-positive and TCR-negative cells. FIG. 3 shows that TCR-positive
cells significantly increase in size after PHA treatment whereas
TCR-negative cells have the some size as untreated cells indicating
that TRAC inactivation rendered them unresponsive to
TCR-signaling.
[0284] Functional Analysis of T Cells with Targeted .beta.2m
Gene
[0285] Similarly to the above, the TALEN-transfected cells and
control cells (transfected without RNA) were stained with
fluorochrome labeled antibody against B2M protein as well as an
antibody recognizing all three classes MHC-I molecules (HLA-A, -B
or-C). TALEN transfection induced loss of surface expression of B2M
and MHC-I molecules in more than 37% of T cells. See FIG. 5
[0286] Genomic Safety of .beta.2m-TALE-Nuclease and
TRAC-TALE-Nuclease in Primary T Lymphocytes
[0287] As our constructs include nuclease subunits, an important
question is whether multiple TALE-nuclease transfection can lead to
genotoxicity and off-target cleavage at `close match` target
sequences or by mispairing of half-TALE-nucleases. To estimate the
impact of TRAC-TALE-nuclease and .beta.2m-TALE-nuclease on the
integrity of the cellular genomes, we listed sequences in the human
genome that presented the potential for off-site cleavage. To
generate this list, we identified all the sequences in the genome
with up to 4 substitutions compared to the original half targets
and then identified the pairs of potential half targets in a head
to head orientation with a spacer of 9 to 30 bp from each other.
This analysis included sites potentially targeted by homodimers of
one half-TALE-nuclease molecule or heterodimers formed by one
.beta.2m half TALE-nuclease and one TRAC half-TALE-nuclease. We
scored the potential off-site targets based on the specificity data
taking into account the cost of individual substitutions and the
position of the substitutions (where mismatches are better
tolerated for bases at the 3' end of the half target). We obtained
173 unique sequences with a score reflecting an estimation of the
likelihood of cleavage. We selected the 15 top scores and analyzed
by deep sequencing the frequency of mutations found at these loci
in T cells simultaneously transfected with .beta.2m and TRAC
TALE-nuclease and purified by magnetic separation as .beta.2m
-negative, TCRO-negative. Results showed that the highest frequency
of insertion/deletion is 7.times.10.sup.-4. These results make the
putative offsite target at least 600 times less likely to be
mutated than the intended targets. The TALE-nuclease reagents used
in this study therefore appear extremely specific.
[0288] Electroporation of T Cells with a Monocistronic mRNA
Encoding for an Anti-CD19 Single Chain Chimeric Antigen Receptor
(CAR):
[0289] 5.times.106 T cells preactivated several days (3-5) with
anti-CD3/CD28 coated beads and IL2 were resuspended in cytoporation
buffer T, and electroporated in 0.4cm cuvettes without mRNA or with
101 .mu.g of mRNA encoding a single chain CAR (SEQ ID NO: 6) using
the program described in Table 7.
[0290] 24 hours post electroporation, cells were stained with a
fixable viability dye eFluor-780 and a PE-conjugated goat anti
mouse IgG F(ab')2 fragment specific to assess the cell surface
expression of the CAR on the live cells. The data is shown in the
FIG. 6. A indicates that the vast majority of the live T cells
electroporated with the monocitronic mRNA described previously
express the CAR at their surface. 24 hours post electroporation, T
cells were cocultured with Daudi (CD19+) cells for 6 hours and
analyzed by flow cytometry to detect the expression of the
degranulation marker CD107a at their surface (Betts, Brenchley et
al. 2003).
[0291] The data shown in FIG. 6 indicates that the majority of the
cells electroporated with the monocistronic mRNA described
previously degranulate in the presence of target cells expressing
CD19. These results clearly demonstrate that the CAR expressed at
the surface of electroporated T cells is active.
[0292] In the following examples, to prolong their survival and
enhance their therapeutic activity, the inventors describe a method
to prevent NK-cell mediated rejection of therapeutic allogeneic T
cells by engineering the allogenic T cells through the inactivation
of the B2M gene using specific TALEN, combined to either: i) the
expression of a chimeric single chain molecule composed of UL18 and
.beta.2M B2M-UL18) or ii) the secretion of NKG2D ligands. The
particularity resides in applying to primary T cells a mechanism
occuring normally in tumor cells or virally infected cells. Thus,
the mechanism of action is potentially different: in tumor cells,
shedding NKG2D ligands leads to their decreased presence at the
surface whereas in engineered cells, secreted the NKG2D ligand(s)
would serve as a decoy for several other NKG2D ligands potentially
still present at the T cell surface.
[0293] Efficient B2M Gene Knock Out Using Specific B2M TALEN.
[0294] Specific TALEN targeting a sequence (T01, SEQ ID N.degree.
81) within the first coding exon of the B2M gene (GenBank accession
number NC_000015) has been produced (left DNA binding domain RVDs:
NN-NN-HD-HD-NG-NG-NI-NN-HD-NG-NN-NG-NN-HD-NG-NG with SEQ ID NO: 82,
and right DNA binding domain RVDs:
NI-NN-HD-HD-NG-HD-HD-NI-NN-NN-HD-HD-NI-NN-NI-NG with SEQ ID NO:
83). The Table 9 below reports sequences for T01 targeting
sequence, as well as for 2 additional targets T02 and T03 and their
corresponding left and right TALE sequences.
TABLE-US-00009 TABLE 9 Description of additional .beta.2m
TALE-nucleases sequences Target SEQ ID name NO: Half TALE-nuclease
sequence T01 80
TCTCGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTA Beta2M
target T01 81
ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTATCG-
ATA TALEN
TCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAAGGTTCGTTC-
GA Beta2M
CAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACACGCGCACATCGTTGCGTTAA-
GCC LEFT
AACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCG-
A
CACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGAGGCCTTGCTCACGG
TGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTG
GCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTTGA
CCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGG
CTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATG
GTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCC
CGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTG
TTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGC
GGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCC
CAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTT
GCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGG
CAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGA
GCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGC
CGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCA
AGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGC
AGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCG
GTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAG
CAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAG
GTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGT
GCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCA
GGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGT
GGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCT
GTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGG
CGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGG
TGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGT
GCCAGGCCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGCGGCAGGCCGGCGC
TGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCTCGTC
GCCTTGGCCTGCCTCGGCGGGCGTCCTGCGCTGGATGCAGTGAAAAAGGGATTGGGGGATCCTATCAGC
CGTTCCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGAGTTGAGGCACAAGCTGAAGTACGTG
CCCCACGAGTACATCGAGCTGATCGAGATCGCCCGGAACAGCACCCAGGACCGTATCCTGGAGATGAAG
GTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCCGAC
GGCGCCATCTACACCGTGGGCTCCCCCATCGACTACGGCGTGATCGTGGACACCAAGGCCTACTCCGGCG
GCTACAACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACCAGGAAC
AAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTCCTGTTCG
TGTCCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTGAACCACATCACCAACTGCAACGG
CGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATCAAGGCCGGCACCCTGACCCTGGA
GGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGCCGACTGATAA T01 82
ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATAAGGAGACCGCCGCTGCCAAGTTCGAGAGAC-
AG TALEN
CACATGGACAGCATCGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGA-
TC Beta2M
AAACCGAAGGTTCGTTCGACAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACAC-
GCG RIGHT
CACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACATGA-
TCG
CAGCGTTGCCAGAGGCGACACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTC
TGGAGGCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTC
TCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACG
GGTGCCCCGCTCAACTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCG
CTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTG
GCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGC
CAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCT
GGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGG
CCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCC
AGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTG
GAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCC
ATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAG
GCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGA
GACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCAT
CGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGG
CCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGA
CGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCG
CCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCC
ACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACG
GTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCC
AGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGLGGCTUTTGCCGGTGCTGTGCCAGGCCCA
CGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGG
TGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCA
GCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACG
GCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTG
CAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAGC
AATGGCGGCGGCAGGCCGGCGCTGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCC
GCGTTGACCAACGACCACCTCGTCGCCTTGGCCTGCCTCGGCGGGCGTCCTGCGCTGGATGCAGTGAAAA
AGGGATTGGGGGATCCTATCAGCCGTTCCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGAGT
TGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGGAACAGCACCC
AGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTrCATGAAGGTGTACGGCTACAGGGGCAAGCACC
TGGGCGGCTCCAGGAAGCCCGACGGCGCCATCTACACCGTGGGCTCCCCCATCGACTACGGCGTGATCGT
GGACACCAAGGCCTACTCCGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGT
GGAGGAGAACCAGACCAGGAACAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGT
GACCGAGTTCAAGTTCCTGTTCGTGTCCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTG
AACCACATCACCAAC1GCAACGGCGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATC
AAGGCCGGCACCCTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGC
CGACTGATAA T02 83
TCCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAAGTCAA Beta2M target
T02 84
ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTATCG-
ATA TALEN
TCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAAGGTTCGTTC-
GA Beta2M
CAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACACGCGCACATCGTTGCGTTAA-
GCC LEFT
AACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCG-
A
CACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGAGGCCTTGCTCACGG
TGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTG
GCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTTGA
CCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGG
CTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGAT
GGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGAC
CCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGC
TGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTG
GTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCC
CGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTG
TTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGT
GGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCG
GAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTT
GCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGG
CAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCA
GCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGC
CGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCA
AGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGC
AGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCG
GTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAG
CAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAG
GTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGT
GCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCA
GGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGT
GGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGC
TGTGCCAGGCCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGCGGCAGGCCGG
CGCTGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCT
CGTCGCCTTGGCCTGCCTCGGCGGGCGTCCTGCGCTGGATGCAGTGAAAAAGGGATTGGGGGATCCTAT
CAGCCGTTCCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGAGTTGAGGCACAAGCTGAAGTA
CGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGGAACAGCACCCAGGACCGTATCCTGGAGAT
GAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGC
CCGACGGCGCCATCTACACCGTGGGCTCCCCCATCGACTACGGCGTGATCGTGGACACCAAGGCCTACTC
CGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACCA
GGAACAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTCCT
GTTCGTGTCCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTGAACCACATCACCAACTGC
AACGGCGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATCAAGGCCGGCACCCTGACC
CTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGCCGACTGATAA T02 85
ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATAAGGAGACCGCCGCTGCCAAGTTCGAGAGAC-
AG TALEN
CACATGGACAGCATCGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGA-
TC Beta2M
AAACCGAAGGTTCGTTCGACAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACAC-
GCG RIGHT
CACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACATGA-
TCG
CAGCGTTGCCAGAGGCGACACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTC
TGGAGGCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTC
TCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACG
GGTGCCCCGCTCAACTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCG
CTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTG
GCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGC
CAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCT
GGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGC
CATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCA
GGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGG
AGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCA
TCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAG
GCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGA
GACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCAT
CGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGG
CCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGA
CGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCG
CCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCC
CACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGAC
GGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGC
CAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCC
ACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACG
GTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCC
AGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCA
CGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGG
TCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAG
CAATGGCGGCGGCAGGCCGGCGCTGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGC
CGCGTTGACCAACGACCACCTCGTCGCCTTGGCCTGCCTCGGCGGGCGTCCTGCGCTGGATGCAGTGAAA
AAGGGATTGGGGGATCCTATCAGCCGTTCCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGA
GTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGGAACAGCAC
CCAGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGCAAGCA
CCTGGGCGGCTCCAGGAAGCCCGACGGCGCCATCTACACCGTGGGCTCCCCCATCGACTACGGCGTGATC
GTGGACACCAAGGCCTACTCCGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTAC
GTGGAGGAGAACCAGACCAGGAACAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGC
GTGACCGAGTTCAAGTTCCTGTTCGTGTCCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGC
TGAACCACATCACCAACTGCAACGGCGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGA
TCAAGGCCGGCACCCTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCG
GCCGACTGATAA T03 86 TTAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATCCA
Beta2M target T03 87
ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTATCG-
ATA TALEN
TCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAAGGTTCGTTC-
GA Beta2M
CAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACACGCGCACATCGTTGCGTTAA-
GCC LEFT
AACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCG-
A
CACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGAGGCCTTGCTCACGG
TGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTG
GCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTTGA
CCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCG
CTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATG
GTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCC
CGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTG
TTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGT
GGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCC
CAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTT
GCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGG
CAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCA
GCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGC
CGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCA
AGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGC
AGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCG
GTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAG
CAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAG
GTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGT
GCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCA
GGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGT
GGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCT
GTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGG
CGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGG
TGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGT
GCCAGGCCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGCGGCAGGCCGGCGC
TGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCTCGTC
GCCTTGGCCTGCCTCGGCGGGCGTCCTGCGCTGGATGCAGTGAAAAAGGGATTGGGGGATCCTATCAGC
CGTTCCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGAGTTGAGGCACAAGCTGAAGTACGTG
CCCCACGAGTACATCGAGCTGATCGAGATCGCCCGGAACAGCACCCAGGACCGTATCCTGGAGATGAAG
GTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCCGAC
GGCGCCATCTACACCGTGGGCTCCCCCATCGACTACGGCGTGATCGTGGACACCAAGGCCTACTCCGGCG
GCTACAACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACCAGGAAC
AAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTCCTGTTCG
TGTCCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTGAACCACATCACCAACTGCAACGG
CGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATCAAGGCCGGCACCCTGACCCTGGA
GGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGCCGACTGATAA
T03 88
ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATAAGGAGACCGCCGCTGCCAAGTTCGAGAGAC-
AG TALEN
CACATGGACAGCATCGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGA-
TC Beta2M
AAACCGAAGGTTCGTTCGACAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACAC-
GCG RIGHT
CACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACATGA-
TCG
CAGCGTTGCCAGAGGCGACACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTC
TGGAGGCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTC
TCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACG
GGTGCCCCGCTCAACTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCG
CTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTG
GCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGC
CAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTG
GAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCC
ATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCA
GGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGA
GACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCAT
CGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGC
CCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGA
CGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCG
CCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCC
ACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACG
GTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCC
AGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCA
CGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGG
TCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCA
GCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCCCAC
GGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTC
CAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGC
AATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGC
TTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCA
GCGGCTGTTGCCGGTGCTGTGCCAGGCCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAGCAA
TGGCGGCGGCAGGCCGGCGCTGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGC
GTTGACCAACGACCACCTCGTCGCCTTGGCCTGCCTCGGCGGGCGTCCTGCGCTGGATGCAGTGAAAAAG
GGATTGGGGGATCCTATCAGCCGTTCCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGAGTTG
AGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGGAACAGCACCCAG
GACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGCAAGCACCTG
GGCGGCTCCAGGAAGCCCGACGGCGCCATCTACACCGTGGGCTCCCCCATCGACTACGGCGTGATCGTG
GACACCAAGGCCTACTCCGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTG
GAGGAGAACCAGACCAGGAACAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGTG
ACCGAGTTCAAGTTCCTGTTCGTGTCCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTGA
ACCACATCACCAACTGCAACGGCGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATCA
AGGCCGGCACCCTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGCC
GACTGATAA
[0295] To test the ability of this B2M specific TALEN to promote
error-prone NHEJ events at the B2M locus, 2 or 10 .mu.g of mRNA
encoding TALEN were electroporated in Primary T cells using Pulse
Agile technology according to the manufacturer protocol. Three days
post transfection, cells were recovered and labeled with a specific
.beta.2-microglobulin antibody coupled to the PhycoErythrin
fluorochrome. Cells are then analyzed by flow cytometry for
viability and .beta.2-m expression. The results are shown on FIG.
10. On the top panel, nearly 100% of untransfected T cells express
.beta.2-m (top right panel). Transfection of T cells with the
specific B2M TALEN reduces dramatically 2-m expression since 38%
(middle right) and 80% of T cells (bottom right panel) become
beta2-m negative when transfected with 2 .mu.g or 10 .mu.g of TALEN
mRNA respectively. These data indicates that B2M knock-out in T
cells can be achieved with high efficacy.
[0296] Production and Expression of the Single Chain Molecule
B2M-UL18 in T Cells
[0297] HCMV UL18 encodes a type I transmembrane glycoprotein that
shares a high level of AA sequence identity with MHC Class I
molecules that associates with beta2-m and binds endogenous
peptides. Since our goal is to express this molecule in T cells
where B2M gene has been invalidated, our strategy is to produce a
chimeric molecule where beta2-m and UL18 is fused as a single chain
polypeptide. SEQ ID N.degree. 89 shows the amino-acid sequence of
the chimeric protein. Lentiviral particles containing the chimeric
B2M-UL18 are transduced into T cells. Expression of transgene is
monitored by FACS analysis using a beta2-m antibody. The results
from this experiment aim to show that a B2M-UL18 chimeric protein
is efficiently expressed in T cells.
[0298] Production and Expression of NKG2D Ligands in T Cells
[0299] NKG2D natural ligands are transmembrane or GPI-anchored
proteins. In order to achieve secretion of these molecules by T
cells, the extra-cellular domains of NKG2D ligands have been fused
in their N-terminus to a secretory peptide form. Amino-acid
sequences of secreted chimeric NKG2D ligands are listed below (SEQ
ID NO:90 to SEQ ID NO:97). Lentiviral particles containing the
chimeric NKG2D ligands are transduced into T cells. Expression of
transgene in culture supernatant is monitored by Western Blot
analysis using specific antibodies. The results from this
experiment aim to show that chimeric NKG2D ligand proteins are
efficiently expressed in T cells.
[0300] Beta2-M Deficient CAR T Cells are Not Recognized by
Allogenic T Cells.
[0301] PBMCs from healthy donor A is co-cultured with irradiated or
mitomycin-treated engineered beta2-m deficient T cells from donor
B. As a control, PBMCs from healthy donor A is co-cultured with
irradiated or mitomycin-treated engineered beta2-m positive T cells
from donor B. 7 days later, cells proliferation from donor A is
measured by XTT colorimetric assay or by CFSE dilution (FACS
analysis). Although cell proliferation is observed in control, no
or limited cell proliferation is observed when engineered T cells
do not express beta2-m. The results from this experiment aim to
show that alloreactive T cells are not able to recognize and
proliferate against beta2-m deficient T cells.
[0302] Efficient Inhibition of NK Mediated Engineered T Cells
Lysis
[0303] NK cells are purified from healthy donor A PBMCs. As
targets, engineered T cells from healthy donor B are produced and
listed below. a) engineered T cells (negative control), b) beta2-m
deficient engineered T cells (positive control), c) beta2-m
deficient engineered T cells expressing B2M-UL18 (SEQ ID N.degree.
89), d-k) beta2-m deficient engineered T cells expressing
respectively SP-MICAed (SEQ ID N.degree. 90), SP-MICBed (SEQ ID
N.degree. 91), SP-ULBP1ed (SEQ ID N.degree. 92), SP-ULBP2ed (SEQ ID
N.degree. 93), SP-ULBP3ed (SEQ ID N.degree. 94), SP-N2DL4ed (SEQID
N.degree. 95), SP-RET1Ged (SEQ ID N.degree. 96), SP-RAETI Led (SEQ
ID N.degree. 97). These sequences are reported in the following
Table 10.
TABLE-US-00010 TABLE 10 Polypeptide sequence of a viral MHC homolog
(UL18) and a panel of NKG2D ligands to be expressed according to
the present invention. SEQ ID NO: Polypeptide sequence Chimeric 89
MALPVTALLLPLALLLHAARPSRSV B2M-UL18 ALAVLALLSLSGLEAIQRTPKIQVY
SRHPAENGKSNFLNCYVSGFHPSDI EVDLLKNGERIEKVEHSDLSFSKDW
SFYLLYYTEFTPTEKDEYACRVNHV TLSQPKIVKWDRDMGGGGSGGGGSG
GGGSGGGGSMTMWCLTLFVLWMLRV VGMHVLRYGYTGIFDDTSHMTLTVV
GIFDGQHFFTYHVNSSDKASSRANG TISWMANVSAAYPTYLDGERAKGDL
IFNQTEQNLLELEIALGYRSQSVLT WTHECNTTENGSFVAGYEGFGWDGE
TLMELKDNLTLVVTGPNYEISWLKQ NKTYIDGKIKNISEGDTTIQRNYLK
GNCTQWSVIYSGFQTPVTHPVVKGG VRNQNDNRAEAFCTSYGFFPGEINI
TFIHYGNKAPDDSEPQCNPLLPTFD GTFHQGCYVAIFCNQNYTCRVTHGN
WTVEIPISVTSPDDSSSGEVPDHPT ANKRYNTMTISSVLLALLLCALLFA
FLHYFTTLKQYLRNLAFAWRYRKVR SS SP-MICAed 90 MGGVLLTQRTLLSLVLALLFPSMAS
MEPHSLRYNLTVLSWDGSVQSGFLT EVHLDGQPFLRCDRQKCRAKPQGQW
AEDVLGNKTWDRETRDLTGNGKDLR MTLAHIKDQKEGLHSLQEIRVCEIH
EDNSTRSSQHFYYDGELFLSQNLET KEWTMPQSSRAQTLAMNVRNFLKED
AMKTKTHYHAMHADCLQELRRYLKS GVVLRRTVPPMVNVTRSEASEGNIT
VTCRASGFYPWNITLSWRQDGVSLS HDTQQWGDVLPDGNGTYQTWVATRI
CQGEEQRFTCYMEHSGNHSTHPVPS GKVLVLQSHW SP-MICBed 91
MGGVLLTQRTLLSLVLALLFPSMAS MAEPHSLRYNLMVLSQDESVQSGFL
AEGHLDGQPFLRYDRQKRRAKPQGQ WAEDVLGAKTWDTETEDLTENGQDL
RRTLTHIKDQKGGLHSLQEIRVCEI HEDSSTRGSRHFYYDGELFLSQNLE
TQESTVPOSSRAQTLAMNVTNFWKE DAMKTKTHYRAMQADCLQKLQRYLK
SGVAIRRTVPPMVNVTCSEVSEGNI TVTCRASSFYPRNITLTWRQDGVSL
SHNTQQWGDVLPDGNGTYQTWVATR IRQGEEQRFTCYMEHSGNHGTHPVP SGKVLVLQSQRTD
SP-ULBP1ed 92 MGGVETCIRTLLSLVLALLFPSMAS MGWVDTHCLCYDFIITPKSRPEPQW
CEVQGLVDERPFLHYDCVNHKAKAF ASLGKKVNVTKTWEEQTETLRDVVD
FLKGQLLDIQVENLIPIEPLTLQAR MSCEHEAHGHGRGSWQFLFNGQKFL
LFDSNNRKWTALHPGAKKMTEKWEK NRDVTMFFQKISLGDCKMWLEEFLM YWEQMLDPT
SP-ULBP2ed 93 MGGVLLTQRTLLSLVLALLFPSMAS MGRADPHSLCYDITVIPKFRPGPRW
CAVQGQVDEKTFLHYDCGNKTVTPV SPLGKKLNVTTAWKAQNPVLREVVD
ILTEQLRDIQLENYTPKEPLTLQAR MSCEQKAEGHSSGSWQFSFDGQIFL
LFDSEKRMWTTVHPGARKMKEKWEN DKVVAMSFHYFSMGDCIGWLEDFLM GMDSTLEPSAG
SP-ULBP3ed 94 MGGVLLTQRTLLSLVLALLFPSMAS MDAHSLWYNFTIIHLPRHGQQWCEV
QSQVDQKNFLSYDCGSDKVLSMGHL EEQLYATDAWGKQLEMLREVGQRLR
LELADTELEDFTPSGPLTLQVRMSC ECEADGYIRGSWQFSFDGRKFLLFD
SNNRKWTVVHAGARRMKEKWEKDSG LTTFFKMVSMRDCKSWLRDFLMHRK KRLEPT
SP-N2DL4ed 95 MGGVLLTQRTLLSLVLALLFPSMAS MHSLCFNFTIKSLSRPGQPWCEAQV
FLNKNLFLQYNSDNNMVKPLGLLGK KVYATSTWGELTQTLGEVGRDLRML
LCDIKPQIKTSDPSTLQVEMFCQRE AERCTGASWQFATNGEKSLLFDAMN
MTWTVINHEASKIKETWKKDRGLEK YFRKLSKGDCDHWLREFLGHWEAMP
EPTVSPVNASDIHWSSSSLPD SP-RET1Ged 96 MGGVLLTQRTLLSLVLALLFPSMAS
MGLADPHSLCYDITVIPKFRPGPRW CAVQGQVDEKTFLHYDCGSKTVTPV
SPLGKKLNVTTAWKAQNPVLREVVD ILTEQLLDIQLENYIPKEPLTLQAR
MSCEQKAEGHGSGSWQLSFDGQIFL LFDSENRMWTTVHPGARKMKEKWEN
DKDMTMSFHYISMGDCTGWLEDFLM GMDSTLEPSAGAPPTMSSGTAQPR SP-RAETILed 97
MGGVLLTQRTLLSLVLALLFPSMAS MRRDDPHSLCYDITVIPKFRPGPRW
CAVQGQVDEKTFLHYDCGNKTVTPV SPLGKKLNVTMAWKAQNPVLREVVD
ILTEQLLDIQLENYTPKEPLTLQAR MSCEQKAEGHSSGSWQFSIDGQTFL
LFDSEKRMWTTVHPGARKMKEKWEN DKDVAMSFHYISMGDCIGWLEDFLM GMDSTLEPSAG
[0304] Cytotoxicity mediated by NK cells was determined by a CFSE
labeling assay. Target cells were labeled with CFSE, washed in PBS,
mixed with NK cells at various E:T cell ratios and incubated for 4
h at 37.degree. C. Cells are then analysed by flow cytometry and
percentages of CFSE positive engineered T cells are measured,
indicating the survival of engineered T cells in the presence of NK
cells. It is intended that although NK mediated cell lysis is
observed in the positive control (beta2-m deficient engineered T
cells), no or limited NK mediated cell lysis is observed when
beta2-m deficient engineered T cells engineered T cells express
B2M-UL18 (SEQ ID N.degree. 89) or secreted NKG2D ligands (SP-MICAed
(SEQ ID N.degree. 90), SP-MICBed (SEQ ID N.degree. 91), SP-ULBP1ed
(SEQ ID N.degree. 92), SP-ULBP2ed (SEQ ID N.degree. 93), SP-ULBP3ed
(SEQ ID N.degree. 94), SP-N2DL4ed (SEQ ID N.degree. 95), SP-RET1Ged
(SEQ ID N.degree. 96), SP-RAETILed (SEQ ID N.degree. 97). The
results from this experiment aim to show that allogenic NK cells
cytotoxicity activity is impaired when chimeric molecules, express
in engineered T cells, act as decoy either for inhibitory signal
receptor (B2M-UL18) or for stimulatory signal receptor (NKG2D
ligands).
LIST OF REFERENCES CITED IN THE DESCRIPTION
[0305] Ashwell, J. D. and R. D. Klusner (1990). "Genetic and
mutational analysis of the T-cell antigen receptor." Annu Rev
Immunol 8: 139-67.
[0306] Betts, M. R., J. M. Brenchley, et al. (2003). "Sensitive and
viable identification of antigen-specific CD8+ T cells by a flow
cytometric assay for degranulation." J Immunol Methods 281(1-2):
65-78.
[0307] Bierer B. E. et al. (1993) "Cyclosporin A and FK506:
molecular mechanisms of immunosuppression and probes for
transplantation biology." Curr Opin Immunol 5(5): 763-73.
[0308] Bix M. et al (1991). "Rejection of class I MHC-deficient
haemopoietic cells by irradiated MHC-matched mice." Nature
349(6307):329-31.
[0309] Boch, J., H. Scholze, et al. (2009). "Breaking the code of
DNA binding specificity of TAL-type III effectors." Science
326(5959): 1509-12.
[0310] Cambier, J. C. (1995). "Antigen and Fc receptor signaling.
The awesome power of the innmunoreceptor tyrosine-based activation
motif (ITAM)." J Immunol 155(7): 3281-5.
[0311] Carter L, et al. (2002). "PD-1:PD-L inhibitory pathway
affects both CD4(+) and CD8(+) T cells and is overcome by IL-2".
Eur. J. Immunol. 32 (3): 634-43.
[0312] Cong, L., F. A. Ran, et al. (2013). "Multiplex genome
engineering using CRISPR/Cas systems." Science 339(6121):
819-23.
[0313] Critchlow, S. E. and S. P. Jackson (1998). "DNA end-joining:
from yeast to man." Trends Biochem Sci 23(10): 394-8.
[0314] Deltcheva, E., K. Chylinski, et al. (2011). "CRISPR RNA
maturation by trans-encoded small RNA and host factor RNase III."
Nature 471(7340): 602-7.
[0315] Gasiunas, G. et al. (2012). "Cas9-crRNA ribonucleoprotein
complex mediates specific DNA cleavage for adaptive immunity in
bacteria." Proc Natl Acad Sci USA 109(39): E2579-86.
[0316] Haseloff and Gerlach (1988). "Simple RNA enzymes with new
and highly specific endoribonuclease activities." Nature 334:
585-591.
[0317] Jena, B., G. Dotti, et al. (2010). "Redirecting T-cell
specificity by introducing a tumor-specific chimeric antigen
receptor." Blood 116(7): 1035-44.
[0318] Jinek, M., K. Chylinski, et al. (2012). "A programmable
dual-RNA-guided DNA endonuclease in adaptive bacterial immunity."
Science 337(6096): 816-21.
[0319] Liu L. et al. (1991). "Calcineurin is a common target of
cyclophilin-cyclosporin A and FKBP-FK506 complexes." Cell 66(4):
807-15.
[0320] Ma, J. L., E. M. Kim, et al. (2003). "Yeast Mre11 and Rad1
proteins define a Ku-independent mechanism to repair double-strand
breaks lacking overlapping end sequences." Mol Cell Biol 23(23):
8820-8.
[0321] Mach B., Steimle V, Reith W (1994). "MHC class II-deficient
combined immunodeficiency: a disease of gene regulation". Immunol.
Rev. 138 (1): 207-21.
[0322] Mali, P., L. Yang, et al. (2013). "RNA-guided human genome
engineering via Cas9. " Science 339(6121): 823-6.
[0323] Moscou, M. J. and A. J. Bogdanove (2009). "A simple cipher
governs DNA recognition by TAL effectors." Science 326(5959):
1501.
[0324] Park, T. S., S. A. Rosenberg, et al. (2011). "Treating
cancer with genetically engineered T cells." Trends Biotechnol
29(11): 550-7.
[0325] Stoddard, B. L. (2005). "Homing endonuclease structure and
function." Q Rev Biophys 38(1): 49-95.
[0326] Urnov F. D. et al. (2010) "Genome editing with engineered
zinc finger nucleases" Nature reviews Genetics 11:636-646
Sequence CWU 1
1
971119PRTHomo sapiens 1Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala
Leu Leu Ser Leu Ser 1 5 10 15 Gly Leu Glu Ala Ile Gln Arg Thr Pro
Lys Ile Gln Val Tyr Ser Arg 20 25 30 His Pro Ala Glu Asn Gly Lys
Ser Asn Phe Leu Asn Cys Tyr Val Ser 35 40 45 Gly Phe His Pro Ser
Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu 50 55 60 Arg Ile Glu
Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp 65 70 75 80 Ser
Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp 85 90
95 Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile
100 105 110 Val Lys Trp Asp Arg Asp Met 115 26673DNAHomo sapiens
2aatataagtg gaggcgtcgc gctggcgggc attcctgaag ctgacagcat tcgggccgag
60atgtctcgct ccgtggcctt agctgtgctc gcgctactct ctctttctgg cctggaggct
120atccagcgtg agtctctcct accctcccgc tctggtcctt cctctcccgc
tctgcaccct 180ctgtggccct cgctgtgctc tctcgctccg tgacttccct
tctccaagtt ctccttggtg 240gcccgccgtg gggctagtcc agggctggat
ctcggggaag cggcggggtg gcctgggagt 300ggggaagggg gtgcgcaccc
gggacgcgcg ctacttgccc ctttcggcgg ggagcagggg 360agacctttgg
cctacggcga cgggagggtc gggacaaagt ttagggcgtc gataagcgtc
420agagcgccga ggttggggga gggtttctct tccgctcttt cgcggggcct
ctggctcccc 480cagcgcagct ggagtggggg acgggtaggc tcgtcccaaa
ggcgcggcgc tgaggtttgt 540gaacgcgtgg aggggcgctt ggggtctggg
ggaggcgtcg cccgggtaag cctgtctgct 600gcggctctgc ttcccttaga
ctggagagct gtggacttcg tctaggcgcc cgctaagttc 660gcatgtccta
gcacctctgg gtctatgtgg ggccacaccg tggggaggaa acagcacgcg
720acgtttgtag aatgcttggc tgtgatacaa agcggtttcg aataattaac
ttatttgttc 780ccatcacatg tcacttttaa aaaattataa gaactacccg
ttattgacat ctttctgtgt 840gccaaggact ttatgtgctt tgcgtcattt
aattttgaaa acagttatct tccgccatag 900ataactacta tggttatctt
ctgcctctca cagatgaaga aactaaggca ccgagatttt 960aagaaactta
attacacagg ggataaatgg cagcaatcga gattgaagtc aagcctaacc
1020agggcttttg cgggagcgca tgccttttgg ctgtaattcg tgcatttttt
tttaagaaaa 1080acgcctgcct tctgcgtgag attctccaga gcaaactggg
cggcatgggc cctgtggtct 1140tttcgtacag agggcttcct ctttggctct
ttgcctggtt gtttccaaga tgtactgtgc 1200ctcttacttt cggttttgaa
aacatgaggg ggttgggcgt ggtagcttac gcctgtaatc 1260ccagcactta
gggaggccga ggcgggagga tggcttgagg tccgtagttg agaccagcct
1320ggccaacatg gtgaagcctg gtctctacaa aaaataataa caaaaattag
ccgggtgtgg 1380tggctcgtgc ctgtggtccc agctgctccg gtggctgagg
cgggaggatc tcttgagctt 1440aggcttttga gctatcatgg cgccagtgca
ctccagcgtg ggcaacagag cgagaccctg 1500tctctcaaaa aagaaaaaaa
aaaaaaaaga aagagaaaag aaaagaaaga aagaagtgaa 1560ggtttgtcag
tcaggggagc tgtaaaacca ttaataaaga taatccaaga tggttaccaa
1620gactgttgag gacgccagag atcttgagca ctttctaagt acctggcaat
acactaagcg 1680cgctcacctt ttcctctggc aaaacatgat cgaaagcaga
atgttttgat catgagaaaa 1740ttgcatttaa tttgaataca atttatttac
aacataaagg ataatgtata tatcaccacc 1800attactggta tttgctggtt
atgttagatg tcattttaaa aaataacaat ctgatattta 1860aaaaaaaatc
ttattttgaa aatttccaaa gtaatacatg ccatgcatag accatttctg
1920gaagatacca caagaaacat gtaatgatga ttgcctctga aggtctattt
tcctcctctg 1980acctgtgtgt gggttttgtt tttgttttac tgtgggcata
aattaatttt tcagttaagt 2040tttggaagct taaataactc tccaaaagtc
ataaagccag taactggttg agcccaaatt 2100caaacccagc ctgtctgata
cttgtcctct tcttagaaaa gattacagtg atgctctcac 2160aaaatcttgc
cgccttccct caaacagaga gttccaggca ggatgaatct gtgctctgat
2220ccctgaggca tttaatatgt tcttattatt agaagctcag atgcaaagag
ctctcttagc 2280ttttaatgtt atgaaaaaaa tcaggtcttc attagattcc
ccaatccacc tcttgatggg 2340gctagtagcc tttccttaat gatagggtgt
ttctagagag atatatctgg tcaaggtggc 2400ctggtactcc tccttctccc
cacagcctcc cagacaagga ggagtagctg ccttttagtg 2460atcatgtacc
ctgaatataa gtgtatttaa aagaatttta tacacatata tttagtgtca
2520atctgtatat ttagtagcac taacacttct cttcattttc aatgaaaaat
atagagttta 2580taatattttc ttcccacttc cccatggatg gtctagtcat
gcctctcatt ttggaaagta 2640ctgtttctga aacattaggc aatatattcc
caacctggct agtttacagc aatcacctgt 2700ggatgctaat taaaacgcaa
atcccactgt cacatgcatt actccatttg atcataatgg 2760aaagtatgtt
ctgtcccatt tgccatagtc ctcacctatc cctgttgtat tttatcgggt
2820ccaactcaac catttaaggt atttgccagc tcttgtatgc atttaggttt
tgtttctttg 2880ttttttagct catgaaatta ggtacaaagt cagagagggg
tctggcatat aaaacctcag 2940cagaaataaa gaggttttgt tgtttggtaa
gaacatacct tgggttggtt gggcacggtg 3000gctcgtgcct gtaatcccaa
cactttggga ggccaaggca ggctgatcac ttgaagttgg 3060gagttcaaga
ccagcctggc caacatggtg aaatcccgtc tctactgaaa atacaaaaat
3120taaccaggca tggtggtgtg tgcctgtagt cccaggaatc acttgaaccc
aggaggcgga 3180ggttgcagtg agctgagatc tcaccactgc acactgcact
ccagcctggg caatggaatg 3240agattccatc ccaaaaaata aaaaaataaa
aaaataaaga acataccttg ggttgatcca 3300cttaggaacc tcagataata
acatctgcca cgtatagagc aattgctatg tcccaggcac 3360tctactagac
acttcataca gtttagaaaa tcagatgggt gtagatcaag gcaggagcag
3420gaaccaaaaa gaaaggcata aacataagaa aaaaaatgga aggggtggaa
acagagtaca 3480ataacatgag taatttgatg ggggctatta tgaactgaga
aatgaacttt gaaaagtatc 3540ttggggccaa atcatgtaga ctcttgagtg
atgtgttaag gaatgctatg agtgctgaga 3600gggcatcaga agtccttgag
agcctccaga gaaaggctct taaaaatgca gcgcaatctc 3660cagtgacaga
agatactgct agaaatctgc tagaaaaaaa acaaaaaagg catgtataga
3720ggaattatga gggaaagata ccaagtcacg gtttattctt caaaatggag
gtggcttgtt 3780gggaaggtgg aagctcattt ggccagagtg gaaatggaat
tgggagaaat cgatgaccaa 3840atgtaaacac ttggtgcctg atatagcttg
acaccaagtt agccccaagt gaaataccct 3900ggcaatatta atgtgtcttt
tcccgatatt cctcaggtac tccaaagatt caggtttact 3960cacgtcatcc
agcagagaat ggaaagtcaa atttcctgaa ttgctatgtg tctgggtttc
4020atccatccga cattgaagtt gacttactga agaatggaga gagaattgaa
aaagtggagc 4080attcagactt gtctttcagc aaggactggt ctttctatct
cttgtactac actgaattca 4140cccccactga aaaagatgag tatgcctgcc
gtgtgaacca tgtgactttg tcacagccca 4200agatagttaa gtggggtaag
tcttacattc ttttgtaagc tgctgaaagt tgtgtatgag 4260tagtcatatc
ataaagctgc tttgatataa aaaaggtcta tggccatact accctgaatg
4320agtcccatcc catctgatat aaacaatctg catattggga ttgtcaggga
atgttcttaa 4380agatcagatt agtggcacct gctgagatac tgatgcacag
catggtttct gaaccagtag 4440tttccctgca gttgagcagg gagcagcagc
agcacttgca caaatacata tacactctta 4500acacttctta cctactggct
tcctctagct tttgtggcag cttcaggtat atttagcact 4560gaacgaacat
ctcaagaagg tataggcctt tgtttgtaag tcctgctgtc ctagcatcct
4620ataatcctgg acttctccag tactttctgg ctggattggt atctgaggct
agtaggaagg 4680gcttgttcct gctgggtagc tctaaacaat gtattcatgg
gtaggaacag cagcctattc 4740tgccagcctt atttctaacc attttagaca
tttgttagta catggtattt taaaagtaaa 4800acttaatgtc ttcctttttt
ttctccactg tctttttcat agatcgagac atgtaagcag 4860catcatggag
gtaagttttt gaccttgaga aaatgttttt gtttcactgt cctgaggact
4920atttatagac agctctaaca tgataaccct cactatgtgg agaacattga
cagagtaaca 4980ttttagcagg gaaagaagaa tcctacaggg tcatgttccc
ttctcctgtg gagtggcatg 5040aagaaggtgt atggccccag gtatggccat
attactgacc ctctacagag agggcaaagg 5100aactgccagt atggtattgc
aggataaagg caggtggtta cccacattac ctgcaaggct 5160ttgatctttc
ttctgccatt tccacattgg acatctctgc tgaggagaga aaatgaacca
5220ctcttttcct ttgtataatg ttgttttatt cttcagacag aagagaggag
ttatacagct 5280ctgcagacat cccattcctg tatggggact gtgtttgcct
cttagaggtt cccaggccac 5340tagaggagat aaagggaaac agattgttat
aacttgatat aatgatacta taatagatgt 5400aactacaagg agctccagaa
gcaagagaga gggaggaact tggacttctc tgcatcttta 5460gttggagtcc
aaaggctttt caatgaaatt ctactgccca gggtacattg atgctgaaac
5520cccattcaaa tctcctgtta tattctagaa cagggaattg atttgggaga
gcatcaggaa 5580ggtggatgat ctgcccagtc acactgttag taaattgtag
agccaggacc tgaactctaa 5640tatagtcatg tgttacttaa tgacggggac
atgttctgag aaatgcttac acaaacctag 5700gtgttgtagc ctactacacg
cataggctac atggtatagc ctattgctcc tagactacaa 5760acctgtacag
cctgttactg tactgaatac tgtgggcagt tgtaacacaa tggtaagtat
5820ttgtgtatct aaacatagaa gttgcagtaa aaatatgcta ttttaatctt
atgagaccac 5880tgtcatatat acagtccatc attgaccaaa acatcatatc
agcatttttt cttctaagat 5940tttgggagca ccaaagggat acactaacag
gatatactct ttataatggg tttggagaac 6000tgtctgcagc tacttctttt
aaaaaggtga tctacacagt agaaattaga caagtttggt 6060aatgagatct
gcaatccaaa taaaataaat tcattgctaa cctttttctt ttcttttcag
6120gtttgaagat gccgcatttg gattggatga attccaaatt ctgcttgctt
gctttttaat 6180attgatatgc ttatacactt acactttatg cacaaaatgt
agggttataa taatgttaac 6240atggacatga tcttctttat aattctactt
tgagtgctgt ctccatgttt gatgtatctg 6300agcaggttgc tccacaggta
gctctaggag ggctggcaac ttagaggtgg ggagcagaga 6360attctcttat
ccaacatcaa catcttggtc agatttgaac tcttcaatct cttgcactca
6420aagcttgtta agatagttaa gcgtgcataa gttaacttcc aatttacata
ctctgcttag 6480aatttggggg aaaatttaga aatataattg acaggattat
tggaaatttg ttataatgaa 6540tgaaacattt tgtcatataa gattcatatt
tacttcttat acatttgata aagtaaggca 6600tggttgtggt taatctggtt
tatttttgtt ccacaagtta aataaatcat aaaacttgat 6660gtgttatctc tta
66733987DNAHomo sapiens 3aatataagtg gaggcgtcgc gctggcgggc
attcctgaag ctgacagcat tcgggccgag 60atgtctcgct ccgtggcctt agctgtgctc
gcgctactct ctctttctgg cctggaggct 120atccagcgta ctccaaagat
tcaggtttac tcacgtcatc cagcagagaa tggaaagtca 180aatttcctga
attgctatgt gtctgggttt catccatccg acattgaagt tgacttactg
240aagaatggag agagaattga aaaagtggag cattcagact tgtctttcag
caaggactgg 300tctttctatc tcttgtacta cactgaattc acccccactg
aaaaagatga gtatgcctgc 360cgtgtgaacc atgtgacttt gtcacagccc
aagatagtta agtgggatcg agacatgtaa 420gcagcatcat ggaggtttga
agatgccgca tttggattgg atgaattcca aattctgctt 480gcttgctttt
taatattgat atgcttatac acttacactt tatgcacaaa atgtagggtt
540ataataatgt taacatggac atgatcttct ttataattct actttgagtg
ctgtctccat 600gtttgatgta tctgagcagg ttgctccaca ggtagctcta
ggagggctgg caacttagag 660gtggggagca gagaattctc ttatccaaca
tcaacatctt ggtcagattt gaactcttca 720atctcttgca ctcaaagctt
gttaagatag ttaagcgtgc ataagttaac ttccaattta 780catactctgc
ttagaatttg ggggaaaatt tagaaatata attgacagga ttattggaaa
840tttgttataa tgaatgaaac attttgtcat ataagattca tatttacttc
ttatacattt 900gataaagtaa ggcatggttg tggttaatct ggtttatttt
tgttccacaa gttaaataaa 960tcataaaact tgatgtgtta tctctta
98741130PRTHomo sapiens 4Met Arg Cys Leu Ala Pro Arg Pro Ala Gly
Ser Tyr Leu Ser Glu Pro 1 5 10 15 Gln Gly Ser Ser Gln Cys Ala Thr
Met Glu Leu Gly Pro Leu Glu Gly 20 25 30 Gly Tyr Leu Glu Leu Leu
Asn Ser Asp Ala Asp Pro Leu Cys Leu Tyr 35 40 45 His Phe Tyr Asp
Gln Met Asp Leu Ala Gly Glu Glu Glu Ile Glu Leu 50 55 60 Tyr Ser
Glu Pro Asp Thr Asp Thr Ile Asn Cys Asp Gln Phe Ser Arg 65 70 75 80
Leu Leu Cys Asp Met Glu Gly Asp Glu Glu Thr Arg Glu Ala Tyr Ala 85
90 95 Asn Ile Ala Glu Leu Asp Gln Tyr Val Phe Gln Asp Ser Gln Leu
Glu 100 105 110 Gly Leu Ser Lys Asp Ile Phe Lys His Ile Gly Pro Asp
Glu Val Ile 115 120 125 Gly Glu Ser Met Glu Met Pro Ala Glu Val Gly
Gln Lys Ser Gln Lys 130 135 140 Arg Pro Phe Pro Glu Glu Leu Pro Ala
Asp Leu Lys His Trp Lys Pro 145 150 155 160 Ala Glu Pro Pro Thr Val
Val Thr Gly Ser Leu Leu Val Gly Pro Val 165 170 175 Ser Asp Cys Ser
Thr Leu Pro Cys Leu Pro Leu Pro Ala Leu Phe Asn 180 185 190 Gln Glu
Pro Ala Ser Gly Gln Met Arg Leu Glu Lys Thr Asp Gln Ile 195 200 205
Pro Met Pro Phe Ser Ser Ser Ser Leu Ser Cys Leu Asn Leu Pro Glu 210
215 220 Gly Pro Ile Gln Phe Val Pro Thr Ile Ser Thr Leu Pro His Gly
Leu 225 230 235 240 Trp Gln Ile Ser Glu Ala Gly Thr Gly Val Ser Ser
Ile Phe Ile Tyr 245 250 255 His Gly Glu Val Pro Gln Ala Ser Gln Val
Pro Pro Pro Ser Gly Phe 260 265 270 Thr Val His Gly Leu Pro Thr Ser
Pro Asp Arg Pro Gly Ser Thr Ser 275 280 285 Pro Phe Ala Pro Ser Ala
Thr Asp Leu Pro Ser Met Pro Glu Pro Ala 290 295 300 Leu Thr Ser Arg
Ala Asn Met Thr Glu His Lys Thr Ser Pro Thr Gln 305 310 315 320 Cys
Pro Ala Ala Gly Glu Val Ser Asn Lys Leu Pro Lys Trp Pro Glu 325 330
335 Pro Val Glu Gln Phe Tyr Arg Ser Leu Gln Asp Thr Tyr Gly Ala Glu
340 345 350 Pro Ala Gly Pro Asp Gly Ile Leu Val Glu Val Asp Leu Val
Gln Ala 355 360 365 Arg Leu Glu Arg Ser Ser Ser Lys Ser Leu Glu Arg
Glu Leu Ala Thr 370 375 380 Pro Asp Trp Ala Glu Arg Gln Leu Ala Gln
Gly Gly Leu Ala Glu Val 385 390 395 400 Leu Leu Ala Ala Lys Glu His
Arg Arg Pro Arg Glu Thr Arg Val Ile 405 410 415 Ala Val Leu Gly Lys
Ala Gly Gln Gly Lys Ser Tyr Trp Ala Gly Ala 420 425 430 Val Ser Arg
Ala Trp Ala Cys Gly Arg Leu Pro Gln Tyr Asp Phe Val 435 440 445 Phe
Ser Val Pro Cys His Cys Leu Asn Arg Pro Gly Asp Ala Tyr Gly 450 455
460 Leu Gln Asp Leu Leu Phe Ser Leu Gly Pro Gln Pro Leu Val Ala Ala
465 470 475 480 Asp Glu Val Phe Ser His Ile Leu Lys Arg Pro Asp Arg
Val Leu Leu 485 490 495 Ile Leu Asp Gly Phe Glu Glu Leu Glu Ala Gln
Asp Gly Phe Leu His 500 505 510 Ser Thr Cys Gly Pro Ala Pro Ala Glu
Pro Cys Ser Leu Arg Gly Leu 515 520 525 Leu Ala Gly Leu Phe Gln Lys
Lys Leu Leu Arg Gly Cys Thr Leu Leu 530 535 540 Leu Thr Ala Arg Pro
Arg Gly Arg Leu Val Gln Ser Leu Ser Lys Ala 545 550 555 560 Asp Ala
Leu Phe Glu Leu Ser Gly Phe Ser Met Glu Gln Ala Gln Ala 565 570 575
Tyr Val Met Arg Tyr Phe Glu Ser Ser Gly Met Thr Glu His Gln Asp 580
585 590 Arg Ala Leu Thr Leu Leu Arg Asp Arg Pro Leu Leu Leu Ser His
Ser 595 600 605 His Ser Pro Thr Leu Cys Arg Ala Val Cys Gln Leu Ser
Glu Ala Leu 610 615 620 Leu Glu Leu Gly Glu Asp Ala Lys Leu Pro Ser
Thr Leu Thr Gly Leu 625 630 635 640 Tyr Val Gly Leu Leu Gly Arg Ala
Ala Leu Asp Ser Pro Pro Gly Ala 645 650 655 Leu Ala Glu Leu Ala Lys
Leu Ala Trp Glu Leu Gly Arg Arg His Gln 660 665 670 Ser Thr Leu Gln
Glu Asp Gln Phe Pro Ser Ala Asp Val Arg Thr Trp 675 680 685 Ala Met
Ala Lys Gly Leu Val Gln His Pro Pro Arg Ala Ala Glu Ser 690 695 700
Glu Leu Ala Phe Pro Ser Phe Leu Leu Gln Cys Phe Leu Gly Ala Leu 705
710 715 720 Trp Leu Ala Leu Ser Gly Glu Ile Lys Asp Lys Glu Leu Pro
Gln Tyr 725 730 735 Leu Ala Leu Thr Pro Arg Lys Lys Arg Pro Tyr Asp
Asn Trp Leu Glu 740 745 750 Gly Val Pro Arg Phe Leu Ala Gly Leu Ile
Phe Gln Pro Pro Ala Arg 755 760 765 Cys Leu Gly Ala Leu Leu Gly Pro
Ser Ala Ala Ala Ser Val Asp Arg 770 775 780 Lys Gln Lys Val Leu Ala
Arg Tyr Leu Lys Arg Leu Gln Pro Gly Thr 785 790 795 800 Leu Arg Ala
Arg Gln Leu Leu Glu Leu Leu His Cys Ala His Glu Ala 805 810 815 Glu
Glu Ala Gly Ile Trp Gln His Val Val Gln Glu Leu Pro Gly Arg 820 825
830 Leu Ser Phe Leu Gly Thr Arg Leu Thr Pro Pro Asp Ala His Val Leu
835 840 845 Gly Lys Ala Leu Glu Ala Ala Gly Gln Asp Phe Ser Leu Asp
Leu Arg 850 855 860 Ser Thr Gly Ile Cys Pro Ser Gly Leu Gly Ser Leu
Val Gly Leu Ser 865 870 875 880 Cys Val Thr Arg Phe Arg Ala Ala Leu
Ser Asp Thr Val Ala Leu Trp 885 890 895 Glu Ser Leu Gln Gln His Gly
Glu Thr Lys Leu Leu Gln Ala Ala Glu 900 905 910 Glu Lys Phe Thr Ile
Glu Pro Phe Lys Ala Lys Ser Leu Lys Asp Val 915 920 925 Glu Asp Leu
Gly Lys Leu Val Gln Thr Gln Arg Thr Arg Ser Ser Ser 930 935 940 Glu
Asp Thr Ala Gly Glu Leu Pro Ala Val Arg Asp Leu Lys Lys Leu 945 950
955 960 Glu Phe Ala Leu Gly Pro Val Ser Gly Pro Gln Ala Phe Pro Lys
Leu 965 970 975 Val Arg Ile Leu Thr Ala Phe Ser Ser Leu Gln His Leu
Asp Leu Asp 980 985
990 Ala Leu Ser Glu Asn Lys Ile Gly Asp Glu Gly Val Ser Gln Leu Ser
995 1000 1005 Ala Thr Phe Pro Gln Leu Lys Ser Leu Glu Thr Leu Asn
Leu Ser 1010 1015 1020 Gln Asn Asn Ile Thr Asp Leu Gly Ala Tyr Lys
Leu Ala Glu Ala 1025 1030 1035 Leu Pro Ser Leu Ala Ala Ser Leu Leu
Arg Leu Ser Leu Tyr Asn 1040 1045 1050 Asn Cys Ile Cys Asp Val Gly
Ala Glu Ser Leu Ala Arg Val Leu 1055 1060 1065 Pro Asp Met Val Ser
Leu Arg Val Met Asp Val Gln Tyr Asn Lys 1070 1075 1080 Phe Thr Ala
Ala Gly Ala Gln Gln Leu Ala Ala Ser Leu Arg Arg 1085 1090 1095 Cys
Pro His Val Glu Thr Leu Ala Met Trp Thr Pro Thr Ile Pro 1100 1105
1110 Phe Ser Val Gln Glu His Leu Gln Gln Gln Asp Ser Arg Ile Ser
1115 1120 1125 Leu Arg 1130 54654DNAHomo sapiens 5ggttagtgat
gaggctagtg atgaggctgt gtgcttctga gctgggcatc cgaaggcatc 60cttggggaag
ctgagggcac gaggaggggc tgccagactc cgggagctgc tgcctggctg
120ggattcctac acaatgcgtt gcctggctcc acgccctgct gggtcctacc
tgtcagagcc 180ccaaggcagc tcacagtgtg ccaccatgga gttggggccc
ctagaaggtg gctacctgga 240gcttcttaac agcgatgctg accccctgtg
cctctaccac ttctatgacc agatggacct 300ggctggagaa gaagagattg
agctctactc agaacccgac acagacacca tcaactgcga 360ccagttcagc
aggctgttgt gtgacatgga aggtgatgaa gagaccaggg aggcttatgc
420caatatcgcg gaactggacc agtatgtctt ccaggactcc cagctggagg
gcctgagcaa 480ggacattttc aagcacatag gaccagatga agtgatcggt
gagagtatgg agatgccagc 540agaagttggg cagaaaagtc agaaaagacc
cttcccagag gagcttccgg cagacctgaa 600gcactggaag ccagctgagc
cccccactgt ggtgactggc agtctcctag tgggaccagt 660gagcgactgc
tccaccctgc cctgcctgcc actgcctgcg ctgttcaacc aggagccagc
720ctccggccag atgcgcctgg agaaaaccga ccagattccc atgcctttct
ccagttcctc 780gttgagctgc ctgaatctcc ctgagggacc catccagttt
gtccccacca tctccactct 840gccccatggg ctctggcaaa tctctgaggc
tggaacaggg gtctccagta tattcatcta 900ccatggtgag gtgccccagg
ccagccaagt accccctccc agtggattca ctgtccacgg 960cctcccaaca
tctccagacc ggccaggctc caccagcccc ttcgctccat cagccactga
1020cctgcccagc atgcctgaac ctgccctgac ctcccgagca aacatgacag
agcacaagac 1080gtcccccacc caatgcccgg cagctggaga ggtctccaac
aagcttccaa aatggcctga 1140gccggtggag cagttctacc gctcactgca
ggacacgtat ggtgccgagc ccgcaggccc 1200ggatggcatc ctagtggagg
tggatctggt gcaggccagg ctggagagga gcagcagcaa 1260gagcctggag
cgggaactgg ccaccccgga ctgggcagaa cggcagctgg cccaaggagg
1320cctggctgag gtgctgttgg ctgccaagga gcaccggcgg ccgcgtgaga
cacgagtgat 1380tgctgtgctg ggcaaagctg gtcagggcaa gagctattgg
gctggggcag tgagccgggc 1440ctgggcttgt ggccggcttc cccagtacga
ctttgtcttc tctgtcccct gccattgctt 1500gaaccgtccg ggggatgcct
atggcctgca ggatctgctc ttctccctgg gcccacagcc 1560actcgtggcg
gccgatgagg ttttcagcca catcttgaag agacctgacc gcgttctgct
1620catcctagac ggcttcgagg agctggaagc gcaagatggc ttcctgcaca
gcacgtgcgg 1680accggcaccg gcggagccct gctccctccg ggggctgctg
gccggccttt tccagaagaa 1740gctgctccga ggttgcaccc tcctcctcac
agcccggccc cggggccgcc tggtccagag 1800cctgagcaag gccgacgccc
tatttgagct gtccggcttc tccatggagc aggcccaggc 1860atacgtgatg
cgctactttg agagctcagg gatgacagag caccaagaca gagccctgac
1920gctcctccgg gaccggccac ttcttctcag tcacagccac agccctactt
tgtgccgggc 1980agtgtgccag ctctcagagg ccctgctgga gcttggggag
gacgccaagc tgccctccac 2040gctcacggga ctctatgtcg gcctgctggg
ccgtgcagcc ctcgacagcc cccccggggc 2100cctggcagag ctggccaagc
tggcctggga gctgggccgc agacatcaaa gtaccctaca 2160ggaggaccag
ttcccatccg cagacgtgag gacctgggcg atggccaaag gcttagtcca
2220acacccaccg cgggccgcag agtccgagct ggccttcccc agcttcctcc
tgcaatgctt 2280cctgggggcc ctgtggctgg ctctgagtgg cgaaatcaag
gacaaggagc tcccgcagta 2340cctagcattg accccaagga agaagaggcc
ctatgacaac tggctggagg gcgtgccacg 2400ctttctggct gggctgatct
tccagcctcc cgcccgctgc ctgggagccc tactcgggcc 2460atcggcggct
gcctcggtgg acaggaagca gaaggtgctt gcgaggtacc tgaagcggct
2520gcagccgggg acactgcggg cgcggcagct gctggagctg ctgcactgcg
cccacgaggc 2580cgaggaggct ggaatttggc agcacgtggt acaggagctc
cccggccgcc tctcttttct 2640gggcacccgc ctcacgcctc ctgatgcaca
tgtactgggc aaggccttgg aggcggcggg 2700ccaagacttc tccctggacc
tccgcagcac tggcatttgc ccctctggat tggggagcct 2760cgtgggactc
agctgtgtca cccgtttcag ggctgccttg agcgacacgg tggcgctgtg
2820ggagtccctg cagcagcatg gggagaccaa gctacttcag gcagcagagg
agaagttcac 2880catcgagcct ttcaaagcca agtccctgaa ggatgtggaa
gacctgggaa agcttgtgca 2940gactcagagg acgagaagtt cctcggaaga
cacagctggg gagctccctg ctgttcggga 3000cctaaagaaa ctggagtttg
cgctgggccc tgtctcaggc ccccaggctt tccccaaact 3060ggtgcggatc
ctcacggcct tttcctccct gcagcatctg gacctggatg cgctgagtga
3120gaacaagatc ggggacgagg gtgtctcgca gctctcagcc accttccccc
agctgaagtc 3180cttggaaacc ctcaatctgt cccagaacaa catcactgac
ctgggtgcct acaaactcgc 3240cgaggccctg ccttcgctcg ctgcatccct
gctcaggcta agcttgtaca ataactgcat 3300ctgcgacgtg ggagccgaga
gcttggctcg tgtgcttccg gacatggtgt ccctccgggt 3360gatggacgtc
cagtacaaca agttcacggc tgccggggcc cagcagctcg ctgccagcct
3420tcggaggtgt cctcatgtgg agacgctggc gatgtggacg cccaccatcc
cattcagtgt 3480ccaggaacac ctgcaacaac aggattcacg gatcagcctg
agatgatccc agctgtgctc 3540tggacaggca tgttctctga ggacactaac
cacgctggac cttgaactgg gtacttgtgg 3600acacagctct tctccaggct
gtatcccatg agcctcagca tcctggcacc cggcccctgc 3660tggttcaggg
ttggcccctg cccggctgcg gaatgaacca catcttgctc tgctgacaga
3720cacaggcccg gctccaggct cctttagcgc ccagttgggt ggatgcctgg
tggcagctgc 3780ggtccaccca ggagccccga ggccttctct gaaggacatt
gcggacagcc acggccaggc 3840cagagggagt gacagaggca gccccattct
gcctgcccag gcccctgcca ccctggggag 3900aaagtacttc ttttttttta
tttttagaca gagtctcact gttgcccagg ctggcgtgca 3960gtggtgcgat
ctgggttcac tgcaacctcc gcctcttggg ttcaagcgat tcttctgctt
4020cagcctcccg agtagctggg actacaggca cccaccatca tgtctggcta
atttttcatt 4080tttagtagag acagggtttt gccatgttgg ccaggctggt
ctcaaactct tgacctcagg 4140tgatccaccc acctcagcct cccaaagtgc
tgggattaca agcgtgagcc actgcaccgg 4200gccacagaga aagtacttct
ccaccctgct ctccgaccag acaccttgac agggcacacc 4260gggcactcag
aagacactga tgggcaaccc ccagcctgct aattccccag attgcaacag
4320gctgggcttc agtggcagct gcttttgtct atgggactca atgcactgac
attgttggcc 4380aaagccaaag ctaggcctgg ccagatgcac cagcccttag
cagggaaaca gctaatggga 4440cactaatggg gcggtgagag gggaacagac
tggaagcaca gcttcatttc ctgtgtcttt 4500tttcactaca ttataaatgt
ctctttaatg tcacaggcag gtccagggtt tgagttcata 4560ccctgttacc
attttggggt acccactgct ctggttatct aatatgtaac aagccacccc
4620aaatcatagt ggcttaaaac aacactcaca ttta 46546495PRTArtificial
Sequenceanti-CD19 Cimeric Antigen Receptor 6Met Glu Thr Asp Thr Leu
Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Ile 20 25 30 Lys Pro
Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr 35 40 45
Phe Thr Ser Tyr Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly 50
55 60 Leu Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys
Tyr 65 70 75 80 Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp
Lys Ser Ser 85 90 95 Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr
Ser Glu Asp Ser Ala 100 105 110 Val Tyr Tyr Cys Ala Arg Gly Thr Tyr
Tyr Tyr Gly Ser Arg Val Phe 115 120 125 Asp Tyr Trp Gly Gln Gly Thr
Thr Leu Thr Val Ser Ser Gly Gly Gly 130 135 140 Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met 145 150 155 160 Thr Gln
Ala Ala Pro Ser Ile Pro Val Thr Pro Gly Glu Ser Val Ser 165 170 175
Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Asn Ser Asn Gly Asn Thr 180
185 190 Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro Gln Leu
Leu 195 200 205 Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro Asp
Arg Phe Ser 210 215 220 Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg
Ile Ser Arg Val Glu 225 230 235 240 Ala Glu Asp Val Gly Val Tyr Tyr
Cys Met Gln His Leu Glu Tyr Pro 245 250 255 Phe Thr Phe Gly Ala Gly
Thr Lys Leu Glu Leu Lys Arg Ser Asp Pro 260 265 270 Thr Thr Thr Pro
Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala 275 280 285 Ser Gln
Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 290 295 300
Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile 305
310 315 320 Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser
Leu Val 325 330 335 Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu
Leu Tyr Ile Phe 340 345 350 Lys Gln Pro Phe Met Arg Pro Val Gln Thr
Thr Gln Glu Glu Asp Gly 355 360 365 Cys Ser Cys Arg Phe Pro Glu Glu
Glu Glu Gly Gly Cys Glu Leu Arg 370 375 380 Val Lys Phe Ser Arg Ser
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln 385 390 395 400 Asn Gln Leu
Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp 405 410 415 Val
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro 420 425
430 Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
435 440 445 Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
Arg Arg 450 455 460 Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
Ser Thr Ala Thr 465 470 475 480 Lys Asp Thr Tyr Asp Ala Leu His Met
Gln Ala Leu Pro Pro Arg 485 490 495 717PRTArtificial
SequenceANti-CD19 CAR 7Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala
Ala Ala Ala Ala Ala 1 5 10 15 Ala 823DNAHomo sapiens 8gagaatcaaa
atcggtgaat agg 23923DNAHomo sapiens 9ttcaaaacct gtcagtgatt ggg
231023DNAHomo sapiens 10tgtgctagac atgaggtcta tgg 231123DNAHomo
sapiens 11cgtcatgagc agattaaacc cgg 231223DNAHomo sapiens
12tcagggttct ggatatctgt ggg 231323DNAHomo sapiens 13gtcagggttc
tggatatctg tgg 231423DNAHomo sapiens 14ttcggaaccc aatcactgac agg
231523DNAHomo sapiens 15taaacccggc cactttcagg agg 231623DNAHomo
sapiens 16aaagtcagat ttgttgctcc agg 231723DNAHomo sapiens
17aacaaatgtg tcacaaagta agg 231823DNAHomo sapiens 18tggatttaga
gtctctcagc tgg 231923DNAHomo sapiens 19taggcagaca gacttgtcac tgg
232023DNAHomo sapiens 20agctggtaca cggcagggtc agg 232123DNAHomo
sapiens 21gctggtacac ggcagggtca ggg 232223DNAHomo sapiens
22tctctcagct ggtacacggc agg 232323DNAHomo sapiens 23tttcaaaacc
tgtcagtgat tgg 232423DNAHomo sapiens 24gattaaaccc ggccactttc agg
232523DNAHomo sapiens 25ctcgaccagc ttgacatcac agg 232623DNAHomo
sapiens 26agagtctctc agctggtaca cgg 232723DNAHomo sapiens
27ctctcagctg gtacacggca ggg 232823DNAHomo sapiens 28aagttcctgt
gatgtcaagc tgg 232923DNAHomo sapiens 29atcctcctcc tgaaagtggc cgg
233023DNAHomo sapiens 30tgctcatgac gctgcggctg tgg 233123DNAHomo
sapiens 31acaaaactgt gctagacatg agg 233223DNAHomo sapiens
32atttgtttga gaatcaaaat cgg 233323DNAHomo sapiens 33catcacagga
actttctaaa agg 233423DNAHomo sapiens 34gtcgagaaaa gctttgaaac agg
233523DNAHomo sapiens 35ccactttcag gaggaggatt cgg 233623DNAHomo
sapiens 36ctgacaggtt ttgaaagttt agg 233723DNAHomo sapiens
37agctttgaaa caggtaagac agg 233823DNAHomo sapiens 38tggaataatg
ctgttgttga agg 233923DNAHomo sapiens 39agagcaacag tgctgtggcc tgg
234023DNAHomo sapiens 40ctgtggtcca gctgaggtga ggg 234123DNAHomo
sapiens 41ctgcggctgt ggtccagctg agg 234223DNAHomo sapiens
42tgtggtccag ctgaggtgag ggg 234323DNAHomo sapiens 43cttcttcccc
agcccaggta agg 234423DNAHomo sapiens 44acacggcagg gtcagggttc tgg
234523DNAHomo sapiens 45cttcaagagc aacagtgctg tgg 234623DNAHomo
sapiens 46ctggggaaga aggtgtcttc tgg 234723DNAHomo sapiens
47tcctcctcct gaaagtggcc ggg 234823DNAHomo sapiens 48ttaatctgct
catgacgctg cgg 234923DNAHomo sapiens 49acccggccac tttcaggagg agg
235023DNAHomo sapiens 50ttcttcccca gcccaggtaa ggg 235123DNAHomo
sapiens 51cttacctggg ctggggaaga agg 235223DNAHomo sapiens
52gacaccttct tccccagccc agg 235323DNAHomo sapiens 53gctgtggtcc
agctgaggtg agg 235423DNAHomo sapiens 54ccgaatcctc ctcctgaaag tgg
235549DNAHomo sapiens 55ttccctccca ggcagctcac agtgtgccac catggagttg
gggccccta 495649DNAHomo sapiens 56tgcctctacc acttctatga ccagatggac
ctggctggag aagaagaga 495749DNAHomo sapiens 57tcttcatcca agggactttt
cctcccagaa cccgacacag acaccatca 495849DNAHomo sapiens 58tgttgtgtga
catggaaggt gatgaagaga ccagggaggc ttatgccaa 495947DNAHomo sapiens
59ccaaagattc aggtttactc acgtcatcca gcagagaatg gaaagtc 476049DNAHomo
sapiens 60ttgtcccaca gatatccaga accctgaccc tgccgtgtac cagctgaga
496149DNAHomo sapiens 61tgtgtttgag ccatcagaag cagagatctc ccacacccaa
aaggccaca 496250DNAHomo sapiens 62ttcccacccg aggtcgctgt gtttgagcca
tcagaagcag agatctccca 506349DNAHomo sapiens 63tttagaaagt tcctgtgatg
tcaagctggt cgagaaaagc tttgaaaca 496449DNAHomo sapiens 64tccagtgaca
agtctgtctg cctattcacc gattttgatt ctcaaacaa 496549DNAHomo sapiens
65tatatcacag acaaaactgt gctagacatg aggtctatgg acttcaaga
496649DNAHomo sapiens 66tgaggtctat ggacttcaag agcaacagtg ctgtggcctg
gagcaacaa 49672814DNAArtificial SequenceTALE-nuclease sequence
67atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgatgt tccagattac
60gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca ggagaagatc
120aaaccgaagg ttcgttcgac agtggcgcag caccacgagg cactggtcgg
ccacgggttt 180acacacgcgc acatcgttgc gttaagccaa cacccggcag
cgttagggac cgtcgctgtc 240aagtatcagg acatgatcgc agcgttgcca
gaggcgacac acgaagcgat cgttggcgtc 300ggcaaacagt ggtccggcgc
acgcgctctg gaggccttgc tcacggtggc gggagagttg 360agaggtccac
cgttacagtt ggacacaggc caacttctca agattgcaaa acgtggcggc
420gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac tgacgggtgc
cccgctcaac 480ttgaccccgg agcaggtggt ggccatcgcc agccacgatg
gcggcaagca ggcgctggag 540acggtccagc ggctgttgcc ggtgctgtgc
caggcccacg gcttgacccc ggagcaggtg 600gtggccatcg ccagccacga
tggcggcaag caggcgctgg agacggtcca gcggctgttg 660ccggtgctgt
gccaggccca cggcttgacc ccggagcagg tggtggccat cgccagcaat
720attggtggca agcaggcgct ggagacggtg caggcgctgt tgccggtgct
gtgccaggcc 780cacggcttga ccccggagca ggtggtggcc atcgccagca
atattggtgg caagcaggcg 840ctggagacgg tgcaggcgct gttgccggtg
ctgtgccagg cccacggctt gaccccggag 900caggtggtgg ccatcgccag
caatattggt ggcaagcagg cgctggagac ggtgcaggcg 960ctgttgccgg
tgctgtgcca ggcccacggc ttgacccccc agcaggtggt ggccatcgcc
1020agcaataatg gtggcaagca ggcgctggag acggtccagc ggctgttgcc
ggtgctgtgc 1080caggcccacg gcttgacccc ggagcaggtg gtggccatcg
ccagcaatat tggtggcaag 1140caggcgctgg agacggtgca ggcgctgttg
ccggtgctgt gccaggccca cggcttgacc 1200ccccagcagg
tggtggccat cgccagcaat ggcggtggca agcaggcgct ggagacggtc
1260cagcggctgt tgccggtgct gtgccaggcc cacggcttga ccccccagca
ggtggtggcc 1320atcgccagca atggcggtgg caagcaggcg ctggagacgg
tccagcggct gttgccggtg 1380ctgtgccagg cccacggctt gaccccggag
caggtggtgg ccatcgccag ccacgatggc 1440ggcaagcagg cgctggagac
ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 1500ttgaccccgg
agcaggtggt ggccatcgcc agcaatattg gtggcaagca ggcgctggag
1560acggtgcagg cgctgttgcc ggtgctgtgc caggcccacg gcttgacccc
ccagcaggtg 1620gtggccatcg ccagcaataa tggtggcaag caggcgctgg
agacggtcca gcggctgttg 1680ccggtgctgt gccaggccca cggcttgacc
ccccagcagg tggtggccat cgccagcaat 1740aatggtggca agcaggcgct
ggagacggtc cagcggctgt tgccggtgct gtgccaggcc 1800cacggcttga
ccccccagca ggtggtggcc atcgccagca atggcggtgg caagcaggcg
1860ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt
gaccccccag 1920caggtggtgg ccatcgccag caatggcggt ggcaagcagg
cgctggagac ggtccagcgg 1980ctgttgccgg tgctgtgcca ggcccacggc
ttgacccctc agcaggtggt ggccatcgcc 2040agcaatggcg gcggcaggcc
ggcgctggag agcattgttg cccagttatc tcgccctgat 2100ccggcgttgg
ccgcgttgac caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt
2160cctgcgctgg atgcagtgaa aaagggattg ggggatccta tcagccgttc
ccagctggtg 2220aagtccgagc tggaggagaa gaaatccgag ttgaggcaca
agctgaagta cgtgccccac 2280gagtacatcg agctgatcga gatcgcccgg
aacagcaccc aggaccgtat cctggagatg 2340aaggtgatgg agttcttcat
gaaggtgtac ggctacaggg gcaagcacct gggcggctcc 2400aggaagcccg
acggcgccat ctacaccgtg ggctccccca tcgactacgg cgtgatcgtg
2460gacaccaagg cctactccgg cggctacaac ctgcccatcg gccaggccga
cgaaatgcag 2520aggtacgtgg aggagaacca gaccaggaac aagcacatca
accccaacga gtggtggaag 2580gtgtacccct ccagcgtgac cgagttcaag
ttcctgttcg tgtccggcca cttcaagggc 2640aactacaagg cccagctgac
caggctgaac cacatcacca actgcaacgg cgccgtgctg 2700tccgtggagg
agctcctgat cggcggcgag atgatcaagg ccggcaccct gaccctggag
2760gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa
2814682832DNAArtificial SequenceTALE-nuclease sequence 68atgggcgatc
ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc 60gagagacagc
acatggacag catcgatatc gccgatctac gcacgctcgg ctacagccag
120cagcaacagg agaagatcaa accgaaggtt cgttcgacag tggcgcagca
ccacgaggca 180ctggtcggcc acgggtttac acacgcgcac atcgttgcgt
taagccaaca cccggcagcg 240ttagggaccg tcgctgtcaa gtatcaggac
atgatcgcag cgttgccaga ggcgacacac 300gaagcgatcg ttggcgtcgg
caaacagtgg tccggcgcac gcgctctgga ggccttgctc 360acggtggcgg
gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag
420attgcaaaac gtggcggcgt gaccgcagtg gaggcagtgc atgcatggcg
caatgcactg 480acgggtgccc cgctcaactt gaccccccag caggtggtgg
ccatcgccag caataatggt 540ggcaagcagg cgctggagac ggtccagcgg
ctgttgccgg tgctgtgcca ggcccacggc 600ttgaccccgg agcaggtggt
ggccatcgcc agcaatattg gtggcaagca ggcgctggag 660acggtgcagg
cgctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg
720gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca
gcggctgttg 780ccggtgctgt gccaggccca cggcttgacc ccccagcagg
tggtggccat cgccagcaat 840ggcggtggca agcaggcgct ggagacggtc
cagcggctgt tgccggtgct gtgccaggcc 900cacggcttga ccccccagca
ggtggtggcc atcgccagca atggcggtgg caagcaggcg 960ctggagacgg
tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccccag
1020caggtggtgg ccatcgccag caatggcggt ggcaagcagg cgctggagac
ggtccagcgg 1080ctgttgccgg tgctgtgcca ggcccacggc ttgaccccgg
agcaggtggt ggccatcgcc 1140agccacgatg gcggcaagca ggcgctggag
acggtccagc ggctgttgcc ggtgctgtgc 1200caggcccacg gcttgacccc
ggagcaggtg gtggccatcg ccagccacga tggcggcaag 1260caggcgctgg
agacggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc
1320ccggagcagg tggtggccat cgccagcaat attggtggca agcaggcgct
ggagacggtg 1380caggcgctgt tgccggtgct gtgccaggcc cacggcttga
ccccccagca ggtggtggcc 1440atcgccagca atggcggtgg caagcaggcg
ctggagacgg tccagcggct gttgccggtg 1500ctgtgccagg cccacggctt
gaccccccag caggtggtgg ccatcgccag caatggcggt 1560ggcaagcagg
cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc
1620ttgaccccgg agcaggtggt ggccatcgcc agccacgatg gcggcaagca
ggcgctggag 1680acggtccagc ggctgttgcc ggtgctgtgc caggcccacg
gcttgacccc ccagcaggtg 1740gtggccatcg ccagcaatgg cggtggcaag
caggcgctgg agacggtcca gcggctgttg 1800ccggtgctgt gccaggccca
cggcttgacc ccggagcagg tggtggccat cgccagccac 1860gatggcggca
agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc
1920cacggcttga ccccccagca ggtggtggcc atcgccagca atggcggtgg
caagcaggcg 1980ctggagacgg tccagcggct gttgccggtg ctgtgccagg
cccacggctt gacccctcag 2040caggtggtgg ccatcgccag caatggcggc
ggcaggccgg cgctggagag cattgttgcc 2100cagttatctc gccctgatcc
ggcgttggcc gcgttgacca acgaccacct cgtcgccttg 2160gcctgcctcg
gcgggcgtcc tgcgctggat gcagtgaaaa agggattggg ggatcctatc
2220agccgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt
gaggcacaag 2280ctgaagtacg tgccccacga gtacatcgag ctgatcgaga
tcgcccggaa cagcacccag 2340gaccgtatcc tggagatgaa ggtgatggag
ttcttcatga aggtgtacgg ctacaggggc 2400aagcacctgg gcggctccag
gaagcccgac ggcgccatct acaccgtggg ctcccccatc 2460gactacggcg
tgatcgtgga caccaaggcc tactccggcg gctacaacct gcccatcggc
2520caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa
gcacatcaac 2580cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg
agttcaagtt cctgttcgtg 2640tccggccact tcaagggcaa ctacaaggcc
cagctgacca ggctgaacca catcaccaac 2700tgcaacggcg ccgtgctgtc
cgtggaggag ctcctgatcg gcggcgagat gatcaaggcc 2760ggcaccctga
ccctggagga ggtgaggagg aagttcaaca acggcgagat caacttcgcg
2820gccgactgat aa 2832692814DNAArtificial SequenceTALE-nuclease
sequence 69atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgatgt
tccagattac 60gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca
ggagaagatc 120aaaccgaagg ttcgttcgac agtggcgcag caccacgagg
cactggtcgg ccacgggttt 180acacacgcgc acatcgttgc gttaagccaa
cacccggcag cgttagggac cgtcgctgtc 240aagtatcagg acatgatcgc
agcgttgcca gaggcgacac acgaagcgat cgttggcgtc 300ggcaaacagt
ggtccggcgc acgcgctctg gaggccttgc tcacggtggc gggagagttg
360agaggtccac cgttacagtt ggacacaggc caacttctca agattgcaaa
acgtggcggc 420gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac
tgacgggtgc cccgctcaac 480ttgacccccc agcaggtggt ggccatcgcc
agcaatggcg gtggcaagca ggcgctggag 540acggtccagc ggctgttgcc
ggtgctgtgc caggcccacg gcttgacccc ccagcaggtg 600gtggccatcg
ccagcaataa tggtggcaag caggcgctgg agacggtcca gcggctgttg
660ccggtgctgt gccaggccca cggcttgacc ccccagcagg tggtggccat
cgccagcaat 720ggcggtggca agcaggcgct ggagacggtc cagcggctgt
tgccggtgct gtgccaggcc 780cacggcttga ccccggagca ggtggtggcc
atcgccagcc acgatggcgg caagcaggcg 840ctggagacgg tccagcggct
gttgccggtg ctgtgccagg cccacggctt gaccccggag 900caggtggtgg
ccatcgccag ccacgatggc ggcaagcagg cgctggagac ggtccagcgg
960ctgttgccgg tgctgtgcca ggcccacggc ttgaccccgg agcaggtggt
ggccatcgcc 1020agccacgatg gcggcaagca ggcgctggag acggtccagc
ggctgttgcc ggtgctgtgc 1080caggcccacg gcttgacccc ggagcaggtg
gtggccatcg ccagcaatat tggtggcaag 1140caggcgctgg agacggtgca
ggcgctgttg ccggtgctgt gccaggccca cggcttgacc 1200ccggagcagg
tggtggccat cgccagccac gatggcggca agcaggcgct ggagacggtc
1260cagcggctgt tgccggtgct gtgccaggcc cacggcttga ccccggagca
ggtggtggcc 1320atcgccagca atattggtgg caagcaggcg ctggagacgg
tgcaggcgct gttgccggtg 1380ctgtgccagg cccacggctt gaccccccag
caggtggtgg ccatcgccag caataatggt 1440ggcaagcagg cgctggagac
ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 1500ttgaccccgg
agcaggtggt ggccatcgcc agcaatattg gtggcaagca ggcgctggag
1560acggtgcagg cgctgttgcc ggtgctgtgc caggcccacg gcttgacccc
ccagcaggtg 1620gtggccatcg ccagcaatgg cggtggcaag caggcgctgg
agacggtcca gcggctgttg 1680ccggtgctgt gccaggccca cggcttgacc
ccggagcagg tggtggccat cgccagcaat 1740attggtggca agcaggcgct
ggagacggtg caggcgctgt tgccggtgct gtgccaggcc 1800cacggcttga
ccccccagca ggtggtggcc atcgccagca atggcggtgg caagcaggcg
1860ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt
gaccccggag 1920caggtggtgg ccatcgccag ccacgatggc ggcaagcagg
cgctggagac ggtccagcgg 1980ctgttgccgg tgctgtgcca ggcccacggc
ttgacccctc agcaggtggt ggccatcgcc 2040agcaatggcg gcggcaggcc
ggcgctggag agcattgttg cccagttatc tcgccctgat 2100ccggcgttgg
ccgcgttgac caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt
2160cctgcgctgg atgcagtgaa aaagggattg ggggatccta tcagccgttc
ccagctggtg 2220aagtccgagc tggaggagaa gaaatccgag ttgaggcaca
agctgaagta cgtgccccac 2280gagtacatcg agctgatcga gatcgcccgg
aacagcaccc aggaccgtat cctggagatg 2340aaggtgatgg agttcttcat
gaaggtgtac ggctacaggg gcaagcacct gggcggctcc 2400aggaagcccg
acggcgccat ctacaccgtg ggctccccca tcgactacgg cgtgatcgtg
2460gacaccaagg cctactccgg cggctacaac ctgcccatcg gccaggccga
cgaaatgcag 2520aggtacgtgg aggagaacca gaccaggaac aagcacatca
accccaacga gtggtggaag 2580gtgtacccct ccagcgtgac cgagttcaag
ttcctgttcg tgtccggcca cttcaagggc 2640aactacaagg cccagctgac
caggctgaac cacatcacca actgcaacgg cgccgtgctg 2700tccgtggagg
agctcctgat cggcggcgag atgatcaagg ccggcaccct gaccctggag
2760gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa
2814702832DNAArtificial SequenceTALE-nuclease sequence 70atgggcgatc
ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc 60gagagacagc
acatggacag catcgatatc gccgatctac gcacgctcgg ctacagccag
120cagcaacagg agaagatcaa accgaaggtt cgttcgacag tggcgcagca
ccacgaggca 180ctggtcggcc acgggtttac acacgcgcac atcgttgcgt
taagccaaca cccggcagcg 240ttagggaccg tcgctgtcaa gtatcaggac
atgatcgcag cgttgccaga ggcgacacac 300gaagcgatcg ttggcgtcgg
caaacagtgg tccggcgcac gcgctctgga ggccttgctc 360acggtggcgg
gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag
420attgcaaaac gtggcggcgt gaccgcagtg gaggcagtgc atgcatggcg
caatgcactg 480acgggtgccc cgctcaactt gaccccggag caggtggtgg
ccatcgccag ccacgatggc 540ggcaagcagg cgctggagac ggtccagcgg
ctgttgccgg tgctgtgcca ggcccacggc 600ttgacccccc agcaggtggt
ggccatcgcc agcaatggcg gtggcaagca ggcgctggag 660acggtccagc
ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg
720gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca
gcggctgttg 780ccggtgctgt gccaggccca cggcttgacc ccggagcagg
tggtggccat cgccagcaat 840attggtggca agcaggcgct ggagacggtg
caggcgctgt tgccggtgct gtgccaggcc 900cacggcttga ccccccagca
ggtggtggcc atcgccagca ataatggtgg caagcaggcg 960ctggagacgg
tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccggag
1020caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac
ggtccagcgg 1080ctgttgccgg tgctgtgcca ggcccacggc ttgacccccc
agcaggtggt ggccatcgcc 1140agcaatggcg gtggcaagca ggcgctggag
acggtccagc ggctgttgcc ggtgctgtgc 1200caggcccacg gcttgacccc
ccagcaggtg gtggccatcg ccagcaataa tggtggcaag 1260caggcgctgg
agacggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc
1320ccccagcagg tggtggccat cgccagcaat aatggtggca agcaggcgct
ggagacggtc 1380cagcggctgt tgccggtgct gtgccaggcc cacggcttga
ccccccagca ggtggtggcc 1440atcgccagca atggcggtgg caagcaggcg
ctggagacgg tccagcggct gttgccggtg 1500ctgtgccagg cccacggctt
gaccccggag caggtggtgg ccatcgccag caatattggt 1560ggcaagcagg
cgctggagac ggtgcaggcg ctgttgccgg tgctgtgcca ggcccacggc
1620ttgaccccgg agcaggtggt ggccatcgcc agccacgatg gcggcaagca
ggcgctggag 1680acggtccagc ggctgttgcc ggtgctgtgc caggcccacg
gcttgacccc ggagcaggtg 1740gtggccatcg ccagcaatat tggtggcaag
caggcgctgg agacggtgca ggcgctgttg 1800ccggtgctgt gccaggccca
cggcttgacc ccggagcagg tggtggccat cgccagccac 1860gatggcggca
agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc
1920cacggcttga ccccccagca ggtggtggcc atcgccagca ataatggtgg
caagcaggcg 1980ctggagacgg tccagcggct gttgccggtg ctgtgccagg
cccacggctt gacccctcag 2040caggtggtgg ccatcgccag caatggcggc
ggcaggccgg cgctggagag cattgttgcc 2100cagttatctc gccctgatcc
ggcgttggcc gcgttgacca acgaccacct cgtcgccttg 2160gcctgcctcg
gcgggcgtcc tgcgctggat gcagtgaaaa agggattggg ggatcctatc
2220agccgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt
gaggcacaag 2280ctgaagtacg tgccccacga gtacatcgag ctgatcgaga
tcgcccggaa cagcacccag 2340gaccgtatcc tggagatgaa ggtgatggag
ttcttcatga aggtgtacgg ctacaggggc 2400aagcacctgg gcggctccag
gaagcccgac ggcgccatct acaccgtggg ctcccccatc 2460gactacggcg
tgatcgtgga caccaaggcc tactccggcg gctacaacct gcccatcggc
2520caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa
gcacatcaac 2580cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg
agttcaagtt cctgttcgtg 2640tccggccact tcaagggcaa ctacaaggcc
cagctgacca ggctgaacca catcaccaac 2700tgcaacggcg ccgtgctgtc
cgtggaggag ctcctgatcg gcggcgagat gatcaaggcc 2760ggcaccctga
ccctggagga ggtgaggagg aagttcaaca acggcgagat caacttcgcg
2820gccgactgat aa 2832712814DNAArtificial SequenceTALE-nuclease
sequence 71atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgatgt
tccagattac 60gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca
ggagaagatc 120aaaccgaagg ttcgttcgac agtggcgcag caccacgagg
cactggtcgg ccacgggttt 180acacacgcgc acatcgttgc gttaagccaa
cacccggcag cgttagggac cgtcgctgtc 240aagtatcagg acatgatcgc
agcgttgcca gaggcgacac acgaagcgat cgttggcgtc 300ggcaaacagt
ggtccggcgc acgcgctctg gaggccttgc tcacggtggc gggagagttg
360agaggtccac cgttacagtt ggacacaggc caacttctca agattgcaaa
acgtggcggc 420gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac
tgacgggtgc cccgctcaac 480ttgacccccc agcaggtggt ggccatcgcc
agcaataatg gtggcaagca ggcgctggag 540acggtccagc ggctgttgcc
ggtgctgtgc caggcccacg gcttgacccc ccagcaggtg 600gtggccatcg
ccagcaatgg cggtggcaag caggcgctgg agacggtcca gcggctgttg
660ccggtgctgt gccaggccca cggcttgacc ccccagcagg tggtggccat
cgccagcaat 720aatggtggca agcaggcgct ggagacggtc cagcggctgt
tgccggtgct gtgccaggcc 780cacggcttga ccccccagca ggtggtggcc
atcgccagca atggcggtgg caagcaggcg 840ctggagacgg tccagcggct
gttgccggtg ctgtgccagg cccacggctt gaccccccag 900caggtggtgg
ccatcgccag caatggcggt ggcaagcagg cgctggagac ggtccagcgg
960ctgttgccgg tgctgtgcca ggcccacggc ttgacccccc agcaggtggt
ggccatcgcc 1020agcaatggcg gtggcaagca ggcgctggag acggtccagc
ggctgttgcc ggtgctgtgc 1080caggcccacg gcttgacccc ccagcaggtg
gtggccatcg ccagcaataa tggtggcaag 1140caggcgctgg agacggtcca
gcggctgttg ccggtgctgt gccaggccca cggcttgacc 1200ccggagcagg
tggtggccat cgccagcaat attggtggca agcaggcgct ggagacggtg
1260caggcgctgt tgccggtgct gtgccaggcc cacggcttga ccccccagca
ggtggtggcc 1320atcgccagca ataatggtgg caagcaggcg ctggagacgg
tccagcggct gttgccggtg 1380ctgtgccagg cccacggctt gaccccggag
caggtggtgg ccatcgccag ccacgatggc 1440ggcaagcagg cgctggagac
ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 1500ttgaccccgg
agcaggtggt ggccatcgcc agccacgatg gcggcaagca ggcgctggag
1560acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc
ggagcaggtg 1620gtggccatcg ccagcaatat tggtggcaag caggcgctgg
agacggtgca ggcgctgttg 1680ccggtgctgt gccaggccca cggcttgacc
ccccagcagg tggtggccat cgccagcaat 1740ggcggtggca agcaggcgct
ggagacggtc cagcggctgt tgccggtgct gtgccaggcc 1800cacggcttga
ccccggagca ggtggtggcc atcgccagcc acgatggcgg caagcaggcg
1860ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt
gaccccggag 1920caggtggtgg ccatcgccag caatattggt ggcaagcagg
cgctggagac ggtgcaggcg 1980ctgttgccgg tgctgtgcca ggcccacggc
ttgacccctc agcaggtggt ggccatcgcc 2040agcaatggcg gcggcaggcc
ggcgctggag agcattgttg cccagttatc tcgccctgat 2100ccggcgttgg
ccgcgttgac caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt
2160cctgcgctgg atgcagtgaa aaagggattg ggggatccta tcagccgttc
ccagctggtg 2220aagtccgagc tggaggagaa gaaatccgag ttgaggcaca
agctgaagta cgtgccccac 2280gagtacatcg agctgatcga gatcgcccgg
aacagcaccc aggaccgtat cctggagatg 2340aaggtgatgg agttcttcat
gaaggtgtac ggctacaggg gcaagcacct gggcggctcc 2400aggaagcccg
acggcgccat ctacaccgtg ggctccccca tcgactacgg cgtgatcgtg
2460gacaccaagg cctactccgg cggctacaac ctgcccatcg gccaggccga
cgaaatgcag 2520aggtacgtgg aggagaacca gaccaggaac aagcacatca
accccaacga gtggtggaag 2580gtgtacccct ccagcgtgac cgagttcaag
ttcctgttcg tgtccggcca cttcaagggc 2640aactacaagg cccagctgac
caggctgaac cacatcacca actgcaacgg cgccgtgctg 2700tccgtggagg
agctcctgat cggcggcgag atgatcaagg ccggcaccct gaccctggag
2760gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa
2814722832DNAArtificial SequenceTALE-nuclease sequence 72atgggcgatc
ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc 60gagagacagc
acatggacag catcgatatc gccgatctac gcacgctcgg ctacagccag
120cagcaacagg agaagatcaa accgaaggtt cgttcgacag tggcgcagca
ccacgaggca 180ctggtcggcc acgggtttac acacgcgcac atcgttgcgt
taagccaaca cccggcagcg 240ttagggaccg tcgctgtcaa gtatcaggac
atgatcgcag cgttgccaga ggcgacacac 300gaagcgatcg ttggcgtcgg
caaacagtgg tccggcgcac gcgctctgga ggccttgctc 360acggtggcgg
gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag
420attgcaaaac gtggcggcgt gaccgcagtg gaggcagtgc atgcatggcg
caatgcactg 480acgggtgccc cgctcaactt gaccccccag caggtggtgg
ccatcgccag caataatggt 540ggcaagcagg cgctggagac ggtccagcgg
ctgttgccgg tgctgtgcca ggcccacggc 600ttgacccccc agcaggtggt
ggccatcgcc agcaatggcg gtggcaagca ggcgctggag 660acggtccagc
ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ccagcaggtg
720gtggccatcg ccagcaataa tggtggcaag caggcgctgg agacggtcca
gcggctgttg 780ccggtgctgt gccaggccca cggcttgacc ccccagcagg
tggtggccat cgccagcaat 840aatggtggca agcaggcgct ggagacggtc
cagcggctgt tgccggtgct gtgccaggcc 900cacggcttga ccccggagca
ggtggtggcc atcgccagcc acgatggcgg caagcaggcg 960ctggagacgg
tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccggag
1020caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac
ggtccagcgg 1080ctgttgccgg tgctgtgcca ggcccacggc ttgacccccc
agcaggtggt ggccatcgcc 1140agcaatggcg gtggcaagca ggcgctggag
acggtccagc ggctgttgcc ggtgctgtgc 1200caggcccacg gcttgacccc
ccagcaggtg gtggccatcg ccagcaatgg cggtggcaag 1260caggcgctgg
agacggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc
1320ccccagcagg tggtggccat cgccagcaat ggcggtggca agcaggcgct
ggagacggtc 1380cagcggctgt tgccggtgct gtgccaggcc cacggcttga
ccccccagca ggtggtggcc 1440atcgccagca atggcggtgg caagcaggcg
ctggagacgg tccagcggct gttgccggtg 1500ctgtgccagg cccacggctt
gaccccccag caggtggtgg ccatcgccag caataatggt 1560ggcaagcagg
cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc
1620ttgacccccc agcaggtggt ggccatcgcc agcaataatg gtggcaagca
ggcgctggag 1680acggtccagc ggctgttgcc ggtgctgtgc caggcccacg
gcttgacccc ccagcaggtg 1740gtggccatcg
ccagcaataa tggtggcaag caggcgctgg agacggtcca gcggctgttg
1800ccggtgctgt gccaggccca cggcttgacc ccccagcagg tggtggccat
cgccagcaat 1860ggcggtggca agcaggcgct ggagacggtc cagcggctgt
tgccggtgct gtgccaggcc 1920cacggcttga ccccccagca ggtggtggcc
atcgccagca ataatggtgg caagcaggcg 1980ctggagacgg tccagcggct
gttgccggtg ctgtgccagg cccacggctt gacccctcag 2040caggtggtgg
ccatcgccag caatggcggc ggcaggccgg cgctggagag cattgttgcc
2100cagttatctc gccctgatcc ggcgttggcc gcgttgacca acgaccacct
cgtcgccttg 2160gcctgcctcg gcgggcgtcc tgcgctggat gcagtgaaaa
agggattggg ggatcctatc 2220agccgttccc agctggtgaa gtccgagctg
gaggagaaga aatccgagtt gaggcacaag 2280ctgaagtacg tgccccacga
gtacatcgag ctgatcgaga tcgcccggaa cagcacccag 2340gaccgtatcc
tggagatgaa ggtgatggag ttcttcatga aggtgtacgg ctacaggggc
2400aagcacctgg gcggctccag gaagcccgac ggcgccatct acaccgtggg
ctcccccatc 2460gactacggcg tgatcgtgga caccaaggcc tactccggcg
gctacaacct gcccatcggc 2520caggccgacg aaatgcagag gtacgtggag
gagaaccaga ccaggaacaa gcacatcaac 2580cccaacgagt ggtggaaggt
gtacccctcc agcgtgaccg agttcaagtt cctgttcgtg 2640tccggccact
tcaagggcaa ctacaaggcc cagctgacca ggctgaacca catcaccaac
2700tgcaacggcg ccgtgctgtc cgtggaggag ctcctgatcg gcggcgagat
gatcaaggcc 2760ggcaccctga ccctggagga ggtgaggagg aagttcaaca
acggcgagat caacttcgcg 2820gccgactgat aa 2832732814DNAArtificial
SequenceTALE-nuclease sequence 73atgggcgatc ctaaaaagaa acgtaaggtc
atcgattacc catacgatgt tccagattac 60gctatcgata tcgccgatct acgcacgctc
ggctacagcc agcagcaaca ggagaagatc 120aaaccgaagg ttcgttcgac
agtggcgcag caccacgagg cactggtcgg ccacgggttt 180acacacgcgc
acatcgttgc gttaagccaa cacccggcag cgttagggac cgtcgctgtc
240aagtatcagg acatgatcgc agcgttgcca gaggcgacac acgaagcgat
cgttggcgtc 300ggcaaacagt ggtccggcgc acgcgctctg gaggccttgc
tcacggtggc gggagagttg 360agaggtccac cgttacagtt ggacacaggc
caacttctca agattgcaaa acgtggcggc 420gtgaccgcag tggaggcagt
gcatgcatgg cgcaatgcac tgacgggtgc cccgctcaac 480ttgaccccgg
agcaggtggt ggccatcgcc agccacgatg gcggcaagca ggcgctggag
540acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc
ggagcaggtg 600gtggccatcg ccagccacga tggcggcaag caggcgctgg
agacggtcca gcggctgttg 660ccggtgctgt gccaggccca cggcttgacc
ccggagcagg tggtggccat cgccagccac 720gatggcggca agcaggcgct
ggagacggtc cagcggctgt tgccggtgct gtgccaggcc 780cacggcttga
ccccggagca ggtggtggcc atcgccagca atattggtgg caagcaggcg
840ctggagacgg tgcaggcgct gttgccggtg ctgtgccagg cccacggctt
gaccccggag 900caggtggtgg ccatcgccag ccacgatggc ggcaagcagg
cgctggagac ggtccagcgg 960ctgttgccgg tgctgtgcca ggcccacggc
ttgaccccgg agcaggtggt ggccatcgcc 1020agccacgatg gcggcaagca
ggcgctggag acggtccagc ggctgttgcc ggtgctgtgc 1080caggcccacg
gcttgacccc ggagcaggtg gtggccatcg ccagccacga tggcggcaag
1140caggcgctgg agacggtcca gcggctgttg ccggtgctgt gccaggccca
cggcttgacc 1200ccccagcagg tggtggccat cgccagcaat aatggtggca
agcaggcgct ggagacggtc 1260cagcggctgt tgccggtgct gtgccaggcc
cacggcttga ccccggagca ggtggtggcc 1320atcgccagca atattggtgg
caagcaggcg ctggagacgg tgcaggcgct gttgccggtg 1380ctgtgccagg
cccacggctt gaccccccag caggtggtgg ccatcgccag caataatggt
1440ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca
ggcccacggc 1500ttgacccccc agcaggtggt ggccatcgcc agcaataatg
gtggcaagca ggcgctggag 1560acggtccagc ggctgttgcc ggtgctgtgc
caggcccacg gcttgacccc ccagcaggtg 1620gtggccatcg ccagcaatgg
cggtggcaag caggcgctgg agacggtcca gcggctgttg 1680ccggtgctgt
gccaggccca cggcttgacc ccggagcagg tggtggccat cgccagccac
1740gatggcggca agcaggcgct ggagacggtc cagcggctgt tgccggtgct
gtgccaggcc 1800cacggcttga ccccccagca ggtggtggcc atcgccagca
ataatggtgg caagcaggcg 1860ctggagacgg tccagcggct gttgccggtg
ctgtgccagg cccacggctt gaccccggag 1920caggtggtgg ccatcgccag
ccacgatggc ggcaagcagg cgctggagac ggtccagcgg 1980ctgttgccgg
tgctgtgcca ggcccacggc ttgacccctc agcaggtggt ggccatcgcc
2040agcaatggcg gcggcaggcc ggcgctggag agcattgttg cccagttatc
tcgccctgat 2100ccggcgttgg ccgcgttgac caacgaccac ctcgtcgcct
tggcctgcct cggcgggcgt 2160cctgcgctgg atgcagtgaa aaagggattg
ggggatccta tcagccgttc ccagctggtg 2220aagtccgagc tggaggagaa
gaaatccgag ttgaggcaca agctgaagta cgtgccccac 2280gagtacatcg
agctgatcga gatcgcccgg aacagcaccc aggaccgtat cctggagatg
2340aaggtgatgg agttcttcat gaaggtgtac ggctacaggg gcaagcacct
gggcggctcc 2400aggaagcccg acggcgccat ctacaccgtg ggctccccca
tcgactacgg cgtgatcgtg 2460gacaccaagg cctactccgg cggctacaac
ctgcccatcg gccaggccga cgaaatgcag 2520aggtacgtgg aggagaacca
gaccaggaac aagcacatca accccaacga gtggtggaag 2580gtgtacccct
ccagcgtgac cgagttcaag ttcctgttcg tgtccggcca cttcaagggc
2640aactacaagg cccagctgac caggctgaac cacatcacca actgcaacgg
cgccgtgctg 2700tccgtggagg agctcctgat cggcggcgag atgatcaagg
ccggcaccct gaccctggag 2760gaggtgagga ggaagttcaa caacggcgag
atcaacttcg cggccgactg ataa 2814742832DNAArtificial
SequenceTALE-nuclease sequence 74atgggcgatc ctaaaaagaa acgtaaggtc
atcgataagg agaccgccgc tgccaagttc 60gagagacagc acatggacag catcgatatc
gccgatctac gcacgctcgg ctacagccag 120cagcaacagg agaagatcaa
accgaaggtt cgttcgacag tggcgcagca ccacgaggca 180ctggtcggcc
acgggtttac acacgcgcac atcgttgcgt taagccaaca cccggcagcg
240ttagggaccg tcgctgtcaa gtatcaggac atgatcgcag cgttgccaga
ggcgacacac 300gaagcgatcg ttggcgtcgg caaacagtgg tccggcgcac
gcgctctgga ggccttgctc 360acggtggcgg gagagttgag aggtccaccg
ttacagttgg acacaggcca acttctcaag 420attgcaaaac gtggcggcgt
gaccgcagtg gaggcagtgc atgcatggcg caatgcactg 480acgggtgccc
cgctcaactt gaccccccag caggtggtgg ccatcgccag caataatggt
540ggcaagcagg cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca
ggcccacggc 600ttgacccccc agcaggtggt ggccatcgcc agcaataatg
gtggcaagca ggcgctggag 660acggtccagc ggctgttgcc ggtgctgtgc
caggcccacg gcttgacccc ccagcaggtg 720gtggccatcg ccagcaataa
tggtggcaag caggcgctgg agacggtcca gcggctgttg 780ccggtgctgt
gccaggccca cggcttgacc ccggagcagg tggtggccat cgccagcaat
840attggtggca agcaggcgct ggagacggtg caggcgctgt tgccggtgct
gtgccaggcc 900cacggcttga ccccccagca ggtggtggcc atcgccagca
ataatggtgg caagcaggcg 960ctggagacgg tccagcggct gttgccggtg
ctgtgccagg cccacggctt gaccccggag 1020caggtggtgg ccatcgccag
caatattggt ggcaagcagg cgctggagac ggtgcaggcg 1080ctgttgccgg
tgctgtgcca ggcccacggc ttgacccccc agcaggtggt ggccatcgcc
1140agcaatggcg gtggcaagca ggcgctggag acggtccagc ggctgttgcc
ggtgctgtgc 1200caggcccacg gcttgacccc ggagcaggtg gtggccatcg
ccagccacga tggcggcaag 1260caggcgctgg agacggtcca gcggctgttg
ccggtgctgt gccaggccca cggcttgacc 1320ccccagcagg tggtggccat
cgccagcaat ggcggtggca agcaggcgct ggagacggtc 1380cagcggctgt
tgccggtgct gtgccaggcc cacggcttga ccccggagca ggtggtggcc
1440atcgccagcc acgatggcgg caagcaggcg ctggagacgg tccagcggct
gttgccggtg 1500ctgtgccagg cccacggctt gaccccccag caggtggtgg
ccatcgccag caatggcggt 1560ggcaagcagg cgctggagac ggtccagcgg
ctgttgccgg tgctgtgcca ggcccacggc 1620ttgacccccc agcaggtggt
ggccatcgcc agcaataatg gtggcaagca ggcgctggag 1680acggtccagc
ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg
1740gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca
gcggctgttg 1800ccggtgctgt gccaggccca cggcttgacc ccccagcagg
tggtggccat cgccagcaat 1860ggcggtggca agcaggcgct ggagacggtc
cagcggctgt tgccggtgct gtgccaggcc 1920cacggcttga ccccccagca
ggtggtggcc atcgccagca atggcggtgg caagcaggcg 1980ctggagacgg
tccagcggct gttgccggtg ctgtgccagg cccacggctt gacccctcag
2040caggtggtgg ccatcgccag caatggcggc ggcaggccgg cgctggagag
cattgttgcc 2100cagttatctc gccctgatcc ggcgttggcc gcgttgacca
acgaccacct cgtcgccttg 2160gcctgcctcg gcgggcgtcc tgcgctggat
gcagtgaaaa agggattggg ggatcctatc 2220agccgttccc agctggtgaa
gtccgagctg gaggagaaga aatccgagtt gaggcacaag 2280ctgaagtacg
tgccccacga gtacatcgag ctgatcgaga tcgcccggaa cagcacccag
2340gaccgtatcc tggagatgaa ggtgatggag ttcttcatga aggtgtacgg
ctacaggggc 2400aagcacctgg gcggctccag gaagcccgac ggcgccatct
acaccgtggg ctcccccatc 2460gactacggcg tgatcgtgga caccaaggcc
tactccggcg gctacaacct gcccatcggc 2520caggccgacg aaatgcagag
gtacgtggag gagaaccaga ccaggaacaa gcacatcaac 2580cccaacgagt
ggtggaaggt gtacccctcc agcgtgaccg agttcaagtt cctgttcgtg
2640tccggccact tcaagggcaa ctacaaggcc cagctgacca ggctgaacca
catcaccaac 2700tgcaacggcg ccgtgctgtc cgtggaggag ctcctgatcg
gcggcgagat gatcaaggcc 2760ggcaccctga ccctggagga ggtgaggagg
aagttcaaca acggcgagat caacttcgcg 2820gccgactgat aa
28327521DNAArtificial SequencePCR primer 75atcactggca tctggactcc a
217622DNAArtificial SequencePCR primer 76agagccccta ccagaaccag ac
227722DNAArtificial SequencePCR primer 77ggacctagta acataattgt gc
227820DNAArtificial SequencePCR primer 78cctcatgtct agcacagttt
207921DNAArtificial SequencePCR primer 79accagctcag ctccacgtgg t
218058DNAHomo sapiens 80tctcgctccg tggccttagc tgtgctcgcg ctactctctc
tttctggcct ggaggcta 58812814DNAArtificial SequenceBeta2M T01- TALEN
- LEFT 81atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgatgt
tccagattac 60gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca
ggagaagatc 120aaaccgaagg ttcgttcgac agtggcgcag caccacgagg
cactggtcgg ccacgggttt 180acacacgcgc acatcgttgc gttaagccaa
cacccggcag cgttagggac cgtcgctgtc 240aagtatcagg acatgatcgc
agcgttgcca gaggcgacac acgaagcgat cgttggcgtc 300ggcaaacagt
ggtccggcgc acgcgctctg gaggccttgc tcacggtggc gggagagttg
360agaggtccac cgttacagtt ggacacaggc caacttctca agattgcaaa
acgtggcggc 420gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac
tgacgggtgc cccgctcaac 480ttgacccccc agcaggtggt ggccatcgcc
agcaataatg gtggcaagca ggcgctggag 540acggtccagc ggctgttgcc
ggtgctgtgc caggcccacg gcttgacccc ccagcaggtg 600gtggccatcg
ccagcaataa tggtggcaag caggcgctgg agacggtcca gcggctgttg
660ccggtgctgt gccaggccca cggcttgacc ccggagcagg tggtggccat
cgccagccac 720gatggcggca agcaggcgct ggagacggtc cagcggctgt
tgccggtgct gtgccaggcc 780cacggcttga ccccggagca ggtggtggcc
atcgccagcc acgatggcgg caagcaggcg 840ctggagacgg tccagcggct
gttgccggtg ctgtgccagg cccacggctt gaccccccag 900caggtggtgg
ccatcgccag caatggcggt ggcaagcagg cgctggagac ggtccagcgg
960ctgttgccgg tgctgtgcca ggcccacggc ttgacccccc agcaggtggt
ggccatcgcc 1020agcaatggcg gtggcaagca ggcgctggag acggtccagc
ggctgttgcc ggtgctgtgc 1080caggcccacg gcttgacccc ggagcaggtg
gtggccatcg ccagcaatat tggtggcaag 1140caggcgctgg agacggtgca
ggcgctgttg ccggtgctgt gccaggccca cggcttgacc 1200ccccagcagg
tggtggccat cgccagcaat aatggtggca agcaggcgct ggagacggtc
1260cagcggctgt tgccggtgct gtgccaggcc cacggcttga ccccggagca
ggtggtggcc 1320atcgccagcc acgatggcgg caagcaggcg ctggagacgg
tccagcggct gttgccggtg 1380ctgtgccagg cccacggctt gaccccccag
caggtggtgg ccatcgccag caatggcggt 1440ggcaagcagg cgctggagac
ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc 1500ttgacccccc
agcaggtggt ggccatcgcc agcaataatg gtggcaagca ggcgctggag
1560acggtccagc ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc
ccagcaggtg 1620gtggccatcg ccagcaatgg cggtggcaag caggcgctgg
agacggtcca gcggctgttg 1680ccggtgctgt gccaggccca cggcttgacc
ccccagcagg tggtggccat cgccagcaat 1740aatggtggca agcaggcgct
ggagacggtc cagcggctgt tgccggtgct gtgccaggcc 1800cacggcttga
ccccggagca ggtggtggcc atcgccagcc acgatggcgg caagcaggcg
1860ctggagacgg tccagcggct gttgccggtg ctgtgccagg cccacggctt
gaccccccag 1920caggtggtgg ccatcgccag caatggcggt ggcaagcagg
cgctggagac ggtccagcgg 1980ctgttgccgg tgctgtgcca ggcccacggc
ttgacccctc agcaggtggt ggccatcgcc 2040agcaatggcg gcggcaggcc
ggcgctggag agcattgttg cccagttatc tcgccctgat 2100ccggcgttgg
ccgcgttgac caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt
2160cctgcgctgg atgcagtgaa aaagggattg ggggatccta tcagccgttc
ccagctggtg 2220aagtccgagc tggaggagaa gaaatccgag ttgaggcaca
agctgaagta cgtgccccac 2280gagtacatcg agctgatcga gatcgcccgg
aacagcaccc aggaccgtat cctggagatg 2340aaggtgatgg agttcttcat
gaaggtgtac ggctacaggg gcaagcacct gggcggctcc 2400aggaagcccg
acggcgccat ctacaccgtg ggctccccca tcgactacgg cgtgatcgtg
2460gacaccaagg cctactccgg cggctacaac ctgcccatcg gccaggccga
cgaaatgcag 2520aggtacgtgg aggagaacca gaccaggaac aagcacatca
accccaacga gtggtggaag 2580gtgtacccct ccagcgtgac cgagttcaag
ttcctgttcg tgtccggcca cttcaagggc 2640aactacaagg cccagctgac
caggctgaac cacatcacca actgcaacgg cgccgtgctg 2700tccgtggagg
agctcctgat cggcggcgag atgatcaagg ccggcaccct gaccctggag
2760gaggtgagga ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa
2814822832DNAArtificial SequenceBeta2M T01 TALEN -RIGHT
82atgggcgatc ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc
60gagagacagc acatggacag catcgatatc gccgatctac gcacgctcgg ctacagccag
120cagcaacagg agaagatcaa accgaaggtt cgttcgacag tggcgcagca
ccacgaggca 180ctggtcggcc acgggtttac acacgcgcac atcgttgcgt
taagccaaca cccggcagcg 240ttagggaccg tcgctgtcaa gtatcaggac
atgatcgcag cgttgccaga ggcgacacac 300gaagcgatcg ttggcgtcgg
caaacagtgg tccggcgcac gcgctctgga ggccttgctc 360acggtggcgg
gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag
420attgcaaaac gtggcggcgt gaccgcagtg gaggcagtgc atgcatggcg
caatgcactg 480acgggtgccc cgctcaactt gaccccggag caggtggtgg
ccatcgccag caatattggt 540ggcaagcagg cgctggagac ggtgcaggcg
ctgttgccgg tgctgtgcca ggcccacggc 600ttgacccccc agcaggtggt
ggccatcgcc agcaataatg gtggcaagca ggcgctggag 660acggtccagc
ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg
720gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca
gcggctgttg 780ccggtgctgt gccaggccca cggcttgacc ccggagcagg
tggtggccat cgccagccac 840gatggcggca agcaggcgct ggagacggtc
cagcggctgt tgccggtgct gtgccaggcc 900cacggcttga ccccccagca
ggtggtggcc atcgccagca atggcggtgg caagcaggcg 960ctggagacgg
tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccggag
1020caggtggtgg ccatcgccag ccacgatggc ggcaagcagg cgctggagac
ggtccagcgg 1080ctgttgccgg tgctgtgcca ggcccacggc ttgaccccgg
agcaggtggt ggccatcgcc 1140agccacgatg gcggcaagca ggcgctggag
acggtccagc ggctgttgcc ggtgctgtgc 1200caggcccacg gcttgacccc
ggagcaggtg gtggccatcg ccagcaatat tggtggcaag 1260caggcgctgg
agacggtgca ggcgctgttg ccggtgctgt gccaggccca cggcttgacc
1320ccccagcagg tggtggccat cgccagcaat aatggtggca agcaggcgct
ggagacggtc 1380cagcggctgt tgccggtgct gtgccaggcc cacggcttga
ccccccagca ggtggtggcc 1440atcgccagca ataatggtgg caagcaggcg
ctggagacgg tccagcggct gttgccggtg 1500ctgtgccagg cccacggctt
gaccccggag caggtggtgg ccatcgccag ccacgatggc 1560ggcaagcagg
cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc
1620ttgaccccgg agcaggtggt ggccatcgcc agccacgatg gcggcaagca
ggcgctggag 1680acggtccagc ggctgttgcc ggtgctgtgc caggcccacg
gcttgacccc ggagcaggtg 1740gtggccatcg ccagcaatat tggtggcaag
caggcgctgg agacggtgca ggcgctgttg 1800ccggtgctgt gccaggccca
cggcttgacc ccccagcagg tggtggccat cgccagcaat 1860aatggtggca
agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc
1920cacggcttga ccccggagca ggtggtggcc atcgccagca atattggtgg
caagcaggcg 1980ctggagacgg tgcaggcgct gttgccggtg ctgtgccagg
cccacggctt gacccctcag 2040caggtggtgg ccatcgccag caatggcggc
ggcaggccgg cgctggagag cattgttgcc 2100cagttatctc gccctgatcc
ggcgttggcc gcgttgacca acgaccacct cgtcgccttg 2160gcctgcctcg
gcgggcgtcc tgcgctggat gcagtgaaaa agggattggg ggatcctatc
2220agccgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt
gaggcacaag 2280ctgaagtacg tgccccacga gtacatcgag ctgatcgaga
tcgcccggaa cagcacccag 2340gaccgtatcc tggagatgaa ggtgatggag
ttcttcatga aggtgtacgg ctacaggggc 2400aagcacctgg gcggctccag
gaagcccgac ggcgccatct acaccgtggg ctcccccatc 2460gactacggcg
tgatcgtgga caccaaggcc tactccggcg gctacaacct gcccatcggc
2520caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa
gcacatcaac 2580cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg
agttcaagtt cctgttcgtg 2640tccggccact tcaagggcaa ctacaaggcc
cagctgacca ggctgaacca catcaccaac 2700tgcaacggcg ccgtgctgtc
cgtggaggag ctcctgatcg gcggcgagat gatcaaggcc 2760ggcaccctga
ccctggagga ggtgaggagg aagttcaaca acggcgagat caacttcgcg
2820gccgactgat aa 28328350DNAArtificial SequenceB2M T02- TALEN
targeting sequence 83tccaaagatt caggtttact cacgtcatcc agcagagaat
ggaaagtcaa 50842814DNAArtificial SequenceBeta2M T02-TALEN - LEFT
84atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgatgt tccagattac
60gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca ggagaagatc
120aaaccgaagg ttcgttcgac agtggcgcag caccacgagg cactggtcgg
ccacgggttt 180acacacgcgc acatcgttgc gttaagccaa cacccggcag
cgttagggac cgtcgctgtc 240aagtatcagg acatgatcgc agcgttgcca
gaggcgacac acgaagcgat cgttggcgtc 300ggcaaacagt ggtccggcgc
acgcgctctg gaggccttgc tcacggtggc gggagagttg 360agaggtccac
cgttacagtt ggacacaggc caacttctca agattgcaaa acgtggcggc
420gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac tgacgggtgc
cccgctcaac 480ttgaccccgg agcaggtggt ggccatcgcc agccacgatg
gcggcaagca ggcgctggag 540acggtccagc ggctgttgcc ggtgctgtgc
caggcccacg gcttgacccc ggagcaggtg 600gtggccatcg ccagccacga
tggcggcaag caggcgctgg agacggtcca gcggctgttg 660ccggtgctgt
gccaggccca cggcttgacc ccggagcagg tggtggccat cgccagcaat
720attggtggca agcaggcgct ggagacggtg caggcgctgt tgccggtgct
gtgccaggcc 780cacggcttga ccccggagca ggtggtggcc atcgccagca
atattggtgg caagcaggcg 840ctggagacgg tgcaggcgct gttgccggtg
ctgtgccagg cccacggctt gaccccggag 900caggtggtgg ccatcgccag
caatattggt ggcaagcagg cgctggagac ggtgcaggcg 960ctgttgccgg
tgctgtgcca ggcccacggc ttgacccccc agcaggtggt ggccatcgcc
1020agcaataatg gtggcaagca ggcgctggag acggtccagc ggctgttgcc
ggtgctgtgc 1080caggcccacg gcttgacccc ggagcaggtg gtggccatcg
ccagcaatat tggtggcaag 1140caggcgctgg agacggtgca ggcgctgttg
ccggtgctgt gccaggccca cggcttgacc 1200ccccagcagg tggtggccat
cgccagcaat ggcggtggca agcaggcgct ggagacggtc 1260cagcggctgt
tgccggtgct gtgccaggcc cacggcttga ccccccagca ggtggtggcc
1320atcgccagca atggcggtgg caagcaggcg ctggagacgg tccagcggct
gttgccggtg 1380ctgtgccagg cccacggctt gaccccggag caggtggtgg
ccatcgccag ccacgatggc 1440ggcaagcagg cgctggagac ggtccagcgg
ctgttgccgg tgctgtgcca ggcccacggc 1500ttgaccccgg agcaggtggt
ggccatcgcc agcaatattg gtggcaagca ggcgctggag 1560acggtgcagg
cgctgttgcc ggtgctgtgc caggcccacg gcttgacccc ccagcaggtg
1620gtggccatcg ccagcaataa tggtggcaag caggcgctgg agacggtcca
gcggctgttg 1680ccggtgctgt gccaggccca cggcttgacc ccccagcagg
tggtggccat cgccagcaat 1740aatggtggca agcaggcgct ggagacggtc
cagcggctgt tgccggtgct gtgccaggcc 1800cacggcttga ccccccagca
ggtggtggcc atcgccagca atggcggtgg caagcaggcg 1860ctggagacgg
tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccccag
1920caggtggtgg ccatcgccag caatggcggt ggcaagcagg cgctggagac
ggtccagcgg 1980ctgttgccgg tgctgtgcca ggcccacggc ttgacccctc
agcaggtggt ggccatcgcc 2040agcaatggcg gcggcaggcc ggcgctggag
agcattgttg cccagttatc tcgccctgat 2100ccggcgttgg ccgcgttgac
caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt 2160cctgcgctgg
atgcagtgaa aaagggattg ggggatccta tcagccgttc ccagctggtg
2220aagtccgagc tggaggagaa gaaatccgag ttgaggcaca agctgaagta
cgtgccccac 2280gagtacatcg agctgatcga gatcgcccgg aacagcaccc
aggaccgtat cctggagatg 2340aaggtgatgg agttcttcat gaaggtgtac
ggctacaggg gcaagcacct gggcggctcc 2400aggaagcccg acggcgccat
ctacaccgtg ggctccccca tcgactacgg cgtgatcgtg 2460gacaccaagg
cctactccgg cggctacaac ctgcccatcg gccaggccga cgaaatgcag
2520aggtacgtgg aggagaacca gaccaggaac aagcacatca accccaacga
gtggtggaag 2580gtgtacccct ccagcgtgac cgagttcaag ttcctgttcg
tgtccggcca cttcaagggc 2640aactacaagg cccagctgac caggctgaac
cacatcacca actgcaacgg cgccgtgctg 2700tccgtggagg agctcctgat
cggcggcgag atgatcaagg ccggcaccct gaccctggag 2760gaggtgagga
ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa
2814852832DNAArtificial SequenceBeta2M T02-TALEN RIGHT 85atgggcgatc
ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc 60gagagacagc
acatggacag catcgatatc gccgatctac gcacgctcgg ctacagccag
120cagcaacagg agaagatcaa accgaaggtt cgttcgacag tggcgcagca
ccacgaggca 180ctggtcggcc acgggtttac acacgcgcac atcgttgcgt
taagccaaca cccggcagcg 240ttagggaccg tcgctgtcaa gtatcaggac
atgatcgcag cgttgccaga ggcgacacac 300gaagcgatcg ttggcgtcgg
caaacagtgg tccggcgcac gcgctctgga ggccttgctc 360acggtggcgg
gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag
420attgcaaaac gtggcggcgt gaccgcagtg gaggcagtgc atgcatggcg
caatgcactg 480acgggtgccc cgctcaactt gaccccccag caggtggtgg
ccatcgccag caataatggt 540ggcaagcagg cgctggagac ggtccagcgg
ctgttgccgg tgctgtgcca ggcccacggc 600ttgaccccgg agcaggtggt
ggccatcgcc agcaatattg gtggcaagca ggcgctggag 660acggtgcagg
cgctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg
720gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca
gcggctgttg 780ccggtgctgt gccaggccca cggcttgacc ccccagcagg
tggtggccat cgccagcaat 840ggcggtggca agcaggcgct ggagacggtc
cagcggctgt tgccggtgct gtgccaggcc 900cacggcttga ccccccagca
ggtggtggcc atcgccagca atggcggtgg caagcaggcg 960ctggagacgg
tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccccag
1020caggtggtgg ccatcgccag caatggcggt ggcaagcagg cgctggagac
ggtccagcgg 1080ctgttgccgg tgctgtgcca ggcccacggc ttgaccccgg
agcaggtggt ggccatcgcc 1140agccacgatg gcggcaagca ggcgctggag
acggtccagc ggctgttgcc ggtgctgtgc 1200caggcccacg gcttgacccc
ggagcaggtg gtggccatcg ccagccacga tggcggcaag 1260caggcgctgg
agacggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc
1320ccggagcagg tggtggccat cgccagcaat attggtggca agcaggcgct
ggagacggtg 1380caggcgctgt tgccggtgct gtgccaggcc cacggcttga
ccccccagca ggtggtggcc 1440atcgccagca atggcggtgg caagcaggcg
ctggagacgg tccagcggct gttgccggtg 1500ctgtgccagg cccacggctt
gaccccccag caggtggtgg ccatcgccag caatggcggt 1560ggcaagcagg
cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc
1620ttgaccccgg agcaggtggt ggccatcgcc agccacgatg gcggcaagca
ggcgctggag 1680acggtccagc ggctgttgcc ggtgctgtgc caggcccacg
gcttgacccc ccagcaggtg 1740gtggccatcg ccagcaatgg cggtggcaag
caggcgctgg agacggtcca gcggctgttg 1800ccggtgctgt gccaggccca
cggcttgacc ccggagcagg tggtggccat cgccagccac 1860gatggcggca
agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc
1920cacggcttga ccccccagca ggtggtggcc atcgccagca atggcggtgg
caagcaggcg 1980ctggagacgg tccagcggct gttgccggtg ctgtgccagg
cccacggctt gacccctcag 2040caggtggtgg ccatcgccag caatggcggc
ggcaggccgg cgctggagag cattgttgcc 2100cagttatctc gccctgatcc
ggcgttggcc gcgttgacca acgaccacct cgtcgccttg 2160gcctgcctcg
gcgggcgtcc tgcgctggat gcagtgaaaa agggattggg ggatcctatc
2220agccgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt
gaggcacaag 2280ctgaagtacg tgccccacga gtacatcgag ctgatcgaga
tcgcccggaa cagcacccag 2340gaccgtatcc tggagatgaa ggtgatggag
ttcttcatga aggtgtacgg ctacaggggc 2400aagcacctgg gcggctccag
gaagcccgac ggcgccatct acaccgtggg ctcccccatc 2460gactacggcg
tgatcgtgga caccaaggcc tactccggcg gctacaacct gcccatcggc
2520caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa
gcacatcaac 2580cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg
agttcaagtt cctgttcgtg 2640tccggccact tcaagggcaa ctacaaggcc
cagctgacca ggctgaacca catcaccaac 2700tgcaacggcg ccgtgctgtc
cgtggaggag ctcctgatcg gcggcgagat gatcaaggcc 2760ggcaccctga
ccctggagga ggtgaggagg aagttcaaca acggcgagat caacttcgcg
2820gccgactgat aa 28328647DNAArtificial SequenceB2M T03- TALEN
targeting sequence 86ttagctgtgc tcgcgctact ctctctttct ggcctggagg
ctatcca 47872814DNAArtificial SequenceBeta2M T03-TALEN - LEFT
87atgggcgatc ctaaaaagaa acgtaaggtc atcgattacc catacgatgt tccagattac
60gctatcgata tcgccgatct acgcacgctc ggctacagcc agcagcaaca ggagaagatc
120aaaccgaagg ttcgttcgac agtggcgcag caccacgagg cactggtcgg
ccacgggttt 180acacacgcgc acatcgttgc gttaagccaa cacccggcag
cgttagggac cgtcgctgtc 240aagtatcagg acatgatcgc agcgttgcca
gaggcgacac acgaagcgat cgttggcgtc 300ggcaaacagt ggtccggcgc
acgcgctctg gaggccttgc tcacggtggc gggagagttg 360agaggtccac
cgttacagtt ggacacaggc caacttctca agattgcaaa acgtggcggc
420gtgaccgcag tggaggcagt gcatgcatgg cgcaatgcac tgacgggtgc
cccgctcaac 480ttgaccccgg agcaggtggt ggccatcgcc agcaatattg
gtggcaagca ggcgctggag 540acggtgcagg cgctgttgcc ggtgctgtgc
caggcccacg gcttgacccc ccagcaggtg 600gtggccatcg ccagcaataa
tggtggcaag caggcgctgg agacggtcca gcggctgttg 660ccggtgctgt
gccaggccca cggcttgacc ccggagcagg tggtggccat cgccagccac
720gatggcggca agcaggcgct ggagacggtc cagcggctgt tgccggtgct
gtgccaggcc 780cacggcttga ccccccagca ggtggtggcc atcgccagca
atggcggtgg caagcaggcg 840ctggagacgg tccagcggct gttgccggtg
ctgtgccagg cccacggctt gaccccccag 900caggtggtgg ccatcgccag
caataatggt ggcaagcagg cgctggagac ggtccagcgg 960ctgttgccgg
tgctgtgcca ggcccacggc ttgacccccc agcaggtggt ggccatcgcc
1020agcaatggcg gtggcaagca ggcgctggag acggtccagc ggctgttgcc
ggtgctgtgc 1080caggcccacg gcttgacccc ccagcaggtg gtggccatcg
ccagcaataa tggtggcaag 1140caggcgctgg agacggtcca gcggctgttg
ccggtgctgt gccaggccca cggcttgacc 1200ccggagcagg tggtggccat
cgccagccac gatggcggca agcaggcgct ggagacggtc 1260cagcggctgt
tgccggtgct gtgccaggcc cacggcttga ccccccagca ggtggtggcc
1320atcgccagca atggcggtgg caagcaggcg ctggagacgg tccagcggct
gttgccggtg 1380ctgtgccagg cccacggctt gaccccggag caggtggtgg
ccatcgccag ccacgatggc 1440ggcaagcagg cgctggagac ggtccagcgg
ctgttgccgg tgctgtgcca ggcccacggc 1500ttgacccccc agcaggtggt
ggccatcgcc agcaataatg gtggcaagca ggcgctggag 1560acggtccagc
ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg
1620gtggccatcg ccagccacga tggcggcaag caggcgctgg agacggtcca
gcggctgttg 1680ccggtgctgt gccaggccca cggcttgacc ccccagcagg
tggtggccat cgccagcaat 1740aatggtggca agcaggcgct ggagacggtc
cagcggctgt tgccggtgct gtgccaggcc 1800cacggcttga ccccggagca
ggtggtggcc atcgccagcc acgatggcgg caagcaggcg 1860ctggagacgg
tccagcggct gttgccggtg ctgtgccagg cccacggctt gaccccccag
1920caggtggtgg ccatcgccag caatggcggt ggcaagcagg cgctggagac
ggtccagcgg 1980ctgttgccgg tgctgtgcca ggcccacggc ttgacccctc
agcaggtggt ggccatcgcc 2040agcaatggcg gcggcaggcc ggcgctggag
agcattgttg cccagttatc tcgccctgat 2100ccggcgttgg ccgcgttgac
caacgaccac ctcgtcgcct tggcctgcct cggcgggcgt 2160cctgcgctgg
atgcagtgaa aaagggattg ggggatccta tcagccgttc ccagctggtg
2220aagtccgagc tggaggagaa gaaatccgag ttgaggcaca agctgaagta
cgtgccccac 2280gagtacatcg agctgatcga gatcgcccgg aacagcaccc
aggaccgtat cctggagatg 2340aaggtgatgg agttcttcat gaaggtgtac
ggctacaggg gcaagcacct gggcggctcc 2400aggaagcccg acggcgccat
ctacaccgtg ggctccccca tcgactacgg cgtgatcgtg 2460gacaccaagg
cctactccgg cggctacaac ctgcccatcg gccaggccga cgaaatgcag
2520aggtacgtgg aggagaacca gaccaggaac aagcacatca accccaacga
gtggtggaag 2580gtgtacccct ccagcgtgac cgagttcaag ttcctgttcg
tgtccggcca cttcaagggc 2640aactacaagg cccagctgac caggctgaac
cacatcacca actgcaacgg cgccgtgctg 2700tccgtggagg agctcctgat
cggcggcgag atgatcaagg ccggcaccct gaccctggag 2760gaggtgagga
ggaagttcaa caacggcgag atcaacttcg cggccgactg ataa
2814882832DNAArtificial SequenceBeta2M T03-TALEN -RIGHT
88atgggcgatc ctaaaaagaa acgtaaggtc atcgataagg agaccgccgc tgccaagttc
60gagagacagc acatggacag catcgatatc gccgatctac gcacgctcgg ctacagccag
120cagcaacagg agaagatcaa accgaaggtt cgttcgacag tggcgcagca
ccacgaggca 180ctggtcggcc acgggtttac acacgcgcac atcgttgcgt
taagccaaca cccggcagcg 240ttagggaccg tcgctgtcaa gtatcaggac
atgatcgcag cgttgccaga ggcgacacac 300gaagcgatcg ttggcgtcgg
caaacagtgg tccggcgcac gcgctctgga ggccttgctc 360acggtggcgg
gagagttgag aggtccaccg ttacagttgg acacaggcca acttctcaag
420attgcaaaac gtggcggcgt gaccgcagtg gaggcagtgc atgcatggcg
caatgcactg 480acgggtgccc cgctcaactt gaccccccag caggtggtgg
ccatcgccag caataatggt 540ggcaagcagg cgctggagac ggtccagcgg
ctgttgccgg tgctgtgcca ggcccacggc 600ttgacccccc agcaggtggt
ggccatcgcc agcaataatg gtggcaagca ggcgctggag 660acggtccagc
ggctgttgcc ggtgctgtgc caggcccacg gcttgacccc ggagcaggtg
720gtggccatcg ccagcaatat tggtggcaag caggcgctgg agacggtgca
ggcgctgttg 780ccggtgctgt gccaggccca cggcttgacc ccccagcagg
tggtggccat cgccagcaat 840ggcggtggca agcaggcgct ggagacggtc
cagcggctgt tgccggtgct gtgccaggcc 900cacggcttga ccccggagca
ggtggtggcc atcgccagca atattggtgg caagcaggcg 960ctggagacgg
tgcaggcgct gttgccggtg ctgtgccagg cccacggctt gaccccccag
1020caggtggtgg ccatcgccag caataatggt ggcaagcagg cgctggagac
ggtccagcgg 1080ctgttgccgg tgctgtgcca ggcccacggc ttgaccccgg
agcaggtggt ggccatcgcc 1140agccacgatg gcggcaagca ggcgctggag
acggtccagc ggctgttgcc ggtgctgtgc 1200caggcccacg gcttgacccc
ggagcaggtg gtggccatcg ccagccacga tggcggcaag 1260caggcgctgg
agacggtcca gcggctgttg ccggtgctgt gccaggccca cggcttgacc
1320ccccagcagg tggtggccat cgccagcaat ggcggtggca agcaggcgct
ggagacggtc 1380cagcggctgt tgccggtgct gtgccaggcc cacggcttga
ccccggagca ggtggtggcc 1440atcgccagcc acgatggcgg caagcaggcg
ctggagacgg tccagcggct gttgccggtg 1500ctgtgccagg cccacggctt
gaccccggag caggtggtgg ccatcgccag ccacgatggc 1560ggcaagcagg
cgctggagac ggtccagcgg ctgttgccgg tgctgtgcca ggcccacggc
1620ttgaccccgg agcaggtggt ggccatcgcc agcaatattg gtggcaagca
ggcgctggag 1680acggtgcagg cgctgttgcc ggtgctgtgc caggcccacg
gcttgacccc ccagcaggtg 1740gtggccatcg ccagcaataa tggtggcaag
caggcgctgg agacggtcca gcggctgttg 1800ccggtgctgt gccaggccca
cggcttgacc ccccagcagg tggtggccat cgccagcaat 1860aatggtggca
agcaggcgct ggagacggtc cagcggctgt tgccggtgct gtgccaggcc
1920cacggcttga ccccggagca ggtggtggcc atcgccagcc acgatggcgg
caagcaggcg 1980ctggagacgg tccagcggct gttgccggtg ctgtgccagg
cccacggctt gacccctcag 2040caggtggtgg ccatcgccag caatggcggc
ggcaggccgg cgctggagag cattgttgcc 2100cagttatctc gccctgatcc
ggcgttggcc gcgttgacca acgaccacct cgtcgccttg 2160gcctgcctcg
gcgggcgtcc tgcgctggat gcagtgaaaa agggattggg ggatcctatc
2220agccgttccc agctggtgaa gtccgagctg gaggagaaga aatccgagtt
gaggcacaag 2280ctgaagtacg tgccccacga gtacatcgag ctgatcgaga
tcgcccggaa cagcacccag 2340gaccgtatcc tggagatgaa ggtgatggag
ttcttcatga aggtgtacgg ctacaggggc 2400aagcacctgg gcggctccag
gaagcccgac ggcgccatct acaccgtggg ctcccccatc 2460gactacggcg
tgatcgtgga caccaaggcc tactccggcg gctacaacct gcccatcggc
2520caggccgacg aaatgcagag gtacgtggag gagaaccaga ccaggaacaa
gcacatcaac 2580cccaacgagt ggtggaaggt gtacccctcc agcgtgaccg
agttcaagtt cctgttcgtg 2640tccggccact tcaagggcaa ctacaaggcc
cagctgacca ggctgaacca catcaccaac 2700tgcaacggcg ccgtgctgtc
cgtggaggag ctcctgatcg gcggcgagat gatcaaggcc 2760ggcaccctga
ccctggagga ggtgaggagg aagttcaaca acggcgagat caacttcgcg
2820gccgactgat aa 283289526PRTArtificial SequenceChimeric B2M-UL18
89Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1
5 10 15 His Ala Ala Arg Pro Ser Arg Ser Val Ala Leu Ala Val Leu Ala
Leu 20 25 30 Leu Ser Leu Ser Gly Leu Glu Ala Ile Gln Arg Thr Pro
Lys Ile Gln 35 40 45 Val Tyr Ser Arg His Pro Ala Glu Asn Gly Lys
Ser Asn Phe Leu Asn 50 55 60 Cys Tyr Val Ser Gly Phe His Pro Ser
Asp Ile Glu Val Asp Leu Leu 65 70 75 80 Lys Asn Gly Glu Arg Ile Glu
Lys Val Glu His Ser Asp Leu Ser Phe 85 90 95 Ser Lys Asp Trp Ser
Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro 100 105 110 Thr Glu Lys
Asp Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser 115 120 125 Gln
Pro Lys Ile Val Lys Trp Asp Arg Asp Met Gly Gly Gly Gly Ser 130 135
140 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Met
145 150 155 160 Thr Met Trp Cys Leu Thr Leu Phe Val Leu Trp Met Leu
Arg Val Val 165 170 175 Gly Met His Val Leu Arg Tyr Gly Tyr Thr Gly
Ile Phe Asp Asp Thr 180 185 190 Ser His Met Thr Leu Thr Val Val Gly
Ile Phe Asp Gly Gln His Phe 195 200 205 Phe Thr Tyr His Val Asn Ser
Ser Asp Lys Ala Ser Ser Arg Ala Asn 210 215 220 Gly Thr Ile Ser Trp
Met Ala Asn Val Ser Ala Ala Tyr Pro Thr Tyr 225 230 235 240 Leu Asp
Gly Glu Arg Ala Lys Gly Asp Leu Ile Phe Asn Gln Thr Glu 245 250 255
Gln Asn Leu Leu Glu Leu Glu Ile Ala Leu Gly Tyr Arg Ser Gln Ser 260
265 270 Val Leu Thr Trp Thr His Glu Cys Asn Thr Thr Glu Asn Gly Ser
Phe 275 280 285 Val Ala Gly Tyr Glu Gly Phe Gly Trp Asp Gly Glu Thr
Leu Met Glu 290 295 300 Leu Lys Asp Asn Leu Thr Leu Trp Thr Gly Pro
Asn Tyr Glu Ile Ser 305 310 315 320 Trp Leu Lys Gln Asn Lys Thr Tyr
Ile Asp Gly Lys Ile Lys Asn Ile 325 330 335 Ser Glu Gly Asp Thr Thr
Ile Gln Arg Asn Tyr Leu Lys Gly Asn Cys 340 345 350 Thr Gln Trp Ser
Val Ile Tyr Ser Gly Phe Gln Thr Pro Val Thr His 355 360 365 Pro Val
Val Lys Gly Gly Val Arg Asn Gln Asn Asp Asn Arg Ala Glu 370 375 380
Ala Phe Cys Thr Ser Tyr Gly Phe Phe Pro Gly Glu Ile Asn Ile Thr 385
390 395 400 Phe Ile His Tyr Gly Asn Lys Ala Pro Asp Asp Ser Glu Pro
Gln Cys 405 410 415 Asn Pro Leu Leu Pro Thr Phe Asp Gly Thr Phe His
Gln Gly Cys Tyr 420 425 430 Val Ala Ile Phe Cys Asn Gln Asn Tyr Thr
Cys Arg Val Thr His Gly 435 440 445 Asn Trp Thr Val Glu Ile Pro Ile
Ser Val Thr Ser Pro Asp Asp Ser 450 455 460 Ser Ser Gly Glu Val Pro
Asp His Pro Thr Ala Asn Lys Arg Tyr Asn 465 470 475 480 Thr Met Thr
Ile Ser Ser Val Leu Leu Ala Leu Leu Leu Cys Ala Leu 485 490 495 Leu
Phe Ala Phe Leu His Tyr Phe Thr Thr Leu Lys Gln Tyr Leu Arg 500 505
510 Asn Leu Ala Phe Ala Trp Arg Tyr Arg Lys Val Arg Ser Ser 515 520
525 90310PRTArtificial SequenceSP-MICAed 90Met Gly Gly Val Leu Leu
Thr Gln Arg Thr Leu Leu Ser Leu Val Leu 1 5 10 15 Ala Leu Leu Phe
Pro Ser Met Ala Ser Met Glu Pro His Ser Leu Arg 20 25 30 Tyr Asn
Leu Thr Val Leu Ser Trp Asp Gly Ser Val Gln Ser Gly Phe 35 40 45
Leu Thr Glu Val His Leu Asp Gly Gln Pro Phe Leu Arg Cys Asp Arg 50
55 60 Gln Lys Cys Arg Ala Lys Pro Gln Gly Gln Trp Ala Glu Asp Val
Leu 65 70 75 80 Gly Asn Lys Thr Trp Asp Arg Glu Thr Arg Asp Leu Thr
Gly Asn Gly 85 90 95 Lys Asp Leu Arg Met Thr Leu Ala His Ile Lys
Asp Gln Lys Glu Gly 100 105 110 Leu His Ser Leu Gln Glu Ile Arg Val
Cys Glu Ile His Glu Asp Asn 115 120 125 Ser Thr Arg Ser Ser Gln His
Phe Tyr Tyr Asp Gly Glu Leu Phe Leu 130 135 140 Ser Gln Asn Leu Glu
Thr Lys Glu Trp Thr Met Pro Gln Ser Ser Arg 145 150 155 160 Ala Gln
Thr Leu Ala Met Asn Val Arg Asn Phe Leu Lys Glu Asp Ala 165 170 175
Met Lys Thr Lys Thr His Tyr His Ala Met His Ala Asp Cys Leu Gln 180
185 190 Glu Leu Arg Arg Tyr Leu Lys Ser Gly Val Val Leu Arg Arg Thr
Val 195 200 205 Pro Pro Met Val Asn Val Thr Arg Ser Glu Ala Ser Glu
Gly
Asn Ile 210 215 220 Thr Val Thr Cys Arg Ala Ser Gly Phe Tyr Pro Trp
Asn Ile Thr Leu 225 230 235 240 Ser Trp Arg Gln Asp Gly Val Ser Leu
Ser His Asp Thr Gln Gln Trp 245 250 255 Gly Asp Val Leu Pro Asp Gly
Asn Gly Thr Tyr Gln Thr Trp Val Ala 260 265 270 Thr Arg Ile Cys Gln
Gly Glu Glu Gln Arg Phe Thr Cys Tyr Met Glu 275 280 285 His Ser Gly
Asn His Ser Thr His Pro Val Pro Ser Gly Lys Val Leu 290 295 300 Val
Leu Gln Ser His Trp 305 310 91313PRTArtificial SequenceSP-MICBed
91Met Gly Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu 1
5 10 15 Ala Leu Leu Phe Pro Ser Met Ala Ser Met Ala Glu Pro His Ser
Leu 20 25 30 Arg Tyr Asn Leu Met Val Leu Ser Gln Asp Glu Ser Val
Gln Ser Gly 35 40 45 Phe Leu Ala Glu Gly His Leu Asp Gly Gln Pro
Phe Leu Arg Tyr Asp 50 55 60 Arg Gln Lys Arg Arg Ala Lys Pro Gln
Gly Gln Trp Ala Glu Asp Val 65 70 75 80 Leu Gly Ala Lys Thr Trp Asp
Thr Glu Thr Glu Asp Leu Thr Glu Asn 85 90 95 Gly Gln Asp Leu Arg
Arg Thr Leu Thr His Ile Lys Asp Gln Lys Gly 100 105 110 Gly Leu His
Ser Leu Gln Glu Ile Arg Val Cys Glu Ile His Glu Asp 115 120 125 Ser
Ser Thr Arg Gly Ser Arg His Phe Tyr Tyr Asp Gly Glu Leu Phe 130 135
140 Leu Ser Gln Asn Leu Glu Thr Gln Glu Ser Thr Val Pro Gln Ser Ser
145 150 155 160 Arg Ala Gln Thr Leu Ala Met Asn Val Thr Asn Phe Trp
Lys Glu Asp 165 170 175 Ala Met Lys Thr Lys Thr His Tyr Arg Ala Met
Gln Ala Asp Cys Leu 180 185 190 Gln Lys Leu Gln Arg Tyr Leu Lys Ser
Gly Val Ala Ile Arg Arg Thr 195 200 205 Val Pro Pro Met Val Asn Val
Thr Cys Ser Glu Val Ser Glu Gly Asn 210 215 220 Ile Thr Val Thr Cys
Arg Ala Ser Ser Phe Tyr Pro Arg Asn Ile Thr 225 230 235 240 Leu Thr
Trp Arg Gln Asp Gly Val Ser Leu Ser His Asn Thr Gln Gln 245 250 255
Trp Gly Asp Val Leu Pro Asp Gly Asn Gly Thr Tyr Gln Thr Trp Val 260
265 270 Ala Thr Arg Ile Arg Gln Gly Glu Glu Gln Arg Phe Thr Cys Tyr
Met 275 280 285 Glu His Ser Gly Asn His Gly Thr His Pro Val Pro Ser
Gly Lys Val 290 295 300 Leu Val Leu Gln Ser Gln Arg Thr Asp 305 310
92209PRTArtificial SequenceSP-ULBP1ed 92Met Gly Gly Val Leu Leu Thr
Gln Arg Thr Leu Leu Ser Leu Val Leu 1 5 10 15 Ala Leu Leu Phe Pro
Ser Met Ala Ser Met Gly Trp Val Asp Thr His 20 25 30 Cys Leu Cys
Tyr Asp Phe Ile Ile Thr Pro Lys Ser Arg Pro Glu Pro 35 40 45 Gln
Trp Cys Glu Val Gln Gly Leu Val Asp Glu Arg Pro Phe Leu His 50 55
60 Tyr Asp Cys Val Asn His Lys Ala Lys Ala Phe Ala Ser Leu Gly Lys
65 70 75 80 Lys Val Asn Val Thr Lys Thr Trp Glu Glu Gln Thr Glu Thr
Leu Arg 85 90 95 Asp Val Val Asp Phe Leu Lys Gly Gln Leu Leu Asp
Ile Gln Val Glu 100 105 110 Asn Leu Ile Pro Ile Glu Pro Leu Thr Leu
Gln Ala Arg Met Ser Cys 115 120 125 Glu His Glu Ala His Gly His Gly
Arg Gly Ser Trp Gln Phe Leu Phe 130 135 140 Asn Gly Gln Lys Phe Leu
Leu Phe Asp Ser Asn Asn Arg Lys Trp Thr 145 150 155 160 Ala Leu His
Pro Gly Ala Lys Lys Met Thr Glu Lys Trp Glu Lys Asn 165 170 175 Arg
Asp Val Thr Met Phe Phe Gln Lys Ile Ser Leu Gly Asp Cys Lys 180 185
190 Met Trp Leu Glu Glu Phe Leu Met Tyr Trp Glu Gln Met Leu Asp Pro
195 200 205 Thr 93211PRTArtificial SequenceSP-ULBP2ed 93Met Gly Gly
Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu 1 5 10 15 Ala
Leu Leu Phe Pro Ser Met Ala Ser Met Gly Arg Ala Asp Pro His 20 25
30 Ser Leu Cys Tyr Asp Ile Thr Val Ile Pro Lys Phe Arg Pro Gly Pro
35 40 45 Arg Trp Cys Ala Val Gln Gly Gln Val Asp Glu Lys Thr Phe
Leu His 50 55 60 Tyr Asp Cys Gly Asn Lys Thr Val Thr Pro Val Ser
Pro Leu Gly Lys 65 70 75 80 Lys Leu Asn Val Thr Thr Ala Trp Lys Ala
Gln Asn Pro Val Leu Arg 85 90 95 Glu Val Val Asp Ile Leu Thr Glu
Gln Leu Arg Asp Ile Gln Leu Glu 100 105 110 Asn Tyr Thr Pro Lys Glu
Pro Leu Thr Leu Gln Ala Arg Met Ser Cys 115 120 125 Glu Gln Lys Ala
Glu Gly His Ser Ser Gly Ser Trp Gln Phe Ser Phe 130 135 140 Asp Gly
Gln Ile Phe Leu Leu Phe Asp Ser Glu Lys Arg Met Trp Thr 145 150 155
160 Thr Val His Pro Gly Ala Arg Lys Met Lys Glu Lys Trp Glu Asn Asp
165 170 175 Lys Val Val Ala Met Ser Phe His Tyr Phe Ser Met Gly Asp
Cys Ile 180 185 190 Gly Trp Leu Glu Asp Phe Leu Met Gly Met Asp Ser
Thr Leu Glu Pro 195 200 205 Ser Ala Gly 210 94206PRTArtificial
SequenceSP-ULBP3ed 94Met Gly Gly Val Leu Leu Thr Gln Arg Thr Leu
Leu Ser Leu Val Leu 1 5 10 15 Ala Leu Leu Phe Pro Ser Met Ala Ser
Met Asp Ala His Ser Leu Trp 20 25 30 Tyr Asn Phe Thr Ile Ile His
Leu Pro Arg His Gly Gln Gln Trp Cys 35 40 45 Glu Val Gln Ser Gln
Val Asp Gln Lys Asn Phe Leu Ser Tyr Asp Cys 50 55 60 Gly Ser Asp
Lys Val Leu Ser Met Gly His Leu Glu Glu Gln Leu Tyr 65 70 75 80 Ala
Thr Asp Ala Trp Gly Lys Gln Leu Glu Met Leu Arg Glu Val Gly 85 90
95 Gln Arg Leu Arg Leu Glu Leu Ala Asp Thr Glu Leu Glu Asp Phe Thr
100 105 110 Pro Ser Gly Pro Leu Thr Leu Gln Val Arg Met Ser Cys Glu
Cys Glu 115 120 125 Ala Asp Gly Tyr Ile Arg Gly Ser Trp Gln Phe Ser
Phe Asp Gly Arg 130 135 140 Lys Phe Leu Leu Phe Asp Ser Asn Asn Arg
Lys Trp Thr Val Val His 145 150 155 160 Ala Gly Ala Arg Arg Met Lys
Glu Lys Trp Glu Lys Asp Ser Gly Leu 165 170 175 Thr Thr Phe Phe Lys
Met Val Ser Met Arg Asp Cys Lys Ser Trp Leu 180 185 190 Arg Asp Phe
Leu Met His Arg Lys Lys Arg Leu Glu Pro Thr 195 200 205
95221PRTArtificial SequenceSP-N2DL4ed 95Met Gly Gly Val Leu Leu Thr
Gln Arg Thr Leu Leu Ser Leu Val Leu 1 5 10 15 Ala Leu Leu Phe Pro
Ser Met Ala Ser Met His Ser Leu Cys Phe Asn 20 25 30 Phe Thr Ile
Lys Ser Leu Ser Arg Pro Gly Gln Pro Trp Cys Glu Ala 35 40 45 Gln
Val Phe Leu Asn Lys Asn Leu Phe Leu Gln Tyr Asn Ser Asp Asn 50 55
60 Asn Met Val Lys Pro Leu Gly Leu Leu Gly Lys Lys Val Tyr Ala Thr
65 70 75 80 Ser Thr Trp Gly Glu Leu Thr Gln Thr Leu Gly Glu Val Gly
Arg Asp 85 90 95 Leu Arg Met Leu Leu Cys Asp Ile Lys Pro Gln Ile
Lys Thr Ser Asp 100 105 110 Pro Ser Thr Leu Gln Val Glu Met Phe Cys
Gln Arg Glu Ala Glu Arg 115 120 125 Cys Thr Gly Ala Ser Trp Gln Phe
Ala Thr Asn Gly Glu Lys Ser Leu 130 135 140 Leu Phe Asp Ala Met Asn
Met Thr Trp Thr Val Ile Asn His Glu Ala 145 150 155 160 Ser Lys Ile
Lys Glu Thr Trp Lys Lys Asp Arg Gly Leu Glu Lys Tyr 165 170 175 Phe
Arg Lys Leu Ser Lys Gly Asp Cys Asp His Trp Leu Arg Glu Phe 180 185
190 Leu Gly His Trp Glu Ala Met Pro Glu Pro Thr Val Ser Pro Val Asn
195 200 205 Ala Ser Asp Ile His Trp Ser Ser Ser Ser Leu Pro Asp 210
215 220 96224PRTArtificial SequenceSP-RET1Ged 96Met Gly Gly Val Leu
Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu 1 5 10 15 Ala Leu Leu
Phe Pro Ser Met Ala Ser Met Gly Leu Ala Asp Pro His 20 25 30 Ser
Leu Cys Tyr Asp Ile Thr Val Ile Pro Lys Phe Arg Pro Gly Pro 35 40
45 Arg Trp Cys Ala Val Gln Gly Gln Val Asp Glu Lys Thr Phe Leu His
50 55 60 Tyr Asp Cys Gly Ser Lys Thr Val Thr Pro Val Ser Pro Leu
Gly Lys 65 70 75 80 Lys Leu Asn Val Thr Thr Ala Trp Lys Ala Gln Asn
Pro Val Leu Arg 85 90 95 Glu Val Val Asp Ile Leu Thr Glu Gln Leu
Leu Asp Ile Gln Leu Glu 100 105 110 Asn Tyr Ile Pro Lys Glu Pro Leu
Thr Leu Gln Ala Arg Met Ser Cys 115 120 125 Glu Gln Lys Ala Glu Gly
His Gly Ser Gly Ser Trp Gln Leu Ser Phe 130 135 140 Asp Gly Gln Ile
Phe Leu Leu Phe Asp Ser Glu Asn Arg Met Trp Thr 145 150 155 160 Thr
Val His Pro Gly Ala Arg Lys Met Lys Glu Lys Trp Glu Asn Asp 165 170
175 Lys Asp Met Thr Met Ser Phe His Tyr Ile Ser Met Gly Asp Cys Thr
180 185 190 Gly Trp Leu Glu Asp Phe Leu Met Gly Met Asp Ser Thr Leu
Glu Pro 195 200 205 Ser Ala Gly Ala Pro Pro Thr Met Ser Ser Gly Thr
Ala Gln Pro Arg 210 215 220 97211PRTArtificial SequenceSP-RAETILed
97Met Gly Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu 1
5 10 15 Ala Leu Leu Phe Pro Ser Met Ala Ser Met Arg Arg Asp Asp Pro
His 20 25 30 Ser Leu Cys Tyr Asp Ile Thr Val Ile Pro Lys Phe Arg
Pro Gly Pro 35 40 45 Arg Trp Cys Ala Val Gln Gly Gln Val Asp Glu
Lys Thr Phe Leu His 50 55 60 Tyr Asp Cys Gly Asn Lys Thr Val Thr
Pro Val Ser Pro Leu Gly Lys 65 70 75 80 Lys Leu Asn Val Thr Met Ala
Trp Lys Ala Gln Asn Pro Val Leu Arg 85 90 95 Glu Val Val Asp Ile
Leu Thr Glu Gln Leu Leu Asp Ile Gln Leu Glu 100 105 110 Asn Tyr Thr
Pro Lys Glu Pro Leu Thr Leu Gln Ala Arg Met Ser Cys 115 120 125 Glu
Gln Lys Ala Glu Gly His Ser Ser Gly Ser Trp Gln Phe Ser Ile 130 135
140 Asp Gly Gln Thr Phe Leu Leu Phe Asp Ser Glu Lys Arg Met Trp Thr
145 150 155 160 Thr Val His Pro Gly Ala Arg Lys Met Lys Glu Lys Trp
Glu Asn Asp 165 170 175 Lys Asp Val Ala Met Ser Phe His Tyr Ile Ser
Met Gly Asp Cys Ile 180 185 190 Gly Trp Leu Glu Asp Phe Leu Met Gly
Met Asp Ser Thr Leu Glu Pro 195 200 205 Ser Ala Gly 210
* * * * *